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Sub-populations of cancer cells have been identified in tumours, leading to the 
cancer stem cell (CSC) hypothesis, wherein these sub-populations of cells are crucial 
in tumour recurrence and chemoresistance.  This has given! rise to interest in the 
potential to target these cells for effective new anti-cancer therapies. However, little 
is yet known about the role of extracellular matrix (ECM) components such as 
heparan sulphate proteoglycans (HSPGs) in the modulation of CSCs. We 
hypothesised that targeted modulation of HS in CSCs may lead to altered cell 
phenotype and reduced metastatic potential. To study HS involvement in CSC 
homeostasis, an in vitro model of CSCs was established, using flow cytometry to 
detect and isolate a well described breast cancer stem cell (BCSC) subpopulation 
with the marker phenotype CD44+/CD24- in two breast cancer cell (BCC) lines 
(MDA-MB-231 and Hs578-T). Characterization of these CSCs demonstrated that 
they possessed typical properties including higher proliferation, invasion, migration, 
adhesion, and lower apoptosis and drug sensitivity, compared to non-CSCs from the 
same lines. They also expressed elevated levels of pro-angiogenic factors and stem 
cell markers. HS, heparin and modified heparins were then added exogenously to 
these cells in functional assays. This resulted in significant reductions in the 
proportion of CD44+/CD24- cells, in a dose responsive and structure-dependent 
manner.  Some of these compounds also reduced the cell proliferation, invasion, 
migration, adhesion, and chemoresistance of these CSCs, and increased apoptosis, 
indicating a phenotypc switch towards non-metastatic behaviour. Initial investigation 
of the mechanisms involved showed altered stem cell and angiogenesis markers 
including Ang-1, Ang-2, CXCR4 and IL-8. Furthermore, the decrease in the rates of 
invasion, migration and adhesion strongly correlated with differential inhibition of 
FGF2/ERK1/2 and IL-6/STAT3 signaling, and other pathways involving AMPKα 
and mTOR were also implicated in a signaling pathway screen.  
The key conclusions from these studies are that CD44+/CD24- cells with CSC 
properties may be manipulated by targeting their cell surface proteoglycans using HS 
and heparins with divergent structures. This suggest that HSPGs play an important 
role in regulating the homeostasis of BCSCs, and further that this class of 
compounds represent promising novel agents for targetted therapeutic interventions 
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1.1 Proteoglycans  
Proteoglycans (PGs) are major components of metazoan organism’s cell surfaces and 
extracellular matrix (ECM) (Bernfield et al., 1999, Esko et al., 2009, Perrimon and 
Bernfield, 2001, Turnbull et al., 2001). PGs are also involved in binding diverse 
chemokines, cytokines and growth factors (Kjellén and Lindahl, 1991). Moreover, 
they are involved in regulating fundamental cell processes including cell 
proliferation, differentiation and migration, and by assisting in maintenance of 
basement membranes (Iozzo, 2005). PGs are glycoproteins which contain a core 
protein, found covalently O-linked to the glycosaminoglycan (GAG) polysaccharide 
chains (Esko et al., 2009, Kjellén and Lindahl, 1991). 
1.2 Glycosaminoglycans  
Glycosaminoglycans (GAGs) are polysaccharides, consisting mostly of repeating 
disaccharide units of hexosamine and a hexuronic acid, of which there are two types 
of GAGs: galactosaminoglycans and glucosaminoglycans (Gandhi and Mancera, 
2008, Prydz, 2015).  The galactosaminoglycans classified to chondroitin sulphate 
(CS) and dermatan sulphate (DS), while glucosaminoglycans classified to 
hyaluronan, keratan sulphate (KS), heparan sulphate (HS) and heparin. 
Galactosaminoglycans and glucosaminoglycans consisting of the same hexuronic 
acid subunits, either glucuronic acid (GlcA) or iduronic acid (IdoA). The difference 
between them is aminosugar, galactosaminoglycans have the galactosamine sugar or 
glucosaminoglycans have glucosamine sugar (Gandhi and Mancera, 2008). 
Hyaluronan consists of glucosamine and GlcA (Evanko et al., 2007). Unlike the 
other GAGs, KS has galactose monosaccharides instead of uronic acid (Funderburgh, 
2000). Hyaluronan, also known as hyaluoronic acid (HA) is unique since it is 
unsulfated and not found attached to a core protein (Chen and Abatangelo, 1999) 
(Figure 1.1). Of all the GAGs, HS has been the most deeply investigated, often 










Figure 1.1 Carbohydrate sequences of the six types of GAG chains using monosaccharide 
symbols. GAGs are repeating disaccharide units of a hexosamine with either uronic acid or galactose. 
Possible sulphation presence and location (2S, 4S or 6S) is indicated. Sulphate group is lacking in 
hyaluronan, while uronic acids are replaced by galactose in keratan sulphates. The monosaccharide is 
illustrated according to the guidelines of the Nomenclature Committee of the Consortium for 
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1.3 Heparan sulphate 
Heparan sulphate (HS) is a highly sulphated and negatively charged member of the 
glycosaminoglycan (GAG) family of polysaccharides found on the ECM and cell 
surfaces (Gandhi and Mancera, 2008). HS are able to bind and interact with a wide 
variety of proteins important for tumour development, such as chemokines, enzymes 
and growth factors. For example, fibroblast growth factors (FGFs), vascular 
endothelial growth factor (VEGF), hepatocyte growth factor (HGF) and transforming 
growth factor-β (TGF-b), which are all heparin-binding molecules (Sasisekharan et 
al., 2002, Turnbull et al., 2001).  
1.3.1 HS structure 
HS is a linear polysaccharide characterized by α 1-4 linked disaccharide repeating 
unit backbone of uronic acid (either a D-glucuronic acid, GlcA, or L-iduronic acid, 
IdoA) covalently linked to D-glucosamine GlcN units, arranged in sulfated (NS) and 
acetylated (NA) regions (Figure 1.2). The complexity of HS structure derives from 
the different modification of disaccharide units individually within an 
oligosaccharide chain. 48 theoretically disaccharide units can form up to 100-200 
disaccharide units of complete HS chains. Modification of HSPGs exist at the 6-O 
(and rarely 3-O) positions of glucosamine, and 2-O position of uronic acids. 
Therefore, these possible modifications result in fine structural diversity 
(Sasisekharan et al., 2002). The domain structure of HS chains consisting of NS 
domains of various length and sulphation, spaced part by NA domains (Turnbull & 
Gallagher, 1990). Modified regions (NS domains or S-domains) display highly 
diverse saccharide sequences with specific patterns of N- and O-sulphation and of 
GlcA conversion to IdoA residues. Unmodified regions (NA domains) consist 
repeating GlcA-GlcNAc disaccharide units. Other parts of HS chains (NA/NS) 










Figure 1.2 Schematic diagram of chemical structure of HS.  A disaccharide repeat unit backbone 
of uronic acid and glucosamine. The configuration of R groups result in the heterogeneity of HS 
molecular structure. (red; R1 corresponds to O-sulphation at C2 of uronic acid; R2 corresponds to O-




Figure 1.3 Heparan sulphate proteoglycans (HSPGs) overall structure. HS chains are attached to 
the core protein O-linked through serine residues. Binding sites for ligands are defined by the 
arrangement of sulphate groups (NS, 2S, 3S, 6S) and uronic acid epimers (GlcA and IdoA). From 
(Turnbull et al., 2001). 
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1.3.2 Heparan sulphate proteoglycans 
HS chains are usually covalently linked to specific serine residues present in the core 
proteins to form HS proteoglycans (HSPGs), which are expressed mostly on the 
mammalian cell surfaces and in the ECM (Turnbull et al., 2001). HSPGs are divided 
into two main families at the cell surface (syndecans (SDCs) and glypicans (GPCs)), 
and three major families in the ECM (perlecan, agrin and collagen type XVIII) 
categorized by their various core proteins (Figure 1.4) (Sarrazin et al., 2011). The 
syndecan family is composed of four members, ranging from 22-45 kDa in their 
molecular weights (Bonneh-Barkay et al., 1997, Sarrazin et al., 2011). It was found 
that syndecans could also contain a CS chain attached to a serine residue near the cell 
membrane. The syndecans have an extracellular, transmembrane and cytoplasmic 
domain (Bernfield et al., 1999). Syndecan sub-families differ in their tissue 
expression patterns and functions. For example, epithelial cells are rich in SDC-1 and 
are  involved leukocyte-endothelial interactions, wound healing and angiogenesis 
(Stepp et al., 2002), while SDC-2 is the major syndecan of lung, kidney, cartilage, 
bone, and stomach (Essner et al., 2006). SDC-3 is rich in the neuronal cells and brain 
(Kaksonen et al., 2002). SDC-4 is expressed through all embryonic development 
stages and regulates cell migration, adhesion and matrix structure (Couchman et al., 
2001). 
There are six members in the glypican family; their molecular weights are about 60 
kDa. Glypicans are found in various tissues and are involved in biological 
development and the embryonic central nervous system (Bernfield et al., 1999). The 
difference between syndecans and glypicans was found in their core proteins as 
glypican are anchored in the membrane through a glycosylphosphatidylinositol (GPI) 
anchor, whilst syndecans cross the lipid bilayer with a transmembrane region (Lin, 
2004). 
Perlecan and agrin are multi-domain HSPGs found in the ECM. Perlecan has a 
molecular weight of ~400 kDa (Sarrazin et al., 2011) and is found in the connective 
tissues, lung, kidney and has a vital role in development and homeostatic processes 
(Handler et al., 1997). Agrin has about 212 kDa molecular weight (Sarrazin et al., 







neuronal HSPG (Bezakova and Ruegg, 2003, Kröger and Schröder, 2002).  
Collagen XVIII has triple-helical domains and some splice variants are interrupted 
by non-collagenous parts carrying about three HS chains. It is located in the 
basement membrane of various tissues and has a molecular weight of ~ 150 kDa 





Figure 1.4 Classification of cell surface and ECM HSPGs. (A) Syndecan is transmembrane 
proteins that contains a short conserved C-terminal cytoplasmic domain. HS and CS side chains are 
attached to serine residues distal from the extracellular domain. (B) The glypican core proteins are 
linked to the plasma membrane by a GPI linkage. HS attachment sites in glypican are located adjacent 
to the plasma membrane. (C) Perlecans are large multidomain proteins and secreted HSPGs that carry 










1.3.3 Heparin: a close relative of HS 
In 1916, heparin was discovered as an inhibitor of blood coagulation and received 
increasing attention over the next 20 years when it was first tested as an 
anticoagulant drug in patients in the mid 1930s (Wardrop and Keeling, 2008). 
Heparin received its name from the hepatic tissue from which it was first isolated and 
studied. The difference between heparin and HS is related to both quantitative 
differences in sulphation, and location of expression (Table 1.1) (Wardrop and 
Keeling, 2008). HS is expressed on the ECM and cell surfaces of almost all 
mammalian cells, while heparin is synthesised by mast cells and stored in its 
granules (Gandhi and Mancera, 2008, Sasisekharan et al., 2002). As described 
previously, HS and heparin share the same polysaccharide backbone which is a 
repeating uronic-glucosamine disaccharide. Only the degree of sulphation differ in 
these two molecules, although the biosynthesis pathway is the same (Gandhi and 
Mancera, 2008). HS consists of a lower level of sulphation, higher level of acetylated 
glucosamine and lower level of iduronic acid than heparin (Gandhi and Mancera, 
2008). Approximately 85% or more of GlcN residues are N-sulphated and 
approximately 70% or more of the uronic acid is converted to IdoA in heparin. 
Consequently, heparin is typically represented by approximately 1.8–2.4 
sulfates/disaccharide, compared to heterogenous HS sulphation represented by 0.8-
1.8 sulphates/disaccharide (Casu and Lindahl, 2001, Dreyfuss et al., 2009, 
Rabenstein, 2002). Overall, heparin is very well-studied and understood, and is 
widely available in large quantities, and is therefore a long standing model or proxy 












Table 1.1 Structural differences and similarities of heparin and heparan 
sulphate  














Intracellular component of mast 
cells (liver, lungs and skin) 
Extracellular component found 
in the basement membrane and 
as a ubiquitous component of 
cell surface 









units   
 
Major and minor disaccharide-repeating units in heparin and heparan sulphate (X= 
hydrogen (H) or sulphate (SO3⁻), Y=acetyl (Ac), sulphate (SO3⁻) or hydrogen (H)) 










1.3.4 HS Biosynthesis 
Heparin and HS chains are synthesized by a family of enzymes occurring in the 
Golgi apparatus. The biosynthetic pathway employs chain initiation, elongation and 
modification, produced via about eleven different types of membrane bound 
enzymes, many of which are present in multiple isoforms (Figure 1.5). HS chains are 
heterogeneous polysaccharides, due to the fact that these membrane bound enzymes 
do not act to completion (Aikawa et al., 2001, Bernfield et al., 1999).  
1.3.4.1 Initiation of heparin/HS chains 
The first step of heparin/HS biosynthesis is initiated with the addition of xylose (Xyl) 
to core protein serine residues; uridine- 5’-diphosphate (UDP)-Xyl is transferred by 
xylosyltransferase-1/2 to specific acceptor serine residue in the PG core protein, to 
initiate a tetrasaccharide linkage region. There are two XylT isoforms in mammals, 
which both have a role in PG biosynthesis. Two Gal residues are then attached by 
galactosyltransferases-1/2 and GlcA is attached by glucuronyltransferase-1, to 
complete the ‘‘linkage tetrasaccharide’’, - β GlcA-1,3-β Gal-1,3-β Gal-1,4-β Xyl-Ser 
(Pönighaus et al., 2007). 
1.3.4.2 Elongation of heparin/HS chains 
HS chain synthesis is determined by addition of the first GlcNAc residue to the 
tetrasaccharide linker, catalyzed by the action of two heparin/HS dual activity co-
polymerase enzymes (GlcNAc transferase II and GlcA transferase II), which are the 
products of exostosin-like-1/2 related genes (EXT1 and EXT2) (Kim et al., 2001). 
The HS/heparin chain is then polymerized by the continued alternate addition of 
GlcA followed by GlcNAc residues, to form heparin/HS chains, consisting about 50-









1.3.4.3 Modification of HS/heparin chains 
The heparin/HS chain is then modified by various enzymes in the Golgi apparatus 
membranes (summarised in Table 1.2). After initial polymerization steps, a series of 
modification reactions are involved to modify N-deacetylation and N-sulphation of 
the GlcNAc, epimerization of GlcA to IdoA, and O-sulphation at various positions. 
The first modification step is the replacement of the NAc group of GlcNAc residues 
with NS group forming N-sulphated glucosamine (GlcNS); this is catalyzed the N-
deacetylase/N-sulphotranferases (NDSTs), of which four isoenzymes have been 
identified (Raman et al., 2005). Next, the epimerization step is mediated by 
glucuronosyl C5-epimerase, a single enzyme encoded in mammals. C5-epimerase 
catalyzes the conversion of GlcA monosaccharides to form IdoA residues; this 
occurs only in regions with Glc-NS residues (Li et al., 1997). Following the 
epimerization, several sulphotransferase modify the growing NS-domain. 2-O-
sulfation is added at C2 of IdoA or GlcA residues by 2-O- sulphotransferase (2OST). 
Next, further O-sulphation of HS is catalyzed by 6-O-sulphotransferase (6OST) at 
the C6 position of GlcNAc and GlcNS residues. Finally, the 3-O-sulphotransferases 
(3OSTs) act occasionally to add 3-O-sulphates at C3 position of GlcNS residues. 
Importantly, these modification steps are not template-driven and do not occur on all 
potential sites; thus these enzymatic reactions create regions of variable structure and 
sulphation, though cell and tissue specific patterns are known to be generated, 
indicating that these processes must be subject to tight regulatory control by as yet 












Figure 1.5 The biosynthesis of HS chains. HS chains are initiated by synthesis of a tetrasaccharide 
linkage attached to serine residues of the core protein, followed by elongation that is achieved through 
the co-polymerase complex formed by EXT1 and EXT2. The HS chain is then modified sequentially 
by NDSTs, C5 epimerase, and 2-O, 6-O and 3-O sulphotransferases to generate mature HS. 
Monosaccharide is represented according to the guidelines of the Nomenclature Committee of the 
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Table 1.2 HS biosynthetic enzymes and their respective roles 
Enzyme Name  Function  
EXT1 Exostosin1 
 
First step of chain elongation; Alternating 
addition units of GlcA and GlcNAc to the 
non-reducing end of the chain (Busse et 
al., 2007). 
EXT2 Exostosin 2 
 
First step of chain elongation; Alternating 
addition units of GlcA and GlcNAc to the 
non-reducing end of the chain (Busse et 
al., 2007). 
HS20ST Heparan sulphate 2-O 
sulphotransferase 
 
The sulfo group is transferred by 
HS20ST from 3'-phosphoadenosine 5'-
phosphosulfate (PAPS) to the 2-OH 
position of the uronic acid adjacent to N- 
sulphated glucosamine (Kreuger and 
Kjellén, 2012) 
HS30ST1-6 Heparan sulphate 3-O 
sulphotransferases (6 
isoforms) 
The sulfo group is transferred by 
HS30ST1-6 PAPS to the 3-OH position 
of the glucosamine which are N- 
sulphated (Kreuger and Kjellén, 2012) 
HS60ST1-3 Heparan sulphate 6-O 
sulphotransferases (1-3) 
 
The sulfo group is transferred by 
HS60ST1-3 from PAPS to the 6-OH 
position of the glucosamine which is N- 





Replaces acetyl groups with sulphate 
groups at the N-position of the 
glucosamine (Kreuger and Kjellén, 2012) 
Sulf1 6-O-endosulphatase 
 
Removes 6-O sulphate groups (Turnbull 
et al., 2001). 
Sulf2 6-O-endosulphatase 
 
Removes 6-O sulphate groups (Turnbull 





Conversion of glucuronic (GlcA) acid to 







1.4 Chemically modified heparins 
Several attempts have been made to produce and characterize chemically modified 
heparin derivatives by selective chemical de-sulphation by different groups  (Figure 
1.6); this work was undertaken with the aim of producing systematically simplified 
structures of authentic heparin with which to correlate activity relationships and 
generate potential novel therapeutics. 
Methods to produce these saccharides employ different modification of the widely 
available heparin polysaccharide chain. Compared to heterogeneous HS structures, a 
relatively homogeneous polysaccharide is produced by carefully controlled addition 
or removal of the N-acetamido, N-sulfonamido, and O-sulfoxy modifications 
(Powell et al., 2004, Yates et al., 1996). These saccharides can then be used as 
mimetics of HS domains. The characterization of chemically modified heparins is 
normally achieved by nuclear magnetic resonance and disaccharide composition 
analysis; however characterization of these saccharides are also undertaken by other 
techniques such as infrared spectroscopy and mass spectrometry (Grant et al., 1989, 
Yates et al., 1996). Reports of modified heparins that have been characterized have 
described some of the more accessible modifications of heparin, and used as a 
marker for the association of biological activities with existence or the absence some 
groups, in order to establish structure-activity relationships. Several studies have 
established that there is a relationship between a change in activity or interaction and 
the modification types (Chen et al., 2009, Guimond et al., 2006, Irie et al., 2002, 
Yates et al., 2004). Chemically modified heparins were found to be inhibitors of the 
BACE-1 protease involved in Alzheimer’s disease (Patey et al., 2006, Scholefield et 
al., 2003). Moreover, chemically modified heparin were found to block L and P-
selectin-mediated cell adhesion, resulting in prevention of tumour metastasis in 
human colon and ovarian carcinoma respectively (Chen et al., 2009, Wei et al., 
2004). In addition, chemically modified heparin can be used to disrupt the red blood 
cells resetting in severe and cerebral malaria caused by Plasmodium falciparum 








Functionally distinct HS sequences are difficult to define, and the isolation of HS 
material with a given bioactivity in useful quantities is very difficult. As mentioned 
before, the closely related polysaccharide heparin is thus usually used as an 
alternative source of HS, although this approach has several drawbacks. Heparin is 
homogeneous, highly sulphated and consisting of mostly highly charged sequences, 
and thus model only some NS-domains. They also possess some non-specific 
binding activities towards basic proteins, making it difficult to maintain required 
activity but avoid unwanted side effects. This emphasizes the importance of applying 
chemically modified heparin derivatives in initial structure-function studies 
especially into the importance of particular sulfate and acetyl groups (Guimond et al., 
2006). 
!
Compound Name Symbol R1 R2 R3 
1 *Per-sulphate heparin PerS H SO3 SO3 SO3 
2 NAc heparin NAc H SO3 SO3 NAc 
3 2 deS-NS hepar n 2 deS-NS H H SO3 SO3 
4 6 deS-NS heparin 6 deS-NS H SO3 H SO3 
5 2 deS-NAc heparin 2 deS-NAc H H SO3 NAc 
6 6 deS-NAc heparin 6 deS-NAc H SO3 H NAc 
7 2, 6 deS-NS Heparin 2,6 deS-NS H H H SO3 
8 2, 6 deS-NAc Heparin 2,6 deS-NAc H H H NAc 
9 Heparin  SO3 SO3 SO3 
 
Figure 1.6 Predominant disaccharide repeat structures of chemically modified heparins 
(compounds 1-9). The heparin polysaccharide derivatives were prepared from porcine intestinal 
mucosal heparin (Celsus), as described (Yates et al., 1996). * A disaccharide repeat unit backbone of 
uronic acid and glucosamine of PerS H consists of anion group (OSO3−), while heparin consists of 








1.5 HS-protein interactions 
Hundreds of HS/heparin-interacting proteins have been identified to, termed the HS 
interactome (or “heparactome”). These interactions are highly diverse in their nature, 
as they include growth factors, enzymes, cytokines, enzyme inhibitors and ECM 
components (Bernfield et al., 1999, Turnbull et al., 2001). HS/heparin protein 
binding is thought to be mediated principally by anionic binding between the 
negatively charged sulphate and carboxylic acid groups on HS/heparin chains with 
basic amino acids, particularly arginine and lysine, on proteins, though hydrophobic 
interactions and Van der Waals forces have also been implicated in some interactions 
(Fromm et al., 1995, Rabenstein, 2002). 
1.5.1 HS-growth factor interactions 
Growth factors (GF) represent a large family of soluble proteins that regulate a wide 
range of cellular responses, such as, cell growth, proliferation, differentiation, 
migration and apoptosis. For many of these GFs, signaling is regulated via their 
binding to HSPGs on cell surface and the ECM (Forsten-Williams et al., 2008). 
Examples of some of these HS-GF interactions are provided below.  
1.5.1.1 HS-FGF complex 
The Fibroblast growth factor (FGF) family consists of about 22 members to date, 
most of which bind to HS. FGFs transmit their signaling depending on their protein 
receptor specificity, but HS also binds to tyrosine kinase receptors (FGFRs), such as 
FGFR1, 2 and 4 through heparin-binding sequences (Loo et al., 2001, Ornitz, 2000, 
Powell et al., 2002), which activate the intracellular signaling pathway responses. 
The HS-FGF interaction has been extensively studied.  FGF activity depends on 
formation of a HS-FGFR-FGF high affinity complex (Guimond and Turnbull, 1999). 
The mechanism of interactions between FGF with HS involves basic amino acids on 
the FGFs interacting with O-sulphate group and carboxylates in the HS chain. 
However, HS binding with FGF-2 was found to be only 30% ionic (Guimond et al., 
1993). The structural determinants of HS interactions with FGF-2 and its receptors 







HS/heparin needed to serve as co-receptors when added along with FGF-2 to HS-
deficient mouse fibroblasts has been studied, showing that around 12 mers are 
optimal for activity (Cole et al., 2010, Guimond et al., 2006, Jastrebova et al., 2006). 
Furthermore, activity is dependent 6-O sulfate in addition to IdoA2S and NS, 
whereas binding to FGF-2 alone without its receptors requires NS and IdoA2S 
(Figure 1.7) (Guimond et al., 1993). 
1.5.1.2 HS-VEGF complex  
The vascular endothelial growth factors (VEGFs) are a family of endothelial cell 
mitogens. VEGF is identified as a heparin-binding angiogenic growth factor, which 
regulates angiogenesis via promoting endothelial cell proliferation and migration 
(Zhao et al., 2012). In addition, VEGF and its receptors play a pivotal role in most 
aspects of vascular development and function such as tumour angiogenesis 
regulating tumour growth, invasion and metastasis (Hicklin and Ellis, 2005). As a 
result of alternate mRNA splicing, the vegf gene forms at least six VEGF isoforms. 
Each isoform has different biological properties due to each having different 
structures, including the presence or absence of short C-terminal heparin-binding 
domains (HBDs) (Ruhrberg, 2003). The functions of VEGF are flexible, related to 
expression of the different isoforms with various affinities for HS, linking it to 
different signaling receptor complexes.  
VEGF-A isoform (VEGF 165) is the most potent isoform, and binds with moderate 
affinity to heparin; it generates a homodimer containing two disulfide linked 
polypeptides of amino-terminal and disulfide-linked units with two identical 5-
residue C-terminal fragment heparin-binding sites (Zhao et al., 2012). The 
interaction of HS with VEGF regulates the affinity of VEGF165 for its signaling 
receptors. HS contributes to the strength of VEGF165 interactions via 2-O, 6-O, and 
N-sulfation groups, with emphasis on the 6-O sulfates. Moreover, it has been shown 
that an oligosaccharide of about seven monosaccharide residues was sufficient to 
fully occupy the heparin-binding site of a single VEGF165 monomer, suggesting that 
longer sequences with 2 such sites are required to interact with the homodimer of 
VEGF (Robinson et al., 2006). Various studies have found that a lack of HS-VEGF 







uncharacteristic extracellular localisation of VEGF; this indicates that HS plays a 
pivotal role for HS in controlling VEGF diffusion (Xu et al., 2011). 
A number of other HS-growth factor interactions such as hepatocyte growth factor 
(HGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and 
transforming growth factor beta (TGFβ) have been reviewed by Nigam and Bush 
(Table 1.3) (Nigam and Bush, 2014).  
 
!
Figure 1.7 Model of interactions between HSPG, FGF and FGFR. Heparin induced dimerization 
and activation of the FGF receptors. The HS chain of HSPG can bind with FGF molecules for 
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Table 1.3 Summary of the HS selectivity for selected GFs. 
Proteins Selectivity 
Growth factors: 
Fibroblast growth factors 
(FGFs) FGF-1 and FGF-2 
2-O and 6-O sulfation and NS and IdoA2S required 
for binding for FGF-2, whereas NS and IdoA2S 
were sufficient for binding of FGF-2 alone without 
the receptor (Guimond et al., 1993). 
Vascular endothelial growth 
factor (VEGF) 
2-O, 6-O, and N-sulfation, with emphasis on the 6-
O sulfates (Robinson et al., 2006), no selective 
sequence. 
The hepatocyte growth 
factor (HGF)  
6-O-sulfated, NS glucosamine and IdoA, the 
minimal binding sequence 10-12-mer in length 
(Catlow et al., 2003), no selective sequence. 
Transforming growth factor 
beta (TGF-β) (TGF-β1 and 
TGF-β2) 
Heparin and high sulfated HS. Requires high level 
of N-sulfation for binding; no selective sequence 
(Nigam and Bush, 2014) 
Platelet-derived growth 
factors (PDGFs) 
Six–eight monosaccharide units with N, 2-O, and 
6-O-sulfate groups all contribute to the interaction 
(Feyzi et al., 1997); no selective sequence. 
Heparin-binding epidermal 
growth factor (HB–EGF) 
Heparin/ HS optimizes activity (Nigam and Bush, 











1.6 Stem cells 
Stem cells have been recognized as multi-or pluripotent undifferentiated cells with 2 
key properties; firstly to be able to divide and multiply in their unspecialized state to 
generate more stem cells (self-renewal), and the ability to differentiate to give rise to 
cells with specialized functions. However, in most cases, stem cells do not 
differentiate directly to specialized cells. They give rise to progenitor cells that have 
more restricted potential, with a limited capacity to self-renew before differentiating 
into cell types of the specific tissue of origin (Florio, 2011). Normal stem cells are 
generally assigned to one of the following two categories depending on their source; 
embryonic stages are totipotent and pluripotent cells that are a capable of forming 
every cell in the embryo and placenta; or somatic (adult) stem cells which are more 
specialized, continuously forming a range of different cell types for their specific 
tissue compartment (Nemeth and Karpati, 2014, Wagers and Weissman, 2004). 
Normal stem cells in mammals exist in a specialized microenvironment of each 
tissue named ‘niches’ that are anatomically defined, comprised of components of 
ECM, and which support stem cell survival. Normal stem cells from different tissues 
have been shown to be slowly cycling so that only a few times during the lifetime of 
a mouse, a number of these stem cells enter the cell cycle (Greco and Guo, 2010). In 
embryonic development, different niche factors can act on embryonic stem cells to 
change gene expression and promote their differentiation and proliferation for the 
development of the fetus. In contrast adult stem cell niches maintain these cells in a 
deactivated state, for example after tissue injury, the surrounding micro-environment 
can then signal to stem cells to either promote differentiation or self-renewal to form 
new tissues (Florio, 2011, Greco and Guo, 2010). In different tissues, adult stem cell 
niches differ in their cellular location, structure and composition. So far, these have 
been identified in intestine, brain, testis, skin and bone marrow but all tissues and 








1.7 Cancer stem cells (CSCs) 
1.7.1 CSCs: definition and characteristics 
While embryonic and adult stem cells are an integral part of a healthy organism, 
cancer stem cells (CSCs), also known as tumour-initiating cells (TICs), may enhance 
the status of the disease process. The model of stem cells for the regulation of 
plasticity in adult tissues gave new impetus to study of tumours from several tissues 
(Florio, 2011). The CSC hypothesis is contrary to previous understanding of a 
stochastic model that any cell within the tumour is capable of limitless tumour 
growth, with ability to spread throughout the body, and become tumorigenic.  In 
contrast, the CSCs model predicts that only a subset of tumour cells is tumorigenic 
and can generate a new tumour (Figure 1.8). These cells are defined as capable of 
self-renewal and differentiation. An important implication is that CSCs should be 
targeted to develop effective anti-cancer therapies (Girouard and Murphy, 2011). 
Although a small subset (<1%) of cancer cells can extensively proliferate and form 
new tumours, these components are significant because they can lead to tumour 
recurrence, chemo/radio-therapy resistance, and metastasis (Han et al., 2013). Stem 
cell fate depends on controls from intrinsic (gene mutations) and extrinsic 
(microenvironment alterations), and losses or changes in these factors could 
contribute to the carcinogenic process (Florio, 2011, Han et al., 2013).  Therefore, 
CSCs can be defined through four main CSC characteristics; self-renewal, 
differentiation, tumorigenicity and specific surface markers. CSCs subsets are 
maintained through various generations, indicating a self-renewing capacity. In 
addition forming tumorigenic daughter CSCs by symmetrical cell division, the 
pluripotent CSCs can also produce non-tumorigenic bulk populations by 
asymmetrical cell division. Moreover, a small subset of CSCs have tumorigenic 
potential when transplanted into animals and the CSCs subset can be separated from 
the non-stem cells by cell surface markers. Thus, the main two characteristics of 








Figure 1.8 Stochastic versus CSC models of carcinogenesis. (A) The stochastic model predicts that 
every cell within the tumour will be able to randomly become tumorigenic. (B) The CSC model 
predicts that only a small number of cells, known as CSCs, are able to give rise to new or recurring 
tumours and produce differentiated tumour cells. 
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1.7.2 CSCs: isolation and identification 
Like somatic stem cells, the first identification of the hierarchy of CSCs was studied 
in the haematopoietic system. In the 1970s, studies in leukemia demonstrated that a 
small fraction of tumour cells were able to proliferate widely. These cells are called 
leukemic stem cells (Bonnet and Dick, 1997, Dick, Gil et al., 2008, Girouard and 
Murphy, 2011, Wagers and Weissman, 2004). In the 1990s, Lapidot and colleagues 
isolated leukemic stem cells and found a cell surface phenotype (CD34+/CD38-) in 
acute myeloid leukemia (AML) patients (Lapidot et al., 1994). They demonstrated 
that tumour forming cells were found when injected into non-obese diabetic 
(NOD)/severe combined immunodeficiency (SCID) mice. In addition, CD34+/CD38-⁻ 
cells did not initiate the formation of tumours, as these cells were similar to the 
phenotype of normal hematopoietic stem cells. Since their recognition in leukemia, 
CSCs have been identified in a variety of solid tumours such as, liver, prostate, 
A) Stochastic model 















breast, pancreatic, skin, and colon tumours (Gil et al., 2008, Girouard and Murphy, 
2011). 
The identification and isolation of CSCs from mass cell lines or tumour tissues via 
various methods will be important to research on tumour initiation, development, 
diagnostics and therapeutics. CSC populations can be identified based on multiple in 
vitro assays, such as Hoechst dye exclusion side population cells (SP) (Mannelli and 
Gallo, 2012), sphere forming assays (Cao et al., 2011), detection of enzymatic 
activity of aldehyde dehydrogenase-1 (ALDH1) (Sun and Wang, 2010), detection of 
surface markers (Dou and Gu, 2010), serial colony-forming unit assays (Dou et al., 
2007) and migration assays (Biddle et al., 2011). Since normal and CSCs have much 
in common, the properties of SCs, such as the expression of specific surface markers, 
have been used to identify and isolate CSCs. Although all these in vitro assays are 
used to demonstrate the CSC phenotype, in vivo assays are considered as the gold 
standard, such as using the animal models for serial transplantation assays, which can 
enhance the ability of in vitro assays to detect CSCs (Han et al., 2013).  
1.7.3 CSC markers 
CSC populations can be identified and isolated based on the presence or absence of 
various cell-surface proteins (markers) and cytoprotective enzymes (such as ALDH) 
either singly or in combination. Some CSCs markers include CD133+ (brain tumour), 
CD34+/CD38- (leukaemia), CD44+/CD24-, ALDHI+ (breast cancer), and CD133+, 
EpCAM high CD44+, ALDHI+ (colon cancer) among many others (Kamijo, 2012). 
Fluorescence-activated cell sorting (FACS), flow cytometry, immunofluorescent 
staining and polymerase chain reaction (PCR) analysis are used to detect these 
specific cell surface markers of CSCs and are widely used to identify, isolate and 
characterize the CSC subpopulation (Mannelli and Gallo, 2012, Pozzi et al., 2015, 









1.7.3.1 The following markers have been used in the study of breast cancer 
stem cells (BCSCs): CD44 marker  
CD44 is a transmembrane glycoprotein, generally binding to its ligand hyaluronic 
acid as a receptor, promoting cell division, adhesion, migration and signalling. This 
binding is normally responsible for regulating cellular signaling and other biological 
process within cells (Jaggupilli and Elkord, 2012). CD44 contains three major 
domains, including extracellular (ectodomain), transmembrane and an intracellular 
domain. The interaction between extra cellular matrix (ECM) glycosaminoglycan 
hyaluronan and CD44 are currently an exciting area of investigation (Yan et al., 
2015). Hyaluronan has been found to be enriched in the SCs niche and has an 
important role in the behaviour of CD44 in CSCs. The molecular weight of CD44 is 
around 85-200 KDa, encoded by a single gene, containing 20 exons. The standard 
isoform, referred to as CD44s, comprising exons 1-5 and 15-20. The variable exons 
are designated as v1-v10, respectively (Sahlberg et al., 2014).   
1.7.3.2 CD24 marker  
CD24 is a small cell surface glycoprotein, expressed on the external side of the 
plasma membrane. It is of considerable importance in cell differentiation and 
expressed by cells involved in the immune system, such as hematopoietic 
subpopulations of many B and T lymphocytes and differentiating neuroblasts 
(Sahlberg et al., 2014). It also expressed on granulocytes and many carcinomas 
(Ghuwalewala et al., 2016). CD24 has an important role in cell adhesion, invasion 
and migration as measured by various in vitro assays (Keysar and Jimeno, 2010). In 
addition, it is a determinant of stemness in many types of cancer. The distribution of 
CD24 in different type of cancer is under dispute, although patients with colorectal 
cancers expressed CD24 highly and a CD24 positive subset of colon cancer cells 
have these stem-like properties. In contrast, tumor initiating cells from breast cancer 
and head-and-neck cancer have been identified based on being CD24 negative 
(Sahlberg et al., 2014). CD24 consists of a 27 amino-acid, extensive core that is O- 
and N-glycosylated. The linkage of the encoded protein to the cell membrane is via a 







1.8 Breast cancer 
1.8.1 Normal breast cancer  
Breast cancer is one of the most common causes of death through malignant tumours 
among women worldwide, despite different types of treatment regimens such as 
chemotherapy, radiotherapy and endocrine therapy (Ghebeh et al., 2013, 
Prabhakaran et al., 2013, Xu et al., 2012). The main cause of death in most patients 
suffering from breast cancer which is metastatic, having evolved from the primary 
tumour (Lobba et al., 2012). Metastasis of breast cancer cells (BCCs) is the spread 
from the primary tumour to specific organs, depending on a multi-step process 
including: detachment of metastatic cells from the primary site, migration and 
intravasation to the blood supply, circulating through the body, adhesion to 
vasculature, extravasation at the next site via tissue endothelium (Croker et al., 2009, 
Mellor et al., 2007). This process is parallel to the normal leukocyte mechanism 
mediated by chemokines (Müller et al., 2001).  
Breast cancer is highly heterogeneous and classified into five sub-types based on 
histopathological parameters such as receptor status (estrogen (ER), progesterone 
(PR), and/ or human epidermal growth factor receptor 2 (HER2)). These sub-types 
are: luminal A, luminal B, HER2, basal and normal and summarised in table 1.4. 
Each of these subtypes has different prognosis and response to treatment (Holliday 
and Speirs, 2011, Prabhakaran et al., 2013). Basal-like and claudin-low tumors were 
found to lack the ER, PR and HER2 receptors, and are thus referred to as triple-













Table 1.4 Molecular classification of breast carcinoma 
Classification Immunoprofile Other characteristics Example cell 
lines, adapted 
from (Neve et 
al., 2006, Prat et 
al., 2010) 
Luminal A ER+, PR+/-, 
HER2- 
Cells are more 
differentiated and can be 
treated with chemotherapy 
MCF-7, T47D, 
SUM185,  
Luminal B ER+, PR+/-, 
HER2+ 
Cells are more 
differentiated and can be 
treated with chemotherapy 
BT474, ZR-75 
HER2 ER-, PR-, 
HER2+ 
Cells are more 





Basal ER-, PR-, 
HER2- 
Cells are less 
differentiated, low 
response to chemotherapy 
MDA-MB-468 
(claudin-low) ER-, PR-, 
HER2- 
Cells are less 
differentiated, low 




1.8.2 Breast cancer stem cells (BCSCs) 
There is a significant base of literature indicating that the heterogeneity of breast 
cancer tissues may be rooted in the existence of a small subset of CSCs or TICs 
(Gong et al., 2010), with the ability to self-renew and differentiate to support tumour 
growth (Girouard and Murphy, 2011). This theory could explain the failure of 
traditional chemotherapeutic treatments. It has been shown that BCSCs are more 
resistant to chemotherapy and radiotherapy than normal BCCs due to multiple 
molecular mechanism (de Beça et al., 2013, Prabhakaran et al., 2013). 
Several studies have identified a subpopulation of BCSCs based on cell surface 
markers enriched in these cells, with the CD44+/CD24-/low and ALDH+ phenotype the 
most consistently associated with cells displaying stem-like characteristics (de Beça 







of BCCs was first identified by Al-Hajj and colleagues, who found that as few as 
about 100-200 BCSCs with the CD44+/CD24-/low phenotype were able to initiate new 
tumours when introduced into NOD/SCID mice (Al-Hajj et al., 2003). In addition, 
two other cell surface markers have become a standard combination for identifying 
human normal mammary gland cells: Ep-CAM (epithelial specific antigen, ESA) and 
CD49f (α-6-integrin) (Ghebeh et al., 2013). These CSCs have enhanced invasive 
abilities, chemo/radio resistance and poorer prognosis (Olsson et al., 2011). 
1.8.3 Breast cancer cell lines as models of mammary cancer stem cells 
Working with CSC sub-populations derived from cell lines has many advantages, as 
models to further understand the biology of CSCs and therapeutic targets. Triple-
negative breast cancer (TNBC) is the most aggressive and lethal subtype of BCC line 
and is characterised by the absence of HER2, PR and ER receptors. It still poses a 
major challenge (Holliday and Speirs, 2011).  Recently, various studies have also 
demonstrated that angiogenesis plays a pivotal role in the TNBC pathogenesis 
(Ribatti et al., 2016, Rugo, 2012), resulting in the development of a number of novel 
and targeted therapies.  
1.9 Resistance of breast cancer to therapeutic 
1.9.1 CSCs are controversial 
The CSC theory is controversial, due to the existence of small subpopulations, which 
grow slowly in experiments that involve breaking down a tumour, taking out 
particular cells and then transplanting them. Existing traditional cancer treatments 
such as chemotherapy, radiotherapy, and endocrine therapy to treat cancer have been 
developed and widely used in clinic; these conventional treatments aim to eliminate 
the tumor and reduce the risk of metastasis, but they are non-targeting and tumour 
relapse often occurs after therapy, possibly related to the presence of CSCs/TICs 
(Figure 1.9) (Cojoc et al., 2015). The mechanism of BC resistance to therapies 
include various factors such as, high capacity for DNA synthesis, slow cell cycle 
kinetics, the microenvironment properties including hypoxia, anti-apoptosis proteins 
and multiple drug resistance membrane transporters (e.g., ABC transporters) (Cojoc 
et al., 2015, Holliday and Speirs, 2011). To achieve cancer remission or cure, 











Figure 1.9 Conventional cancer therapies versus CSC targeted therapies. Conventional therapy 
can diminish tumor burden but are not able to eliminate CSCs, which can later regenerate and regrow 
the tumour. If the CSCs are eliminated by CSC targeted therapy, there is tumor regression. It will be 
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1.9.2 BCSCs therapy 
Various types of BC treatments have been developed, including hormone therapy, 
chemotherapy, radiotherapy and surgery depending on the stage. Hormonal therapy 
such as Tamoxifin (Tam) and chemotherapy such as doxorubicin (Dox) and cisplatin 
(Cis) are widely used (Holliday and Speirs, 2011, Prabhakaran et al., 2013). Cisplatin 
and doxorubicin are chemotherapeutic anti-cancer drug that have been used 
extensively for the treatment of different types of cancers. Particularly, cisplatin has 
been used in breast cancer in combination with other chemotherapies resulting in 
synergistic or additive effects. The exact mechanism of how cisplatin and 
doxorubicin work are complex, but it is thought that they cause DNA damage by 
interacting with DNA. Cisplatin forms Pt-DNA, adducts at the 1,2-intrastrand 
crosslink, resulting in the activation of various signal transduction pathways 
(Prabhakaran et al., 2013). Doxorubicin  interacts with DNA, preventing formation 
of  the DNA double helix. Doxorubicin was found to induce autophagy. Tamoxifen 
is an estrogen receptor antagonist which blocks the estrogen effect via binding to its 
receptor as an antagonist. The tamoxifen/estrogen receptor complex stops the genes 
being switched on by estrogen. In addition, tamoxifen was found to induce 
autophagy and apoptotic cell death in estrogen-positive BCC lines (Holliday and 
Speirs, 2011). Thus, the identification of anti drugs that are involved in 
tumorigenesis and angiogenesis in TNBC, is essential for the development of 
therapeutic agents targeting this aggressive breast cancer subtype. 
1.9.3 Role of HSPGs in breast carcinoma and BCSCs 
Several lines of evidence demonstrate that the HSPGs syndecans have pivotal 
regulatory roles in various type of cancer cell behavior (Lim et al., 2015). For 
instance, SDC-4 has been reported to modulate cell invasiveness. Moreover, 
previous work by (Beauvais and Rapraeger, 2003) demonstrated that syndecan-1 
promotes cell adhesion and spreading with inhibition of cell invasion.  
Emerging evidence suggests that BCSCs are regulated by signal transduction 
pathways, such as IL-6/JAK2/STAT3 and Wnt pathways (Marotta et al., 2011, 
Okolicsanyi et al., 2014). HSPGs could have an important role in breast cancer by 







are reported to have an important role in breast cancer. High expression of syndecan-
1 in patients with breast cancer is associated with reduced overall survival of patients 
with breast cancer (Ibrahim et al., 2013, Okolicsanyi et al., 2014). In addition, 
(Ibrahim et al., 2013) found that knockdown of syndecan-1 reduced side population 
(SP) and ALDH1-positive cell pool of triple negative MDA-MB-231 and hormone 
receptor positive MCF-7 cells detected by flow cytometry technique. Other studies 
showed that an absence of syndecan-4 in breast cancer correlated with poor 
prognosis and aggressive breast cancer phenotype (Lendorf et al., 2011).  Side chain 
initiation and modification, with specific HS sulphation profiles have been 
investigated for a prominent role in breast cancer progression and metastases 
(Okolicsanyi et al., 2015). It was found that GPCs1-6 have a role in breast tumours. 
The expression of GPC-1 and GPC-6 appears to be significantly increased in MDA-
MB-231 and MCF-7 human BCCs, with moderately expression of glypicans-3 and 
glypicans-4 in both cell lines (Matsuda et al., 2001). These findings mark HSPGs as 
prominent contributor to breast cancer and BCSC.  
The use of HS-related compounds as antitumor chemotherapeutic agents has been 
reported in numerous studies. Low anticoagulant chemically modified heparin has a 
positive effect on P-selectin adhesion reduction in BCCs (Mi et al., 2009). In 
addition, HS/heparin oligosaccharides were found to inhibit HS-dependent tumor 
behaviour such as metastasis formation, tumour growth and migration (Mellor et al., 
2007). Moreover, GPC-3 has also been tested to inhibit aggressive behaviour on 
mouse breast cancer cell line LM3 via maintaining adequate levels of protective 
molecules (Gomes et al., 2013, Peters et al., 2003).  
1.10 CSC-targeted mechanisms and implications 
The intricate regulation of different signaling pathways has a pivotal role in 
embryonic and adult stem cells related to self-renewal, proliferation and 
differentiation; however, the aberrant activation or dysregulation of these signalling 
pathways may also enhance the formation of CSCs (Han et al., 2013, Karamboulas 
and Ailles, 2013). Therefore, signaling pathways in the biology of CSCs are 
increasingly being used to demonstrate mechanisms underlying tumour relapse and 







1.10.1 The signal transducer and activator of transcription 3 (STAT3) 
Interleukin 6 (IL-6) is an interleukin mediator involved in the regulation of the 
inflammatory and infection responses (Xie et al., 2012). The serum level of IL-6 is 
elevated in breast cancer, particularly in advanced metastatic breast cancer patients 
(Bachelot et al., 2003). Previous studies demonstrated that when the CD44+/CD24- 
sub-population of T47D human BCCs are exposed to IL-6, it results in promotion of 
the generation of CSCs by induction of epithelial mesenchymal transition (EMT) 
(Xie et al., 2012). 
The signal transducer and activator of transcription 3 (STAT3) protein is a member 
of a family of transcriptional factors. STAT3 protein is phosphorylated (pSTAT3) by 
receptor-associated janus kinase (JAK), dimerizes, and translocates into the cell 
nucleus (Wei et al., 2014). In particular, full activation of STAT3 protein may occur 
via tyrosine phosphorylation 705 in response to such ligands as IL-6 or EGF. 
Additionally, it becomes activated after phosphorylation of serine 727 via MAPK. In 
view of the important role of STAT3 in regulation of gene expression, STAT3 
promotes malignant stem cells of hematopoietic and various solid tumors such as 
breast and colon CSCs (Aznar et al., 2001, Wei et al., 2014). In addition a number of 
pieces of evidence have also suggested a role for IL-6/STAT3 signaling pathway in 
inducing or maintaining a CD44+/CD24- subpopulation of BCCs (Marotta et al., 
2011, Xie et al., 2012). Interestingly, (Ibrahim et al., 2013) demonstrated that 
Syndecan-1 silencing inhibited proinflammatory signaling in the BCC line (MDA-
MB-231) by downregulation of such receptors and ligands as IL-6/IL6-R, which was 
linked to eliminating STAT3 activation. This finding indicates that SDC-1 depletion 
decreases the SP and CSC sub-population isolated from MDA-MB-231 BCCs 












Figure 1.10 Cell surface HSPGs (Syndecan-1) modulates BCSCs properties through the IL-
6/STAT3, signaling pathways. siRNA-mediated knockdown of Syndecan-1 results in reduction of 
IL-6 and IL6-R expression, possibly due to a reduction of JAK activation. The reduction of the 
expression of IL-6 signaling pathway results in decreased constitutive downstream signaling (STAT3 
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1.10.2 MAP kinase signaling 
A family of protein kinases is one of the largest gene families identified in the human 
genome. Dysregulation and mutation of these proteins play vital roles in human 
disease.  Human protein kinase families are classified as protein-serine/threonine 
kinases, protein-tyrosine kinases, tyrosine-kinase-like proteins and protein kinase 
pseudogenes (pseudokinases). Mitogen-activated protein (MAP) is a member of the 
protein kinase family, consisting of serine and threonine cytoplasmic protein kinases, 
and has been subjected to conserved function and regulation in eukaryotes. This sub-
family includes the p38 kinase family, extracellular signal-regulated kinase (ERK) 
family and the c-Jun N-terminal kinase family (JNK). MAPK is activated by 
catalysing the phosphorylation of such substrate proteins as protein kinases, 
transcription factors and phosphatases, and other functional proteins. In common 
with all protein kinases, ERK1/2 consist N- and C-terminal extensions that are 
involved in signaling specificity (Lu and Xu, 2006, Roskoski, 2012). MAPK/ERK 
signalling pathway is a chain of proteins, located in the cell that induce a signal from 
a receptor on cell surface to the DNA in the nucleus of the cell. Abnormal regulation 
of ERK1/2 pathways has been reported in number of breast cancer progression 
models. In addition, CSCs can be derived from cultured mammary cells following 
ERK1/2 activation and induction of EMT (Whyte et al., 2009).  
FGF signaling is modulated and regulated at multiple levels both extracellular and 
intracellular. FGF ligands are regulated by binding to cell surface HSPGs or binding 
to FGFR–HSPG complexes as co-receptor for FGF ligands, enabling dimerization of 
FGFR intracellular domains and inducing intracellular tyrosine kinase 
phosphorylation (Guimond and Turnbull, 1999, Lin and Wang, 2010). Then 
downstream signaling from FGFR–HSPG results in phosphorylation cascade in 
proteins of the Ras-Raf MAPK pathway. Ras activation induces a further multistep 
phosphorylation cascade, resulting in the activation of MAPKs such as ERK1/2 
(Figure 1.11). Finally, pERK1/2 regulates the transcription of molecules correlating 










Figure 1.11 The role of HSPGs/ERK1/2 signaling in breast cancer. Cell surface HSPGs associated 
with FGF ligands form active dimers and activate the FGFR. FGF/FGFR/HSPG complex induces 
intracellular tyrosine kinase phosphorylation and docking of adapter molecules such as FRS2 protein, 
which in turn activates SOS and GRB2, which then further activates downstream pathways, including 
Ras-Raf-MAPK(ERK1/2). HSPG: Heparan sulfate proteoglycan; FGF: Fibroblast growth factor, 
FGFR: Fibroblast growth factor receptor; FRS2α: FGFR substrate 2α; GRB2: Growth factor receptor-
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1.11 Work leading to current studies  
Preliminary work from our group demonstrated that non-anticoagulant chemically 
modified heparin derivatives are required for inhibiting galectin-3-mediated 
endothelial cancer cell adhesion, angiogenesis and metastasis (Cheng et al., 2015). 
Moreover, FGF has been studied as a model example for regulation of HS-protein 
interaction. HS-FGF2 binding signaling is regulated through various FGFR isoforms 
and there is evidence that HS saccharides are receptor and ligand specific modulators 
of activity. Taken together, and considering the requirement of HS/FGF/FGFR 
binding in regulation downstream signaling such as MAPK and STAT3 in various 
types of cancer, it is likely that HSPGs facilitates FGF signaling and vice versa, in an 
HS-dependent manner, that is relevant to regulation of CSCs.  
This raised a number of questions to be addressed in the current study including; (i) 
is endogenous HS required for CSC functions?; (ii) do HS structures have a pivotal 
role in regulation of CSCs?; and (iii) could this information be exploited to 
synthesize artificial substrates with CSC regulatory properties?  
1.12 Project Aims  
From the above introduction, it is evident that HS is a highly sulphated 
polysaccharide found at the cell surface where it is known to interact with a variety 
of proteins important for tumour development. This interaction invokes changes in 
intracellular signaling pathways that can regulate cellular processes such as 
proliferation, differentiation, adhesion and migration. Evidence suggests that 
different forms of HS, with different degrees and patterns of sulphation, exist at the 
surface of different cell types where it performs cell type-specific functions. The 
broad aim of this thesis was to use HS, heparin and chemically modified heparin 
derivatives to explore possible roles for HS in the regulation of cell fate in cancer 









This will be achievable by:  
1. Determining markers (CD44 and CD24) that will allow CSC-like 
subpopulations to be distinguished in BCC lines. 
2. Developing this model system for characterizing differences between cell 
populations of normal and CSC (CD44-/CD24-, CD44+/CD24-, CD44-/CD24+
 
and CD44+/CD24+) sub-populations from BCC lines in terms of metastatic 
characteristics such as proliferation, invasion, migration, adhesion, apoptotic 
rates, clonogenic properties.  
3. Establishing whether interference with endogenous HS present in CSCs by 
addition of exogenous HS/heparin/modified heparins can alter the phenotype 
of CSCs, making them less likely to form tumours and/or more sensitive to 
chemotherapy.  
4. Investigating a potential role and mechanisms of action of exogenous 
HS/heparin/chemically modified heparins on CSCs via controlling signalling 
and other molecular pathways. 
Overall, this study will explore whether it is possible to regulate cancer cell 
phenotype by manipulating the stem cell niche via HS glycans, and begin to establish 
an understanding of the structure-activity relationships and molecular mechanisms 
involved, hoping ultimately to develop small molecule therapeutics that target CSCs 








2 Materials and methods 
2.1 Materials  
2.1.1 GAGs  
Porcine intestinal mucosal heparin (PMH) was purchased from Celsus Laboratories 
(www.heparin.com, Cat. No. PH-3005, Ohio; USA). Porcine mucosal heparan 
sulfate (PMHS) and chemically modified heparins (PerS H, NAc H, 2 deS-NS H, 6 
deS-NS H, 2 deS-Nac H, 6 deS-NAc H, 2,6 deS-NS H and 2,6 deS-NAc H) were 
contributed by Dr. Edwin Yates and Dr. Yasser Ahmed, Biochemistry Dept., 
University of Liverpool, UK.  
2.1.2 Antibodies and Dyes 
APC-conjugated human CD44 (clone: DB105) # 130-095-177; FITC-conjugated 
human CD44 (clone: DB105) # 130-095-195; Monoclonal CD24 antibodies human 
conjugated to FITC (clone: 32D12) # 130-095-952; CD24-FITC, human (clone: 
32D12) # 130-099-118; CD24-FITC, human (clone: 32D12) # 130-099-118;  
CD133/1 (AC133)-PE, human # 130-080-801; FITC-conjugated mouse IgG1 isotype 
control # 130-092-213; APC-conjugated mouse IgG1 isotype control # 130-092-214 
and PE- conjugated mouse IgG1 # 130-092-212 were bought from (MACS Miltenyi 
Biotec, UK); Annexin V, Alexa Fluor® 488 conjugate # A13201 was from Life 
technology, (Paisley, UK). Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 
(D13.14.4E) XP Rabbit mAb # 4370; P44/42 MAPK (Erk1/2) Antibody # 9102; 
Phospho-STAT3 (Tyr705) Antibody # 9131; STAT3 (D3Z2G) Rabbit mAb # 12640; 
Histone H3 (3H1) Rabbit mAb # 9717; Tubulin (11H10) Rabbit mAb # 2125 were 
purchase from Cell Signaling Technology, UK). Donkey anti-rabbit IgG-HRP:sc-
2313 was acquired from Santa Cruz Biotechnology, UK). DAPI, FluoroPureTM 
grade was purchased from Life technology (Paisley, UK # 000000010236276001). 
Propidium iodide (PI) # P4170-10MG was purchased from Sigma (Poole, UK). 
Precision Plus Protein™ WesternC™ prestained protein standardsv # 161-0376 were 








2.1.3 Cell lines 
Human BCC lines (MDA-MB-231, Hs578-T, MCF-7-A-1, T47D, and ZR-751-1) 
were kindly provided by Prof. Phililp Rudland and Dr. Roger Barraclough, 
Biochemistry Dept., University of Liverpool, UK.  
2.1.4 Chemotherapeutic regents 
All chemotherapeutic agents (cisplatin (Cis), tamoxifen citrate (Tam) and 
doxorubicin (Dox) were purchased from Sigma-Aldrich (Dorset, UK).  
Recombinant Human IL-6 Protein # 206-IL-010 was purchased from R&D Systems 
(Wiesbaden, Germany). FGF-2 was kindly provided by Prof. David Fernig 
Biochemistry Dept., University of Liverpool, UK.  
2.1.5 Hormone solutions 
Hydrocortisone-water soluble 100 mg # H0396 and Insulin from porcine pancreas 10 
mg # I5523 were purchased from Sigm-Aldrich, life technology (Dorset, UK). 
2.1.6 Reagents  
All common chemicals were of analytical grade; a list of chemicals, their suppliers 
and catalogue numbers shown in Table 2.1.  
Table 2.1 Chemicals used and suppliers 
!Reagents and Solutions Suppliers and catalogue 
number  
Accutase® solution, 100 ml Sigma-aldrich, Cat. No.  
A6964 
30% Acrylamide/Bis Solution 19:1 500 ml BIO-RAD, CAT.  No.161-
0154 
Agar ultrapure (Nobel agar) 100 gm Affymetrix, Cat. No. 10907 
Agarose,low gelling temperature 5 g Sigma-aldrich, Cat. No. 
A9414 
Ammonium Persulfate BIO-RAD, Cat. No. 161-
0700 
Bovine Serum Albumin (BSA), 100 g Sigma, Cat. No. A9647 
Cell Lysis Buffer Cell Signaling Technology, 











Santa Cruz Biotechnology, 
Cat. No. sc-37007 
Clarity TM Western ECL Substrate BIO-RAD, www.bio-
rad.com, Cat. No. 170-5061 
Dimethyl sulfoxide (DMSO) Sigma, Cat. No. D2650-
100ML 
Distel Ready-to-use spray (1:100), clear  
unfragranced, 500 ml 
Star lab, Cat. No.  TM301 
Distel concentrate, clear, unfragranced, 5 L 
container 
Star lab, Cat. No.   M309 
DNase I recombinant, Rnase-free Roche, Cat. No. 
04716728001 
Dulbecco’s Modified Eagle Medium 1x 
(DMEM) medium 
Gibco by life technologies, 
CAT.  No. 41966-029 
Dulbecco’s phosphate buffered saline PBS 
(1x) 500 ml (Cell culture)  
Invitrogen / Gibco, No. 
14190-094 
EDTA  Sigma, Cat. No. E5134  
Ethanol  BDH, Cat. No. 1047 
EUN1170  
Fibronectin from bovin plasma 1 mg Sigma, Cat. No. F4759 
L-glutamine 200 mM 
 
Invitrogen / Gibco, No. 
25030-024  
Glycine Fisher Sientific, G/0800/60 
Guava Check Kit  Merck Millipore, Cat. No. 
4500-0020 
Guava ICF Instrument Cleaning Fluid, 
100ml 
Merck Millipore, Cat. No. 
4200-0140  
HAEMA – LT-SYS ® Quick-Stain (Diff-
Quick) 
Labor + Technik, Cat. No.  
LT-SYS 
Hank’s  Balanced Salt Solution 1x (HBSS)  
 
Invitrogen/ Gibco, No. 
24020-091  
Heat inactivated fetal bovine serum (FBS) 
500 ml 
Gibco by life technologies, 
Cat. No. 10500-064 
High Pure RNA Isolation Kit Roche, Cat. No. 
11828665001 
Hydrochloric acid  BDH, Cat. No. 450023K 
LightCycler® 480 SYBR Green I Master Roche, Cat. No. 
04707516001 
MEM Non-essential amino acid solution 
100x  
Sigma life science, Cat. No. 
M7145 
2-Mercaptoethanol, 100 ml Sigma, No. M3148-100ML 
Methanol, 2.5 L Thermo Fisher Scientific, 
No. M/4000/PC17  
Minimum essential medium (MEM) 1X Gibco by life technologies, 
CAT.  No. 31095-029 










diphenyl-2H-tetrazolium bromide)  
PBS (Dulbecco A Tablet) (Lysis) 
 
OXOID, Cat. No. BR0014G 
PathScan® Intracellular Signaling Array Kit 
(Chemiluminescent Readout) 
Cell Signaling Technology, 
Cat. No. 7323 
Pen/ Strep 10.000 units  
 
Invitrogen / Gibco, No. 
15140-122  
Pierce TM BCA Protein Assay Kit 1 L Thermo Fisher Scientific, 
Cat. No. 23227 
Ponceau S solution Sigma Aldrich, Cat. No. 
P7170-1L 
Precision Protein™ StrepTactin-HRP 
Conjugate  125 µl 
BIO-RAD, Cat. No. 
1610381 
RNaseZapTM 250 ml Sigma-aldrich, Cat. No. 
R2020 
siRNA Transfection Reagent  Santa Cruz Biotechnology, 
Cat. No. sc-29528 
RPMI 1640 medium (1x) 500 ml 
 
Invitrogen/Gibco, Cat. No. 
21875-034  
Sodium chloride  Fisher Sientific, Cat. No.  
S/3160/60 
Sodium pyruvate 100 ml Sigma life science, Cat. No. 
S8636 
Sodium dodecyl sulfate 500 g Fisher Sientific, No.  
S/5200/53 
Sodium orthovanadate (Na3OV4) ≥90% 
(titration) 




rad.com, Cat. No. 161-0800  
Transcriptor High Fidelity cDNA Synthesis 
Kit 
Roche, Cat. No. 
05081955001 
Tris (hydroxymethyl) methylamine  Fisher Sientific, Cat. No.  
T/P630/60 
Trypsin-EDTA solution  Sigma, Cat. No. T3924-100 
ml 
0.4% Trypsin Blue Solution Sigma, Cat. No. T8154- 20 
ml 
10% Tween 20 Solution 
 
BIO-RAD, Cat. No. 161-
0781 
Water  Deionised obtained from a 








2.1.7 Buffers  
2.1.7.1 Preparation of Western blot buffers  
PBS 
1 Tablet was added to 100 ml distilled water (dH2O) and sterilized by autoclaving at 
115°C for 10 min. 
1.5 M Tris-HCl pH 8.8  
181.65 g Tris base was dissolved in approximately 800 ml of dH2O. The pH was 
adjusted to 8.8 with fuming HCL. 200 ml of dH2O was added to bring the volume to 
1 L. 
1 M Tris-HCl pH 6.8 
60.55 g Tris base was dissolved in 700 ml of dH2O. The pH was adjusted to 6.8 with 
fuming HCl and volume adjusted to 1 L with dH2O and stored at RT.  
10X Tris-Glycine Buffer 
 For 1 L, 30.3 g Tris base and 144.0 g Glycine added to 900 ml dH2O and stored at 
RT.  
1X SDS-PAGE Running Buffer (1 L) 
For protein separation during SDS-polyacrylamide gel electrophoresis: 100 ml 10x 
Tris-Glycine Buffer and 10 ml 10% SDS was diluted to 1L dH2O and stored at 4°C. 
1X Tris-glycine Transfer Buffer (1 L)  
For protein transfer from SDS-PAGE gels to nitrocellulose membrane: 100 ml 10x 










10X Tris-buffered saline (TBS) 1 L 
 24.2 g Tris base and 80 g NaCl were added to 800 ml dH2O. The pH was adjusted to 
7.4 with fuming HCl and the volume made to 1 L with dH2O and stored at RT.  
1X Tris-buffered saline with Tween (TBST) 1 L 
For washing nitrocellulose membranes for during western blotting:  100 ml 10x TBS 
and 2 ml Tween-20 were made to 1 L with dH2O or distilled water and stored at RT. 
10X SDS 
 5 g SDS added to 100 ml dH2O or distilled water and stored at RT. 
2X Loading buffer 
Loading sample buffer was used protein extraction and for loading of protein 
samples onto SDS-polyacrylamide gels for SDS-PAGE and Western Blotting: 4% 
SDS, 20% glycerol, 10% (v/v) 2-mercaptoethanol and 0.004% (w/v) bromophenol 
blue in 0.125 M Tris-HCl, pH 6.8. 
Blocking buffer (5% BSA) 
 For 100 ml, 0.5 g of BSA added 100 ml of 1x TBS-T and stored at 4°C. 
Preparation of sodium orthovanadate Na3VO4 stock solution (100X) 
1 mM stock was prepared in dH2O adjusted to pH 10. Orange colour was observed 
due to decavanadate. The solution was boiled by heating in a microwave for 5 to 15 
sec until translucent. Colourless monovanadate was observed over several hours due 
to depolymerisation of decavanadate; the solution was placed on ice for 5 min. Then, 
solution was readjusted to pH 10. The cycles of boiling, cooling and adjusting pH 
were repeated many times until reaching the point of stabilization at pH 10. Solution 









Preparation of cOmplete solution (100X conc.)  
One cOmplete tablet was dissolved in 500 µl dH2O, PH 7. Stock solution was aliquot 
and stored at -20°C.  
 Lysis buffers (RIPA buffer) 
 For 100 ml, 150 mM NaCl, 1.0% IGEPAL, 0.5% sodium deoxycholate, 0.1% SDS 
and 50 mM Tris-HCl, pH 8.0 were added to the final volume 100 ml of dH2O into a 
cylinder Filtered through a 0.45 filter and stored at 4°C. 
Immediately prior to lysing cells, 200x 200 mM sodium fluoride (NaF), 100x sodium 
orthovanadate (Na3OV4) and 100x complete protease inhibitor cocktail were 
combined/250 µl of RIPA lysis buffer to prevent proteolysis and maintain 
phosphorylation status of proteins. 
Stripping buffer (100 ml) 
2% SDS (20 ml of 10% SDS), 62.5 mM Tris-HCl pH 6.8 (12.5 ml Tris-HCl pH 6.8, 
0.5M), 67.5 ml dH2O and 100mM β-Mercaptoethanol (700 µl of liquid b-ME) were 
mixed and sored at RT. 
2.1.7.2 Preparation of PathScan buffers and antibodies 
Preparation of 1X cell lysis buffer for PathScan assay 
1x Cell lysis buffer were thawed, mixed thoroughly and supplemented with complete 
protease inhibitor cocktail to a final concentration of 1 mM.  
1X Array wash buffer  
1x Array wash buffer was prepared by diluting of 1 mL of 20x Array wash buffer in 
19 ml dH2O and kept at RT.  
1X Detection antibody cocktail  
For running 1 slide: 150 µl of 10x Detection antibody cocktail was diluted with 1350 







1X HRP-linked streptavidin 
For running 1 slide: 150 µl of 10x HRP-linked Streptavidin was diluted with 1350 µl 
of array diluent buffer and kept on ice. 
1X LumiGLO® and peroxide solution 
To make 10 ml of 1x LumiGLO® and peroxide solution, 9 ml of dH2O were 
combined with 0.5 ml of 20x LumiGLO® and 0.5 ml of 20x Peroxide. 1x 
LumiGLO® and peroxide solution was Diluted and combined immediately before 
use. 
2.1.7.3 Preparation of fibronectin 
Fibronectin stock was prepared by dissolving 1 mg/ml fibronectin in 0.9% PBS and 
aliquots have been made and saved at -20°C.  Immediately, before coating, a final 
concentration of 15 µg/ml has been made and 2.5 µg/cm2 of culture cells has been 
added, 5 µg/well of fibronectin was coated in a 24-well plate.    
2.1.7.4 Preparation of hormone solutions 
Insulin  
Stock: Insulin stock was prepared by dissolving 1 mg/mL insulin in 0.9% PBS + 
0.005 m HCl (4.5 µl cHCl in 10 ml), then filter sterilized. 
Routine Solution: 5 µg/ml in 0.001m HCl in PBS. 
1 mL Stock (1 mg/ml) + 0.18 ml cHCl + 200 ml sterile saline.   
Then 5 ml aliquots were prepared in bijou bottles, and stored in -20oC. One aliquot 
per 500 ml bottle of medium was used.  
Hydrocortisone  
Stock: 1 mg/ml in 100% Ethanol. 







1 ml stock (1mg/ml) + 50 ml Ethanol + 150 ml sterile PBS. 
Then, 5 ml aliquots were prepared in bijou bottles and stored in -20oC. One aliquot 
per 500 ml bottle of medium was used.  
2.1.8 Equipment  
Equipment used in this study is listed in Table 2.2 
Table 2.2 Equipment used and suppliers 
Equipment Suppliers and catalogue number 
Centrifuge Centrifuge 5804, Eppendorf, Cat. No. 
1T5804 000.013 
Analytical balance Mettler and Toledo, Cat. No. AB54-S 
Centrifugal evaporator  Speed Vac SPD121P, ThermoSavant, 
uk.vwr.com, Cat. No. 195-227 
Cover glass VWR, cat no: 631-0149 
Dissecting microscope  Motic, K401, GDC Microscopes (Surrey, 
UK)  
DVC camera  Model. 1310c-FW-OO; digital images 
recorded using DVC view version 2.2.8 
software  
Filter syringe  Sterile Minisart® 0.2µm CE, Sartorius 
stedim biotech, Cat. No. 16534. 
Filter Bottle top  
 
Polysulfone Nalgene®, uk.vwr.com, Cat. 
No. 516-0578 with 0.2 µm, 47 mm I.D. 
cellulose acetate membrane filters, Nalge 
Nunc, Fisher Scientific, Cat. No. 
13TFDM-309-100Q. 
Freeze dryer  Heto PowerDry PL3000,  
Gel electrophoresis system 
• Power Supplies 300V 
• Mini Trans-Blot Cell Module 
1703811 
• Mini-PROTEAN Tetra Cell 
Handcasting accessory kit 









• Mini-PROTEAN system Casting 
stand 1658050 
• Mini PROTEAN System Glas 
Plates 1653308 
• Supported Nitrocellulose 
Membrane 162-0094 
• Mini-PROTEAN TGX Gels 456-
1031 
Heat block Grant, Cat. No. QBT2 
LightCycler® 480 Instrument II    96-
well version 
Roche, Cat. No. 05015278001 
LightCycler® 480 Multiwell Plate 96 Roche, Cat. No. 04729692001 
Microcentrifuge  Eppendorf minispin,  
PH meter  Jenway, Cat. No. 3505 
Plates:  
• 96 wells Maxisorp:  
• 96 conical-bottom wells:  
• 4 wells plate:  
Corning® 96 wells TC: 
• Corning® BioCoat™ Matrigel® 
Invasion Chambers with 8.0µm 
polyethylene terephthalate (PET) 
Membrane in two 24 Well Plates, 
24/Pack, 24/Case. 
• Corning® Costar® Transwell® cell 
culture inserts 6.5mm 
Transwell® with 8.0µm Pore 
Polycarbonate Membrane Insert, 
Sterile (Corning, Bedford, USA). 
 
Nunc, uk.vwr.com, Cat. No. 735-0083 
Nunc, uk.vwr.com, Cat. No. 732-0191 
Nunc, uk.vwr.com, Cat. No. 734-2176  
Corning, www.corning.com, Cat. No. 
#3595  
Corning, www.catalog2.corning.com, 
Cat. No. #354480) 
 
Corning, www.catalog2.corning.com, 
Cat. No. #3422) 
Plate reader Thermo MultiSKAN EX 
Rocker-GYRO Stuart Scientific www.stuart-
equipment.com 
Rotator  SB2, Stuart Scientific www.stuart-
equipment.com 








• 1.5 mL Micro tubes, Cat. No. 
72.690.001 
• 0.5 mL Micro, Cat. No. 72.699 
• 2.0 mL Crystal clear M/C tubes, 
Cat. No. E 1420-2000 
• CELLSTAR® Centrifuge Tubes, 
Polypropylene, Sterile, Greiner 
Bio-One, 15 ml, 188261  
• CELLSTAR® Centrifuge Tubes, 
Polypropylene, Sterile, Greiner 
Bio-One, 10 ml, 227261 
 
• SARSTEDT, (autoclaved)  
 




Vortex VWR, uk.vwr.com, Galaxy mini 
Water bath Grant JB Series, www.grant.co.uk 
2.2 Methods 
2.2.1 Cell culture  
2.2.1.1 BCC medium 
MDA-MB-231 and Hs578-T cell lines: High glucose DMEM medium was 
supplemented with 10% (Heat inactivated FBS sreum), 1 µg/ml insulin from porcine 
pancreas, 500 ng/ml hydrocortisone-water soluble, 1% pen/strep and 2 mM/l-
glutamine. 
T47D and ZR-75-1 cell lines: PRMI-1640 medium was supplemented with 10% 
(Heat inactivated FBS sreum), 1 µg/ml insulin from porcine pancreas, 500 ng/ml 
hydrocortisone-water soluble, 1% pen/strep, 2 mM/L-glutamine and 1 mM Sodium 
Pyruvate (NaP) 
MCF-7-A-1 cell line: To make the complete growth medium, the following 
components were added to the base MEM medium: 0.01 mg/ml human recombinant 
insulin, 500 ng/ml hydrocortisone-water soluble, 2 mM L-Glutamine, 1% pen/strep, 








2.2.1.2 Routine culture of BCCs 
Human BCC lines (MDA-MB-231, Hs578-T, T47D, ZR-75-1 and MCF-7-A) were 
routinely maintained in standard tissue culture flasks in growth medium 
supplemented with 10% (Heat inactivated FBS), 1µg/ml insulin from porcine 
pancreas, 500 ng/ml hydrocortisone-water soluble, 1% pen/strep and 2 mmol/l L-
glutamine. All cultures were maintained at 37oC in a humidified atmosphere 
containing 5% CO2. Cells were then washed twice with PBS, trypsinized with 0.1% 
trypsin and 0.1% EDTA and passaged at a ratio of 1:3 three times a week. 
2.2.1.3 Freezing cells 
It is important for future studies to freeze cells as a seed stock and store them as soon 
as they become available from sub-culturing. Cryopreservation ensures that there is a 
back-up of cells if needed at any time or in case of loss of cell supply or 
contamination. Freezing medium was made by supplementing the cells in normal 
growth medium, with addition of an equal volume of 40% warm FBS and 10% 
DMSO. Briefly, medium was removed from the T75 cm2 culture flask and cells were 
washed twice with PBS, followed by trypsinisation with 1x trypsin/EDTA for 3-5 
min. Once cells were detached, cells were neutralized with equal volumes of growth 
medium. 90% confluent viable cells were counted in order to achieve a good 
recovery after freezing, before harvesting the cells by centrifuging at 1000 rpm for 5 
min; the supernatant was again discarded and cells were re-suspended and seeded at 
a concentration of 2×106 cells/ml in freezing medium. New cryovials were labeled 
with the cell line name, cell concentration, passage number and date. Typically a 0.5 
ml volume of cells was added in a cryovial, and freezed slowly by placing them at -
20°C for 2-3 hrs, then overnight at -80°C. The cells were then transferred to liquid 
nitrogen if long-term storage was necessary. 
2.2.1.4 Thawing frozen Cells  
Thawing frozen cells is stressful to the desired cells, so thawing cells with a good 
and fast technique is crucial way to ensure the viability and functionality of a high 







The cryovial containing the frozen cells was removed from liquid nitrogen and 
thawed rapidly (<1 min) in a 37°C water bath by holding and gentle flicking of the 
cryovial on water bath surface. The outside of the cryovial was dried and wiped with 
70% ethanol solution before opening to avoid contamination.  The cells were then re-
suspended slowly into pre-warmed growth medium and centrifuged at 1000 rpm for 
3 min. Medium was removed and cells re-suspended with appropriate medium 
depending on cell type. And cells were finally transferred to a T75 cm2 culture flask 
and incubated at 37°C, 5% CO2. 
2.2.1.5 Cytotoxicity cell culture preparation 
2.2.1.5.1 Chemotherapeutic agents preparation 
Doxorubicin (Dox): The stock solution of doxorubicin was made by adding 10 mg 
of doxorubicin to 100 µl of DMSO and suspended in 10 ml of dH2O to a final 
concentration 1 mg/ml. 
Cisplatin (Cis): The stock solution of cisplatin was made by dissolving this agent in 
PBS for a final concentration of 100 mM. 
Tamoxifen (Tam): The stock solution of tamoxifen citrate was prepared by 
dissolving tamoxifen in PBS at a concentration of 10 mM.  
In order to obtain pharmacologically relevant final concentrations of these 
chemotherapeutic agents, the stock solutions were diluted in the culture medium to 
indicated concentrations when inducing apoptosis. 
Due to their toxicity, all precautions for handling Tam, Dox, and Cis were taken 
according the COSHH assessment and material safety data sheet delivered by the 
manufacturer.   
2.2.1.5.2 Cytotoxicity cell culture     
Approximately 1x105 cells/ml of isolated cell populations were seeded and placed in 
24 well plates containing 2 ml of growth medium and incubated for 24 hrs in a 
humidified incubator of 5% CO2. Cells were treated the following day with different 







1, 10 µM and Tam 1, 10, 100, 1000, 10000, 100000 nM; and incubated for different 
time points 24, 48 and 72 hrs.  
2.2.1.5.3 HS/heparins and chemically modified heparin treatments 
To examine the effects of HS/ heparin and chemically modified heparins on BCSC 
apoptosis, 1x105 cells/ml of isolated cells were cultured in 6 well plates and 
incubated for 24 hrs in a humidified incubator of 5% CO2. Cells were treated the 
following day with the optimum concentration of chemotherapeutic agents (Dox; 5 
µg/ml, Cis; 0.1 µM, Tam; 10 µM) with or without 10 ng/ml HS/heparin or 
chemically modified heparin (PerS H, NAc H, 2-deS-NS H and 2,6 deS-NS H) and 
incubated for 48 hrs, before measurement of apoptosis (see section 2.2.1.5.2). Cells 
were compared with a negative control that was incubated in the absence of inducing 
agents. 
2.2.2 Flow cytometry 
2.2.2.1 Flow cytometric analysis of BCS-like cell surface marker expression 
Based on cell surface marker phenotype, cells were grown in monolayer culture in 




flask in complete medium, 
cultured for 48 hrs. After the incubation period, cells were washed twice with PBS 
and harvested with accutase as a replacement for trypsin/EDTA. The resulting 
detached cells were centrifuged at 300 xg for 5 min. Medium was removed and 
blocked with PBS containing 5% FBS and incubated on ice for 20 min. After 
blocking, flurochrome-conjugated monoclonal antibodies against human CD44 
(APC, FITC); CD24 (FITC, PE, APC); CD133 PE or their respective isotype 
controls (FITC, APC and PE-conjugated mouse IgG1 isotype controls) were added to 
the BCC suspensions at the concentrations recommended by the manufacturer (Table 
2.3). A total of 1×105
 
cells/100 µl were incubated with specific antibodies at 4°C in 
the dark for 30 min. Unbound antibody was washed out with two cycles of washing 
with PBS + 5% FBS and resuspended in 0.5 ml (per million cells) of PBS + 5% FBS. 
The cells were then analysed using flow cytometry analysis (FACSCalibur cytometer 
from Becton Dickinson) and at least 40,000 events per sample were collected. 
Positive staining was considered based on the negative of an isotype control. 









calculated from histograms and dot plots using Flowing Software (version 2.5.0). 
2.2.2.2 Role of heparin/HS and heparin derivatives on stem-like cells in BCC 
lines 
MDA-MB-231 and Hs578-T cells were cultured at a density of 2×105
 
in 10% FBS 
DMEM medium in 25 cm2 culture flasks at 37 °C in a 5% CO2 incubator for 24 hrs. 
After that, the medium was discarded and replaced with an equal volume (5 ml) of 
fresh medium containing various concentrations (0, 1, 10, 100, ng/ml, 1, 10, 100 
µg/ml) of heparin, HS and modified heparins (Porcine Mucosal Heparin (PMH), 
Porcine Mucosal HS (PMHS), PerS H (1), NAc H (2), 2 deS-NS H (3), 6 deS- NS H 
(4), 2 deS-NAc H (5), 6 deS-NAc H (6), 2,6 deS-NS H (7) and 2,6 deS-NAc H (8)), 
then cells were incubated for an additional 48 hrs. Cells were washed twice with PBS 
and harvested with accutase for 7 min at 37°C. The resulting detached cells were 
centrifuged at 300 xg for 5 min then washed with PBS containing 5% FBS and 
incubated on ice for 20 min. Cells were labelled with a combination of 1:1000 of 
CD44 APC and 1:100 of CD24 FITC or their respective isotype controls and 
incubated at 4°C in the dark for 20 min. After incubation, cells were washed through 
two cycles of washing with PBS + 5% FBS and resuspended in 0.5 ml of PBS + 5% 
FBS. The cells were then analysed by flow cytometry (FACSCalibur cytometer from 
Becton Dickinson) and at least 30,000 events per sample were collected. Percentages 
of cells expressing CD44+/CD24-
 
were calculated from histograms and dot plots 
using Flowing Software (version 2.5.0). 
2.2.2.3 Fluorescent-activated cell sorting (FACS) 
Cell sorting was performed by Miss Carolyn Rainer and Sandra C. P. Cachinho, 
using flow cytometry (FACSAria III cell sorter, Becton Dickinson); at the cell 
sorting and flow cytometry core facility, Technology Directorate, University of 
Liverpool, UK). MDA-MB-231 and Hs578-T cells were prepared in a single-cell 
suspension form at a concentration of 5×106 cells/ml. In brief, cells were harvested 
using accutase for 7 min and transferred to 15 ml conical tube containing FBS and 
centrifuged at 300 xg for 5 min. The supernatant was then discarded and cells re-
suspended in 1 ml of normal growth medium. Cells were counted by hemoytometer 







suspension with PBS/10%FBS. Cell suspensions were filtered through a 0.22 µm 
MilliexGP filter unit to help disaggregate clumps prior to analysis and incubated on 
ice for 20 min. After the incubation period, each cell line was labeled with a 
combination of two different fluorescent dyes (APC-conjugated human CD44 and 
Monoclonal CD24 human conjugated to FITC antibodies) and their isotypes as a 
negative controls (FITC-conjugated mouse IgG1 and APC-conjugated mouse IgG1 
isotype control) at the concentrations recommended by the manufacturer (Table 2.3). 
Labeled cells were incubated at 4°C, protected from light for 30 min. Unbound 
antibody was washed out through two cycles of washing with PBS + 5% FBS and re-
suspended in 1.5 ml (per 5×106 cells) of PBS + 5% FBS. At the end of experiment, 
cells were labeled with DAPI staining at a concentration of 1:10000. A minimum of 
10,000 events was recorded for all samples. Negative isotype controls were set in the 
first quadrant in the right bottom of the plot and gates were administrated. CD44-
/CD24- resides in the P7, CD44+/CD24- in P4, CD44+/CD24+ in P6 and CD44-
/CD24+ in P5. CD44-/CD24-, CD44+/CD24-, CD44+/CD24+ and CD44-/CD24+ cells 
were isolated in four separate tubes and cultured in 75cm2 culture flasks at 37 °C in a 
5% CO2 incubator. The culture medium was changed daily and the cell morphology 
was observed. When the cell number reached confluency, the cells were tested in 
different experiments to characterize the CSC properties and to evaluate the role of 















Table 2.3 Antibody concentrations used in FACS 
 
Antibodies Dilution factor  Sample volume 
APC-conjugated human CD44 1.1000 100 µl 
FITC- conjugated human CD44 1.1000 100 µl 
FITC- conjugated human CD24 1:100 100 µl 
APC-conjugated human CD24 1:50 100 µl 
PE-conjugated human CD24 1:50 100 µl 
CD133/1 (AC133)-PE, human 1:11 100!μl 
FITC-conjugated mouse IgG1 isotype control 1:100 100 µl 
APC-conjugated mouse IgG1 isotype control 1:100 100 µl 
PE- mouse IgG2b, isotype control 1:100 100!μl 
2.2.2.4 Apoptosis by flow cytometry 
The indices for MDA-MB-231 and Hs578-T BCC apoptosis and necrosis were 
quantified using flow cytometry as a percentage of Phosphatidylserine (PS) 
translocation. PS is expressed on the membrane and precedes the loss of membrane 
integrity resulting from either early apoptosis (detected by Annexin V, Alexa Fluor® 
488 conjugate binding) or late apoptosis (DNA of necrotic processes that was 
quantified by propidium-iodide (PI) uptake due to leaky plasma membrane).  
Cells were harvested and washed twice with PBS followed by trypsinisation with 
accutase for 7 min. Cells were centrifuged at 1000 rpm for 5 min. The media was 
removed and cells re-suspended at 1x106 cells/ml in fresh medium in a 75cm2 culture 
flask. To measure apoptotic responses of cells, cells were treated with appropriate 
treatments (see section 2.2.1.5.2, 2.2.1.5.3). Cells were compared with a negative 
control that was incubated in the absence of inducing agents. Incubated was carried 
out for appropriate time points (see section 2.2.1.5.2). Cells were harvested again 
after the incubation period and washed twice with PBS, followed by trypsinization 







hemocytometer to seed at 1×106 cells/ml. Cells were then re-suspended in 1 ml fresh 
medium and transferred to 24 well-plate. 25 µl of cell suspension containing 1x106 
cells/ml were transfered to 96 well microtiter plate and incubated with 25 µl of 
HBSS and 0.5 µl of Annexin V, Alexa Fluor® 488 conjugate for 15 min, protected 
from light at RT. During this time, 1 mg/ml PI stock solution was prepared by adding 
25 µl of PI to 200 µl of HBSS. Following this, 200 µl of PI with HBSS was added to 
106 cells in each well in a 96-well microtiter plate just prior to the flow analysis. 
According to the manufacturer’s instructions, 5000 gated cells were quantified using 
the Guava Viacount flow cytometer (Millipore). In the early stage of apoptosis, DNA 
content could be stained with Annexin V, Alexa Fluor® 488 conjugate, whereas cells 
in the late stage of apoptosis (necrotic stage) were stained by PI staining.   
After each measurement of apoptosis by flow cytometry using annexinV/PI staining, 
the absolute numbers of cells were counted. Briefly, the measurement of % of cells 
that expressed apoptotic markers (e.g. Annexin V, Alexa Fluor® 488 conjugate 
binding) could underestimate the cell death level due to cell necrosis or lysis. 
Therefore, the measurement of apoptosis in all experiments, both the absolute 
number of cells and the % of apoptotic cells, were routinely measured. In all 
experiments, it was found that the cell number that recovered after incubation was 
always > 95% of the initial incubation (1x106 cells/ml). This indicates that there is no 
major effect on the values for % apoptosis with this small loss of cells. Therefore, (% 
apoptosis) values are presented in all experiment in this thesis. 
2.2.3 Microscopy 
2.2.3.1 Bright phase 
CD44+/CD24- sorted cells from MDA-MB-231 and Hs578-T human BCCs were 
cultured in 6 well tissue culture plates (Corning) at 20×103 cells/ well for 24 hrs. 
After that, cells were treated with either 10 mM sodium chloride (NaCl) or 10 mM 
sodium chlorate (NaClO3) for a further 48 hrs. Cells were analysed using a bright 








2.2.4 Cell viability assay (Dye exclusion method) 
Briefly, FACS sorted cells from MDA-MB-231 or Hs578-T human BCCs were 
cultured in 24 well tissue culture plates (Corning) at density of 4×104 cells/ well for 
various time points (24, 48 and 72 hrs). After each time point, cells were washed 
twice with PBS and trypsinized using EDTA/PBS (2-5 nM) for 5 min. Detached cells 
were collected and centrifuged at 1000 rpm for 5 min. Cell suspensions were diluted 
in 0.4% sterile filtered Trypan blue solution at a ratio of 1:1. Cells were counting 
using a hemocytometer chamber under a microscope at low magnification. The 
number of total and blue staining cells were counted.  
Viable cells = [1.00 – (Number of blue cells ÷ Number of total cells)] 
2.2.5 Cell proliferation (MTT assay) 
Briefly, MDA-MB-231 and Hs578-T sorted cell suspensions were harvested by 
centrifugation at 1000 rpm for 5 min after washing twice with PBS and trypsinizing 
with EDTA/PBS (2-5 nM). Media was removed and cells re-suspended in fresh 
medium. 100 µl of cell sub-populations were seeded in a 96-well microtiter cell 
culture plate at a density of 5×103
 
cells/well. Incubation time was carried out for 
appropriate time points. 10 µl (5 mg/ml) of 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl-tetrazolium bromide (MTT reagent) was added to each well including 
controls and incubated for 4 hrs at 37°C. Cells were combined with 100 µl of 
detergent reagent (DMSO) to all wells to dissolve the formazan produced, then, 
incubated overnight at 37°C. Cell proliferation was determined according to the 
colorimetric comparison by reading optical density (OD) values from a microplate 
reader (Thermo, Multiskan EX, UK) at an absorption wavelength of 570 nm. The 
average values of triplicate culture readings was measured. 
2.2.6 In vitro cell adhesion assay 
For evaluating cellular adhesion, 24-well plates were coated with 15 µg/ml of 
fibronectin, evaporated under a hood for 20 min, using 3 ml of 5x104 cells/well for 
either each sorted cell population (CD44-/CD24-, CD44+/CD24-, CD44+/CD24+ and 







heparin derivatives. Cells were washed twice with PBS and trypsinized with 0.1% 
trypsin and 0.1% EDTA and incubated for 3-5 min. After trypsinization, cells re-
suspended with equal volume of normal growth medium and centrifuged at 1000 rpm 
for 5 min.  Substrates were removed and re-suspended with normal growth medium 
and seeded at the required number of cells. Cells were incubated for different time 
courses (0, 1, 3, 5 hrs) at 37°C in humidified incubator with 5% CO2. After allowing 
cells to adhere for the fixed time, the plates were taken from the incubator and the 
media were rinsed away; non-adherent cells were removed and washed twice with 
PBS. After that, adherent cells were trypsinized with 250 µl/well of 0.1% trypsin and 
0.1% EDTA and incubated at 37 °C for 3 min. Cells were re-suspended (1 ml/well) 
in normal growth medium with 10% FBS. For each replicate (n=3), the mean 
numbers of adherent cells in triplicate were counted using a hemocytometer by light 
microscope at 10x magnification, using four independent fields. Data are expressed 
as a mean number of adherent cells compared to untreated control cells.  
2.2.7 In vitro matrigel invasion assay 
The invasive potential of BCCs was assessed in vitro in a Matrigel invasion 
chambers with 8.0 µm PET membrane. Under sterile conditions, the Matrigel 
invasion chamber plate was removed from -20°C storage and warmed at RT for 20 
min. 500 µl of warm normal growth medium was added to the interior of the inserts 
and incubated in a humidified tissue culture incubator for 1 hr at 37°C, 5% CO2 
atmosphere to rehydrate the basement membrane layer. After rehydration, the normal 
growth medium was removed thoroughly but gently without disturbing the Matrigel 
membrane layer. 600 µl of fresh DMEM medium supplemented with 1 µg/ml insulin, 
500 ng/ml hydrocortisone, 1% pen/strep and 2mmol/l L-glutamine and 5 % heat 
inactivated FBS was added to a new clean 24 well-plate to serve as a chemoattractant 
to induce invasion. Chambers were transferred by using sterile forceps to the wells 
containing the chemoattractant. Immediately, 12×103 cells of four sub-populations of 
MDA-MB-231 and Hs578-T sorted cells (CD44-/CD24-, CD44+/CD24-, 
CD44+/CD24+ and CD44-/CD24+) either untreated or treated with heparin derivatives 
were seeded in 100 µl fresh medium containing 1% heat inactivated FBS and added 
into each upper chamber and incubated for 24 hrs in a humidified cell culture 







the non-invading cells were removed gently from the upper surface of the membrane 
by swapping gently the interior of the inserts using cotton-tipped swabs.  At the end 
of the experiment, the chambers were washed with PBS then transferred sequentially 
by sterile forceps to a clean well containing a 500 µl of Diff-Quik solution through 
each stain solution for 2 min in each stain solution. Each insert was transferred to the 
microscope slide and cover slip was placed on top of the membrane and gentle 
pressure applied to expel any air bubbles. A light microscope was used to count 
invading cells under 10 magnification objective with four individual fields/inserts. 
Data are expressed as the number of invaded cells per well. The in vitro invasion 
assay was conducted in triplicate, and repeated three times. 
2.2.8 In vitro migration assay 
An in vitro transwell migration assay was conducted using 24-well plates with 
6.5mm Transwell inserts (8.0µm Pore Polycarbonate Membrane Coated with Cultrex 
Basement Membrane Extract). The principal technical setup of an in vitro transwell 
migration assay equals the transwell invasion assay that was described above, and 
outlined in Figure 2.1. The procedure was similarly measured by the placement of a 
coating of Cultrex Basement Membrane Extract on top of the membrane. In brief, the 
migration transwell plate was rehydrated with 500 µl warm medium and incubated 
for 1 hrs at 37°C, in 5% CO2 atmosphere. After incubation, rehydration medium was 
carefully removed and chemoatractant media (5% FBS) as placed into the 24 well 
plate. 12×103 MDA-MB-231 and H578-T sorted cells (CD44-/CD24-, CD44+/CD24-, 
CD44+/CD24+ and CD44-/CD24+) untreated or treated with heparin derivatives were 
plated with conditioned medium (containing 1% FBS) on the top of the Transwell. 
Cells were incubated in humidified cell culture at 37°C, 5% CO2 atmosphere. After 
24 hrs incubation, non-migrated cells in the insert were carefully removed and 
migrated cells were stained with Diff-Quik solution. The number of migrated cells 
was observed with a light microscope under 10 magnifications. Mean numbers of 
migrated cells for triplicates were calculated. The in vitro migration assay was 








Figure 2.1 Schematic diagram of the invasion and migration assays. Invasion and migration 
assays were used to culture MDA-MB-231 and Hs578-T sub-population cells-based on either matrigel 
or polycarbonate membrane. Cells were seeded at 12×103/100 µl 1% FBS medium and added to upper 
chamber. 600 µl chemoattractant 5% FBS medium was added to the lower chamber in 24 well plate. 
Invaded or migrated cells were stained and counted. 
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2.2.9 Soft agar colon formation assay 
In preparation for the assay, 2.5% semi-solid agar base layer (w/v) was made by 
dissolving 2.5 g of Ultrapure noble agar into 100 ml of distilled water (dH2O). Agar 
mixture (Ultrapure noble agar /dH2O) was autoclaved to sterilize and stored at 4 °C 
to insure solidification and heated at the time of the experiment until agar was 
completely dissolved. For plating of bottom layer of agar, 1.2x normal growth 
medium was prepared by supplementing DMEM medium with all supplements 
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melted agar base layer (w/v), pre-warmed 1.2x normal growth medium and 50 ml 
conical tube in a tube holder were placed in an ice bucket containing 40°C water and 
transferred to tissue culture hood.  
2.5% (w/v) autoclaved agar mixture/dH2O was diluted 1:4 into 1.2 x concentrated 
normal growth medium and the tube was inverted several times to mix. 50µl of semi-
solid agar base layer containing of 0.5% agar (w/v) in normal growth medium were 
plated into 96-well plates. As shown in Figure 2.2 plates were covered and the agar 
mixture allowed to solidify at 4°C, for 5 min. Once the lower layer of agar has 
solidified, preparation of the upper layer was began 1.5 % (w/v) low melting 
temperature agarose was prepared by microwaving in dH2O and subsequently placed 
in a 40°C water bath until needed to keep it in liquid phase. CD44-/CD24-, 
CD44+/CD24-, CD44+/CD24+ and CD44-/CD24+ sorted populations from MDA-MB-
231 and Hs578-T BCCs were grown to 70-80% confluence, harvested by 
trypsinization and diluted 1:3 in normal growth medium. Cells were counted using a 
hemocytometer and seeded at 2.5×104 cells/ml in 1.2x warm medium. For this cell 
number, cell suspension was diluted in a 1:4 ratio of warm 1.5% (w/v) agarose 
melted in a microwave and 50 µl (1×103 cells) were quickly and gently pipetted 2-3x 
to distribute cells and then placed onto agar base layer. The cell/agar mixtures were 
allowed to solidify at 4°C for 10 min, and then overlaid with 50 µl of normal growth 
medium (Figure 2.2). Plates were incubated at 37°C, 10% (v/v) CO2 humidified cell 
culture incubator for four weeks.  Normal growth medium were changed every week 
for four weeks by gently pipetting off the top medium layer and gently using a multi-
channel pipette and adding new warm fresh medium. After four weeks, colonies 
were fixed and then stained with 0.4% crystal violet in 50% methanol crystal violet 















Figure 2.2 Schematic diagram assay principle for the soft agar colony formation assay. Cell 
colonies form after four weeks incubation in agar matrix. 
 
 
Base agar matrix is added 
Cell /agar mixture on top of the 
solidified base agar matrix is added  
Formation of cell colonies  
Base agar matrix layer  
  Cell suspension/ agar matrix layer  
Transformed cells  







2.2.10 Western blot analysis 
2.2.10.1 Protein extraction from MDA-MB-231 and Hs578-T BCC lines for 
Western blotting 
To prepare samples for running on a gel, cells need to be lysed to release proteins of 
interest. This solubilizes the proteins so they can migrate individually through a 
separating gel. 
For protein extraction, cells were lysed to release proteins of interest. Briefly, cells 
were grown in 10 cm culture dishes and incubated for 48 hrs. After incubation time, 
cells were starved for 6 hrs with normal growth medium without FBS. Cells were 
stimulated with either 20 ng/ml FGF2 or 10 ng/ml IL-6 and treated with different HS 
and modified heparins at low concentration (10 ng/ml) at a appropriate time points. 
After each time point, plates were placed on ice and cells were washed twice with 
cold PBS. 250 µl cold RIPA buffer supplemented with 200x of 200 mM Sodium 
fluoride (NaF), 100X Sodium orthovanadate (Na3OV4) and 100x complete protease 
inhibitor cocktail were added to each plate and incubated for 5 min. Adherent cells 
were scraped off the dish using a plastic cell scraper and gently the cell suspension 
transferred into a microcentrifuge tube and incubated for 30 min on ice with agitation 
every 10 min. After incubation, the cells were centrifuged at 4°C at 12,000 rpm for 
10 min. The supernatants were aspirated and placed in a clean fresh 1.5 ml tube and 
stored at - 20°C until use for Western blotting. 
2.2.10.2 BCA Protein Assay 
2.2.10.2.1 Preparation of Diluted Albumin (BSA) Standards  
Table 2.4 was used as a guide to prepare a set of protein standards.  
2.2.10.2.2 Preparation of the BCA working reagent (WR) 
The following formula was used to determine the total volume of BCA working 
reagent (WR) required: (# standards + # unknowns) x (# replicates) x (volume of WR 
per sample) = total volume WR required. 
10 µl of each standard and unknown sample were loaded in triplicate into each 96-







incubated on a plate shaker at 37°C for 30 min. After incubation, the absorbance of 
all triplicate standards and samples were measured using the spectrophotometer at 
570 nm. A standard curve was plotted by plotting the average blank-corrected 570 
nm measurement for each BSA standard vs. its concentration in µg/ml. The standard 
curve was used to determine the protein concentration of each unknown sample 
(Figure 2.3). 
 
Table 2.4 Preparation of diluted BSA standards 





A 0 300 µl of stock 2,000 
B 125 375 µl of stock 1,500 
C 325 325 µl of stock 1,000 
D 175 175 µl of vial B dilution 750 
E 325 325 µl of vial C dilution 500 
F 325 325 µl of vial E dilution 250 
G 325 325 µl of vial F dilution 125 
H 400 325 µl of vial G dilution 25 
I 400 0 0 = Blank 
!
Figure 2.3 Colour response curves for BSA using the standard microplate protocol (37°C at 30 

































2.2.10.3 SDS-PAGE  
Proteins were separated based on their molecular weight on SDS-polyacrylamide 
gels. Briefly, samples were pre-heated for 10 min at 95°C and immediately placed on 
ice. 40 µl of each sample was loaded using gel loading tips. Protein extracts were run 
on Tris-buffered SDS-polyacrylamide gels, made according to Table 2.5 or 
purchased from Bio-Rad (7.5%, 10% or 12% Mini-PROTEAN® TGX™ Precast 
Gels), in 1x SDS-PAGE running buffer, with the acrylamide concentration of the 
separating gel varying depending on the size of the proteins being separated. To 
determine protein size, 10 µl Precision Plus Protein™ WesternC™ prestained protein 
standards were used on each gel. Samples were run at approximately 140 volts until 
the proteins had clearly stacked, and then voltage was turned down to 100 volts with 
time varying depending on the level and size of separation required. 








Component Separating Gel (10ml) 
 
Stacking gel (5ml) 
6% 8% 10% 12% 15% 
DdH2O 5.3 ml 4.6 ml 2.5 ml 3.0 ml 3.5 ml 3.4 ml 
30% 
Acrylamide 
2.0 ml 2.7 ml 2.5 ml 2.5 ml 2.5 ml 0.83 ml 
1.5M Tris-HCl 
pH 8.8. 
2.5 ml 2.5 ml 2.5 ml 2.5 ml 2.5 ml - 
1M Tris-HCl 
pH 6.8 
- - - - - 0.1 ml 
10% SDS 0.1 ml 0.1 ml 0.1 ml 0.1 ml 0.1 ml 0.05 ml 
10% APS 0.1 ml 0.1 ml 0.1 ml 0.1 ml 0.1 ml 0.05 ml 







2.2.10.4 Transfer of proteins and staining  
After separation by SDS-PAGE proteins were transferred onto a nitrocellulose 
membrane. Before setting up the transfer apparatus, four blotting paper per gel and 
membrane were pre-wetted with Tris-Glycine transfer buffer. The soaked sponge and 
two blotting papers were layered onto the black side of the transfer sandwich. Gel 
and membrane were layered onto the blotting paper. Two pieces of transfer-buffer 
wet blotting paper were layered on top of the membrane. Proteins were transferred 
with ice pack cooling at 250 mA constant for 1.5 hrs at 4°C. After blotting, 
membranes were stained for 30 sec with Ponceau S solution to check transfer was 
successful and to label the lanes with a pencil. Membranes then were transferred into 
RO water. After the de-staining, membranes were washed three times in 0.1% TBST 
to remove the Ponceau stain and incubated in blocking buffer (5% BSA) at room 
temperature for 1 hr to reduce non-specific binding of the antibody before incubation 
with a suitable primary antibody (Table 2.6) diluted in blocking buffer (BSA) 
overnight at 4°C on a roller. Membranes were then washed three times in 1% TBST 
for 10 minutes and incubated with an appropriate horseradish peroxidase (HRP) 
conjugated secondary antibody (Table 2.7) plus StrepTactin-HRP conjugate 
(1:10,000, Bio-Rad), detection in blocking buffer (BSA) for 1 hr at room temperature 
on a roller. Membranes were then washed three times in 1% TBST and twice in 10% 
TBS for 10 minutes. 
2.2.10.5 Imaging and data analysis 
ECL chemiluminescent substrate was used to detect the HRP-conjugated secondary 
antibodies on the membrane. The chemiluminescent signal was detected and imaged 
using the ImageQuant™ LAS 4000 Biomolecular Imager (GE Healthcare) and 
exposure for a length of time dependent on the signal intensity  
The membranes were scanned and the intensities were compared using Image Studio 
Lite software V5.2 (Lil-COR Biotechnology, UK. Ltd). For relative quantification, 
equal sized rectangular boxes were drawn for each antibody around bands images 
and the mean value for each protein band was calculated. To correct for slight 







levels) were divided by that of histone and α-tubulin house-keeping proteins as 
ontrols. Finally, the intensity of each normalized protein phosphorylation value was 
divided by its total protein values. The mean value of three separate experiments ± 
SEM were calculated.  
 
Table 2.6 Primary antibodies used in Western blots 
Primary Antibody Supplier Species Concentration 
pP42/44 MAPK (Erk1/2) 
(Thr202/Tyr204  
Cell Signaling Rabbit 1µg/ml 
P42/44 MAPK (Erk1/2) Cell Signaling Rabbit 5µg/ml 
Phospho-Stat3 (Tyr705) Cell Signaling Mouse 1µg/ml 
Stat3 (D3Z2G) Cell Signaling Mouse 1:10 
Histone H3 (3H1) Cell Signaling Rat 1:10 
Tubulin (11H10) Cell Signaling Rat 1:20 
    
 
 
Table 2.7 Secondary antibodies used in Western blots 
Secondary Antibody Supplier Species Concentration 
Anti-mouse HRP Santa Cruz Donkey 1:10,000 (anti GFP);  
1:5000 (anti-Histone) 
Anti-rabbit HRP Santa Cruz Donkey 1:10,000 
Anti-rat HRP Santa Cruz Goat 1:2000 
 
2.2.10.6 Stripping WB membrane (harsher conditions) 
After imaging, membranes were washed 3 times for 5 min in TBS-T and submerged 
in stripping buffer and incubated at 50°C for 30 min with occasional agitation. 
Membranes were then washed 2 times for 10 minutes in TBS-T at RT using large 
volumes of buffer. Membranes were probed with ECL to check antibody has been 








2.2.11 Real Time Polymerase Chain Reaction  
2.2.11.1 RNA extraction  
MDA-MB-231 and Hs578-T sorted cells were cultured in T75 cell culture flasks and 
incubated for 24 hrs at 37°C, then medium were removed and replaced with fresh 
growth medium. Different HS mimetic heparin compounds, (PerS H, 2,6 deS-NS H, 
PMH and PMHS) at appropriate concentrations (10 ng/ml) were added and incubated 
for 48 hrs at 37°C. After the incubation period, cells were washed twice with PBS 
and harvested with 0.1% trypsin and 0.1% EDTA. 106 cultured cells were re-
suspended in 200 µl PBS in a 1.5 ml clean microfuge tube. 400 µl Lysis/-Binding 
buffer were added and vortexed for 15 sec. Samples were transferred to a high pure 
filter tube and centrifuged at 8,000 xg for 15 sec. After centrifugation, the 
flowthrough liquids were discarded. A combination of 90 µl DNase incubation buffer 
and 10 µl DNase l, were added to the samples and incubated at RT for 15 min. 500 µl 
wash buffer l was added to the upper reservoir of the filter tube followed by 
centrifugation at 8,000 xg for 15 sec. The flowthrough liquids were discarded after 
centrifugation and filter tubes were combined with the used collection tube. The 
remaining pellet was washed with 500 µl wash buffer 11 and debris removed by 
centrifugation at 8,000 xg for 15 sec. A further 200 µl of wash buffer 11 was added 
and centrifuged for two min at maximum speed (approx. 13,000 xg) to remove any 
residual wash buffer. Collection tubes were discarded and the filter tubes were 
inserted into a sterile, clean 1.5 ml microfuge tube. RNA was eluted with 100 µl 
Elution buffer and centrifuged at 8,000 xg for 1 min. RNA concentration was 
measured using a NanoDrop™ (see section 2.2.9.2). If the eluted RNA was to be 
stored, rather than used directly for cDNA synthesis, the pellet was stored at -80°C 
for later analysis. 
2.2.11.2 RNA quantification 
RNA was measured using the Thermo Scientific NanoDrop™ 1000 
Spectrophotometer according to the manufacturer’s instructions. 1 µl of sample was 
quantified using the absorbance over a 220 nm-750 nm spectrum and gives an output 







2.2.11.3 DNase treatment  
To degrade DNA in applications that are sensitive to the presence of RNase, 
recombinant DNase 1, RNase-free, was used and the mixture was prepared in a final 
volume of 20 µl as shown in Table 2.8, and incubated at RT for 20 min. The reaction 
was stopped by adding 2 µl of 0.2 M EDTA (pH 8.0) and incubated at 75°C for 10 
min. Samples were placed on ice in preparation for the reverse transcriptase reaction. 
Table 2.8 Digestion of Genomic DNA in RNA samples 
Component Final concentration  
Total RNA  10-50 µg 
10X incubation buffer 5 µl 
DNase 1 recombinant, RNase-free 25-10 units 
Optionally: Protector RNase Inhibitor 10 units 
Water, RNase-free Up to 20 µl  
2.2.11.4 cDNA synthesis 
cDNA was synthesised with Transcriptor High Fidelity cDNA Synthesis Kit for RT- 
polymerase chain reaction (PCR) (Roche, UK) according to kit instructions. 9.4 µl 
RNA samples and water (PCR grade) were transferred to a 0.2 ml microfuge tube 
and 2 µl of 60 µM stock of random hexamer primers were added to make 11.4 µl 
total volume. The template-primer mixtures were denatured by heating at 65°C for 
10 min in a block cycler with a heated lid (to minimize evaporation). The samples 
were chilled on ice for 1 min, and pulse centrifuged. 4 µl of 1x (8mM MgCl2) 
Transcriptor High Fidelity Reserve Transcriptase Reaction Buffer, 5 µl of 20 U 
Protector RNase Inhibitor, 2 µl of 1 mM Deoxynucleotide mix, 1 µl of 5 mM DTT 
and 1.1 µl of 22 U Transcriptor High Fidelity Reserve Transcriptase were added to 







at 25°C for 5 min. A further incubation at 55°C for 10 min and inactivation of 
transcriptor high fidelity reverse transcriptase was achieved by heating to 85°C for 5 
min. The reaction was stopped by placing samples on ice. At this point the reaction 
tube was stored at 4°C for 1 to 2 hrs or at -20°C if for a longer period. Summary of 
thermal cycling conditions was shown in table 2.9. 
Table 2.9 Thermocycling conditions for reverse transcription 
 Temperature Incubation time 
Step1 25 ºC 5 min 
Step 2 55 °C 10 min 
Step 3  85 °C 5 min 
Step 3 4 °C ∞ 
2.2.11.5 Reverse transcriptase 
cDNA was generated from RNA using a cDNA kit (Applied Biosystems, CS, USA) 
according to manufacturer instructions. Each reaction mixture consisted of: 10 µl 
RNA sample (200 ng – 1 µg total RNA), 2 µl 10x RT buffer, 2 µl 10x RT random 
primers, 0.8 µl 25x dNTP mix, 1 µl reverse transcriptase, 1 µl RNase inhibitor and 
3.2 µl PCR grade water. The final reaction volume was 20 µl. Reaction mixtures 
were centrifuged briefly to eliminate air bubbles and spin down the contents. The 
reverse transcription was run in a DNA Engine DYAD peltier theromcycler (M 
Research Inc. UK), with the thermal cycling conditions detailed in Table 2.10. 
Table 2.10 Thermocycling conditions for reverse transcription 
 Temperature Incubation time 
Step1 37 ºC 60 min 
Step 2 95 °C 5 min 









Oligonucleotides were purchased from Bio Rad, UK, synthesised by MWG Biotech 
and diluted in water (PCR grade) according to the manufacturer’s recommendations 
to give 100 µm stock solutions (stored at -80°C). A 10 µm stock was made with 
water (PCR grade) for use in PCR and sequencing (stored at -20°C). A list of primers 
is given in Table 2.11. 
 
Table 2.11 Primer list 
Gene Primer Sequence  




F 5′-CGCAGCTCAGGAAGAATGTG-3′  
R 5′-TGAAGTACACTGGCATTGACG-3′  
ABCG2  
 
F 5′-CACCTTATTGGCCTCAGGAA-3′  
R 5′-CCTGCTTGGAAGGCTCTATG-3′  
VEGFA  
 




F 5′-AAAAAAGGACAGTGCTGTGAAG-3′  








R 5′-AGTCAGCAGGAGGGCAGGGA-3′  
GAPDH F 5′-GTGGACCTGACCTGCCGTCT-3′ 
R 5′-GGAGGAGTGGGTGTCGCTGT-3′  
18S rRNA  
 




F 5′-GAGAAAGGAGAC ATGTAACAAGAGT-3′ 








In a 1.5 ml reaction tube on ice, the PCR mix was prepared for one 20 µl reaction 
and were carried out in a total volume of 20 µl made up of 3 µl water PCR grade, 1 
µl of 20x PCR primer and 10 µl of  2x master mix. The mixture was mixed gently by 
pipetting up and down. 15 µl PCR mix was added into each well of the LightCycler 
480 Multiwell Plate. 5 µl of DNA template was added to each well. The LightCycler 
480 Multiwell Plate were sealed with LightCycler 480 Multiwell Sealing Foil. The 
multiwell plate was centrifuged at 1,500 xg for 2 min. Reactions were carried out 
using the LightCycler 480 instrument (Roche, UK) using the conditions shown in 
Table 2.1. Reactions were done in duplicate per biological repeat and the quantity of 
immunoprecipitated DNA was calculated by % Input. Thermal cycling parameters 
for primers are shown in Table 2.12. 
 
Table 2.12 Thermal cycling conditions used for qPCR 
Programs Temp °C  Acquisition Time Cycles Ramp °C  










































2.2.11.8 Taqman low density array microfluidic cards 
Taqman low density array (TLDA) microfluidic cards were custom designed by the 
Troeberg lab group (Oxford University, ARUK Centre for Osteoarthritis 
Pathogenesis, Kennedy Institute of Rheumatology), to consist of pre-selected 
Taqman gene probes (Appendix 1.1). Each card could be run with total of 8 samples, 
testing for 48 genes, including the house keeping gene control 18s. Each reaction 
mixture well contained a final volume of 100 µl consisting of 50 µl cDNA template 







Biosystems, USA). Prior to loading, reaction mixtures were vortexed and 
centrifuged, then added to the card. The card was centrifuged twice at 12,000 rpm for 
1 min and sealed with the microfluidic card sealer. Finally, samples were run on the 
ViiA™ 7 Real-Time PCR System (Applied Biosystems, USA).  The thermocycling 
conditions are shown in Table 2.13 
Table 2.13 Thermal cycling parameters for primes 
Programs Temp °C  Incubation time Cycles 













Anneal/Extend 60  1 min 40 
 
2.2.11.9 Gene expression analysis 
Since all primer pairs reported efficiency close to 100%, the data was calculated 
using the delta-delta ct method (2−ΔCt method), an adapted version of the 2−ΔΔCt 
method (Livak and Schmittgen, 2001, Yuan et al., 2006) to calculate relative change 
in expression between different BCSCs, assuming primer efficiency. 
Relative change in expression compared to control conditions = 2 
-∆∆Ct
 




ΔΔCT=(CT(target, untreated)−CT(ref, untreated))−(CT(target, treated)−CT(ref, 
treated)). 







detectable above background due to the accumulation of amplified product. This 
value is proportional to the starting target sequence copy number. Ct was measured 
in the exponential phase and, therefore, it was not affected by possible limiting 
components in the reaction. For every run performed, the threshold was set at the 
same fluorescence value (100 relative fluorescence units [RFU]). 
Taqman clustering results are achieved by using the Canberra distance metric 
(d p, q = ! !!!!!!!!!!
!
!!! ), where p and q are vectors. 
Control conditions were considered to be either CD44-/CD24- sorted cells from 
MDA-MB-231 and Hs578-T or CD44+/CD24- untreated cells. Treated samples were 
any conditions other than this. 
2.2.12 PathScan® analysis 
2.2.12.1 Cell Lysates assay for PathScan assay 
Protein lysate from the CD44+/CD24- sub-population of MDA-MB-231 and Hs578-T 
BCC cells were prepared. Briefly, cells were grown in 10 cm culture dishes and 
incubated for 24 hrs prior to treatment with compounds (10 ng/ml of PMH, PMHS, 
PerS H (1), NAc H (2), 2 deS-NS H (3), 6 deS- NS H (4), 2 deS-NAc H (5), 6 deS-
NAc H (6), 2,6 deS-NS H (7) or 2,6 deS-NAc H (8)). Cells were then incubated for 
an additional 48 hrs. A further cell preparation was done by stimulating cells 
additionally with FGF2. Cells were grown in 10 cm culture dishes and incubated for 
48 hrs. After incubation, cells were starved for 6 hrs with normal growth medium 
without FBS. Cells were stimulated with 1 µg/ml FGF2 and treated or not with 
different HS and modified heparin compounds at low concentration (10 ng/ml) for 60 
min. After time incubation of cell culture, plates were placed on ice and cells were 
washed twice with cold PBS. 500 µl of cold lysis buffer were added to each plate and 
incubated on ice for 3 min. The plates were tilted and adherent cells were scraped 
using the scraper. Then, the cell lysates were collected and transferred to clean 
microcentrifuge tubes. Cell lysates were centrifuged at maximum speed for 3 
minutes at 4°C. The supernatants were aspirated and placed in a clean fresh 1.5 ml 
tube to help remove any particles or large cell debris and stored at - 80°C until use 







2.2.12.2 Assembled array preparation 
The protective plastic film was removed and the multi-well gasket was placed on the 
bench top, with the silicone layer facing up. The glass slide was carefully placed on 
top of the multi-well gasket with the nitro-cellulose pads facing down. The metal clip 
was inserted into the groove in the gasket and the clip rotated into the locked 
position.  
2.2.12.3 PathScan procedure  
100 µl of array blocking buffer was added to each well, covered with sealing tape 
and incubated for 15 min at RT on an orbital shaker. Array blocking buffer was 
decanted by gently flicking out the Array Blocking Buffer into a sink. 75 µl of 
diluted lysate was added to each well and covered with sealing tape. Then, cell 
lysates in individual wells were incubated overnight at 4°C on an orbital shaker. 
Each well content was decanted again by gently flicking out the diluted lysate into a 
sink. 100 µl (1x) Array Wash Buffer was added to each well and incubated for 5 min 
at RT on an orbital shaker. The washing step was repeated three more times. Then, 
75 µl of (1x) detection antibody cocktail was added to each well, covered with 
sealing tape and incubated for 1 hr at RT on an orbital shaker.  Each well content was 
then decanted by gently flicking out the fluid into a sink and washed four times with 
100 µl (1x) array wash buffer for 5 min. 75 µl of (1x) HRP-linked streptavidin was 
added to each well, covered with sealing tape and incubated for 30 min at RT on an 
orbital shaker. After the incubation period, the washing step was repeated four times 
for 5 min.  
2.2.12.4 Imaging and data analysis 
The slide was removed from the multi-well gasket and placed face up in a clean 
plastic plate, followed by washing with 10 ml (1x) array wash buffer. (1x) Array 
wash buffer was removed and LumiGLO®/Peroxide reagent was covered to the top 
of the slide and incubated for 2 min. Images of the slide were taken using the 
ImageQuant™ LAS 4000 Biomolecular Imager (GE Healthcare). The slide was 
scanned and the intensities were compared using Quantity One software. For relative 







calculated. To correct for slight loading differences, the intensity of the negative 
background (b) was subtracted from each dot (eg. phosphorylated levels). Finally, 
the mean value of duplicate repeat of each normalized protein phosphorylation value 
was multiplyed by 100. The mean value of two separate experiments ± SD in 
duplicate was calculated.  
2.2.12.5 Statistical analysis 
All data are reported as the means ± SD, a part from Pathscan quantification data 
which are presented as means ± SEM. Significant differences were determined using 
the Student t test to compare between groups, with significance set to *P<0.05, 
**P<0.01, ***P<0.001. All statistical analysis and graphs were plotted using Excel 
2007.  
Prior to publication either a Bonferroni correction will need to be applied to all 







3 Expression of CSC markers in a sub-population of human 
BCCs: Correlation with enhanced metastatic and malignant 
properties 
!
3.1 General introduction and aims 
A large body of literature has identified CD44 as a putative CSC marker in breast 
tumours (Al-Hajj et al., 2003, Lee et al., 2015, Olsson et al., 2011). In addition to 
CD44, another putative CSC marker reported in human BCCs include low or no 
expression of CD24 (Al-Hajj et al., 2003, de Beça et al., 2013); however, the 
percentage of cells expressing these markers differed from one cell line to the other 
(Ricardo et al., 2011). Nevertheless, CD44 and CD24 have been used extensively in 
combination to isolate CSCs from BCCs and tumours based on their CD44+/CD24-
/low phenotype (Fillmore and Kuperwasser, 2007, Liu et al., 2014b). In addition to 
this CD44+/CD24-/low phenotype, isolation strategies in human BCCs using 
combinations with ALDH and CD133 cell surface markers have also been 
successfully identified (Croker et al., 2009).  
CSCs isolated via CD44+/CD24-/low phenotype have been demonstrated to have 
enhanced capacity for invasion, migration, adhesion, and resistance to 
chemotherapeutic agents (Abdullah and Chow, 2013, Kim et al., 2009, Kim et al., 
Mukherjee et al., 2014, Sheridan et al., 2006). However, recently some studies 
demonstrated conflicting results regarding correlations between clinical value and 
prognostic significance of CD44 and CD24 markers in breast cancer. (Mylona et al., 
2008) demonstrated that cells with CD44+/CD24−/low phenotype exert no significant 
impact on a patients' prognosis. In addition, one paper found that patients with 
tumors expressing the CD44−/CD24+ phenotype had the worst prognosis, compared 
to tumors rich in CD44+/CD24−/low cells. Furthermore, (Abraham et al., 2005) 
suggested that BCCs with CD44+/CD24−/low phenotype may not be associated with 
the clinical outcome or the patients' survival, emphasizing the fact that putative 
tumorigenic ability may not be limited to cells displaying this phenotype. Thus other 
BCSC markers may remain to be identified. Nevertheless, it was considered that the 







having CSC properties prompted the screening of a number of BCC lines in order to 
establish a model system for exploring the possible role of HS in regulation of CSCs. 
The aims of the work in this chapter were to: 
• Establish a model system using human BCC lines to study whether it is 
possible to regulate the CSC phenotype by manipulating the stem cell niche 
via HS glycans. 
• Measure multiple CSC markers (CD44, CD24 and CD133) to be able to 
define and separate CSC-like sub-populations in human BCC lines.  
• Use a combination of anti-CD44 and anti-CD24 antibodies and FACS to 
identify and isolate CSCs and other sub-populations (CD44-/CD24-, 
CD44+/CD24-, CD44+/CD24+ and CD44-/CD24+) from 2 selected BCC lines 
(MDA-MB-231 and Hs578-T).  
• To investigate whether CD44+/CD24- sub-populations from MDA-MB-231 
and Hs578-T cells have expected CSC properties by systemically analyzing 
their proliferation, invasion, migration capacity, adhesion, colony formation 
and chemosensitivity. 
3.2 The differential expression of some human BCC lines to CSC markers 
Previous results reported that CD44, CD24 and CD133 are markers for CSCs in 
breast tumours (Al-Hajj et al., 2003, Atkinson et al., 2013, Meyer et al., 2010). Flow 
cytometery was used to assess the expression of these 3 markers in 5 BCC lines, 
namely MCF-7-A, T-47D, ZR-75-1, MDA-MB-231 and Hs578-T; flow cytometry 
histograms of cells are shown in Figure 3.1. Two regions are shown (R1 and R2 
regions); R2 demonstrates the cell expression of the CSC markers compared to the 
R1 antibody isotype control (Figure 3.1).  
MCF-7-A, T-47D and ZR-75-1 cells did not show significant expression of CD44 
(2.59 ± 2.03, 5.03 ± 1.87 and 8.5 ± 4.8% respectively), and conversely showed high 
positive expression of CD24 (47.8 ± 1.9, 81.65 ± 2.02 and 77.96 ± 2.93% 
respectively) (Figure 3.1A, B, C). In contrast, MDA-MB-231 and Hs578-T cells 
consistently displayed the highest expression of CD44 (67.8 ± 2.46 and 50.83 ± 2.29 







respectively (Figure 3.1D, E).  The T-47D cell line was the only line to show 
expression of CD133 on their surfaces (Figure 3.1B); MCF-7-A, ZR-75-1, MDA-
MB-231 and Hs578-T cells were all negative for CD133 expression (Figure 3.1A, C, 
D, E).  
Quantitative analysis of expression in human BCC lines of the CSC markers 
conjugated to a number of alternative fluorochromes are shown in Figure 3.2. The 
expression levels of CD44 (FITC or APC), CD24 (FITC, PE or APC) and CD133 
(PE alone) were analyzed by FACS. Consistent data was obtained irrespective of the 
fluorochrome used, and was in full support of the analysis described above. MCF-7-
A and ZR-75-1 cells express low levels of CD44 conjugated to either (FITC or 
APC), negatively expressed CD133 conjugated to PE, with high positive expression 
of CD24 conjugated to either FITC, PE or APC. T-47D cells expressed very low 
levels of CD44 (with FITC or APC) and positively expressed CD24 (FITC, PE or 
APC) and CD133 PE. MDA-MB-231 and Hs578-T cells showed the highest 
expression of CD44 (with FITC or APC), with very low expression of CD24 (FITC, 
PE or APC) and negative expression of CD133 PE. Marker expression data are 








Figure 3.1 Percentage of cells expressing CSC markers CD44, CD24 and CD133 in human BCC 
lines. Single-cell suspensions of 106 cells from (A) MCF-7-A-1, (B) T47-D, (C) ZR-751-1, (D) MDA-
MB-231 and (E) Hs578-T were stained with either anti-human CD44, CD24 and CD133 conjugated 
to APC, FITC and PE respectively, or appropriate APC, FITC and PE IgG1 isotype controls. Cells 
were analysed in a BD FACSCalibur flow cytometer.  CD44, CD24 and CD133 fluorescence intensity 
histograms of R2 positive cell subpopulations with CD44, CD24 and CD133 (signal above threshold) 
versus R1 isotype controls (signal below threshold). Approximately 30,000 events were 
collected/sample. Data from one of four representative experiments are shown. 
 





































































































Figure 3.2 MCF-7-A, T-47D, ZR-75-1, MDA-MB-231 and Hs578-T cell lines were maintained as 
described in Methods. Upon reaching 80% confluence, total cells were incubated with either an anti-
CD44 antibody conjugated to (FITC or APC), an anti-CD24 antibody conjugated to (FITC, PE or 
APC), or an anti-CD133 antibody conjugated to PE fluorochrome, or appropriate FITC, PE and APC-
conjugated IgG isotype controls. The expression levels of CD44, CD24 and CD133 were analyzed by 
FACS (as in Figure 3.1). Data shown represent the mean ± SD, n=4 independent experiments (each 
with duplicate measurements).!
!
Table 3.1 Summary of CSC marker expression in different human BCC lines 
Cell line/Marker CD44 CD24 CD133 
MCF-7-A + +++ - 
T-47D + +++ + 
ZR-75-1 + +++ - 
MDA-MB-231 +++ ++ - 
Hs578-T +++ ++ - 
 
Abbreviations -, not detectable; +, <5%; ++, 5-50% of the cells express the marker 














































































3.3 Human BCC lines contain sub-populations of cells that differ 
quantitatively in their expression of CSC markers 
In order to test the hypothesis that human BCC lines differ in the proportion of 
CD44+/CD24- cells, the four BCC lines were characterized using FACS analysis for 
surface expression of CSC markers CD44 and CD24. Isotype controls were 
conducted for all cell lines investigated (Figure 3.3). 
FACS analysis (n=4) of the least aggressive MCF-7-A and T-47D cell lines showed 
that these cells had the lowest proportion of CD44+/CD24− cells (1.77 ± 0.66% and 
0.03 ± 0.04% respectively) (Figure. 3.3A, B), whereas the most aggressive MDA-
MB-231 cell line had the highest proportion of CD44+/CD24− cells (47.52 ± 2.08%) 
(Figure 3.3C). The moderately metastatic Hs578-T cell line also contained a 
CD44+/CD24- population (31.14 ± 2.46%; Figure 3.3D).  This indicates a large 
amount of MDA-MB-231 and Hs578-T cells expressing these surface markers. The 
opposite was observed for the CD44-/CD24+ sub-population which was enriched in 
MCF-7-A and T-47D cell lines (34.77 ± 3.85% and 47.46 ± 4.67%), and was almost 
absent in the MDA-MB-231 and Hs578-T cell lines contained (7.05± 1.95 and 6.4 ± 
1.3% respectively) (Figure 3.3).  
A quantitative analysis is summarised in Figure 3.4 and Table 3.1, showing that the 
MDA-MB-231 cells contained significantly more cells with a CD44+/CD24− 
phenotype than any of the other cell lines (P<0.001), and that the Hs578-T cell line 
had significantly more cells with a CD44+/CD24− phenotype than either the MCF-7 
or T-47D cell lines (P<0.001) (Figure 3.4). In addition, Table 3.2 shows the tumor 
type and classification based on gene expression profiling or expression of markers 








Figure 3.3 Human BCC lines contain sub-populations of cells that differ quantitatively in their 
expression of CSC markers. Flow cytometry analysis was carried out for CD44 and CD24 on (A) 
MCF7-A-1, (B) T-47D, (C) MDA-MB-231 and (D) Hs578-T cells. Cell were maintained as described 
in Methods. 105 single-cell suspensions of cells were subjected to double staining with anti-human 
CD44 and CD24. Left-hand panels show representative dot plots of APC versus FITC IgG-1 isotype 
control. Right-hand panels show dot plots of CD44 conjugated to APC versus CD24 conjugated to 
FITC expression. Cells in the red regions correspond to a designatedCD44+/CD24- Population. 
Approximately 30,000 events were collected/sample. Data from one of four representative 













































































































Figure 3.4 Quantitative analysis of expression of CD44 /CD24 surface markers in human BCC 
lines. MCF-7-A-1, T-47D, MDA-MB-231 and Hs578-T cell lines were maintained as described in 
Methods. Upon reaching 80% confluence, total cells were incubated with an anti-CD44 antibody 
conjugated to APC and an anti-CD24 antibody conjugated to FITC, or appropriate APC and FITC-
conjugated IgG isotype controls. The percentage of CD44+/CD24- expressing cells were analyzed by 
FACS as in Figure 3.3 (in duplicate). Data are presented as the mean ± SD from 4 independent 
experiments (n=4) (each with duplicate measurements). *** MDA-MB-231 and Hs578-T have 




Table 3.2 Summary of CSC marker CD44/CD24 sub-populations of various 

































































































MDA$MB$231$ 47.52)±)2.08) 2.56)±)0.76) 7.05)±)1.95) 42.85)±)3.39) Adenocarcinoma$ Claudin$low$







3.4 Strategy for isolation of CD44+/CD24- cells from human BCC lines 
Since the MDA-MB-231 and Hs578-T human BCC lines demonstrated that they had 
the most distinct sub-sets of cells with stem-like characteristics (CSC markers) these 
cell lines were chosen for further studies as models to establish the effect of HS and 
chemically modified heparin on cell morphology, growth rates and molecular 
mechanisms. Flow cytometery was used to assess the isolation of suitable CSC sub-
populations based on the marker expression pattern CD44+/CD24-; the cell sorting 
strategies developed are represented in Figure 3.5 (MDA-MB-231) and Figure 3.6 
(Hs578-T).  
CD44 and CD24 antibody staining resulted in four distinct sub-populations 
designated here for simplicity as P4, P5, P6 and P7 (P7=CD44-/CD24-, 
P4=CD44+/CD24-, P6=CD44+/CD24+ and P5=CD44-/CD24+). These four 
phenotypic subpopulations were separated by FACSAria (as described in Methods). 
The percentages of CD44+/CD24-, CD44+/CD24+, CD44-/CD24+, and CD44-/CD24- 
cells for MDA-MB-231 cell line were 52.7%, 9.3%, 1.7%, and 19.2%, respectively 
(Figure 3.5). The percentages of CD44+/CD24-, CD44+/CD24+, CD44-/CD24+, and 
CD44-/CD24- cells for Hs578-T cell line were 36.3%, 3.8%, 8.0%, and 49.5%, 
respectively (Figure 3.6).  The phenotype of the putative CSC sub-population was 
characterized as described in the following sections. This was undertaken in order to 
confirm that they displayed the expected behaviour of CSCs linked with tumor 








Figure 3.5 Strategy for isolation of CD44+/CD24- cells from MDA-MB-231 human BCC line. 
FACS was used to isolate CD44+ and CD24- sub-population from MDA-MB-231 cells for functional 
assays (see Figure 3.3). Cells were concurrently labelled with DAPI, and the fluorescent antibodies 
anti-CD44 APC and anti-CD24 FITC. Cell sub-populations were isolated using a four colour protocol 
on a FACSAria cell sorter (CD44+/CD24−, CD44+/CD24+, CD44-/CD24+ and CD44−/CD24- sub-
populations were collected). (A–C): Representative schematic of a sequentially gated MDA-MB-231 
cell line sort. (A) Unstained cells (Isotype IgG) were set as a control based on light scatter (left panel) 
and on expression of APC/FITC flurochrome (right panel). (B) Cells were first selected for viability 
based on light scatter (P1, left panel) and for double discrimination (P2, right panel). (C) Cells were 
then selected based on DAPI negativity (P3, left panel) and finally, divided into four sub-populations 
based on expression of CD44 and CD24 expression  phenotype (gated on P4 (CD44+/CD24-) ≈ 52.7% 
+ P5 (CD44-/CD24+) ≈ 1.7% + P6 (CD44+/CD24+) ≈ 9.3% + P7 (CD44-/CD24-) ≈ 19.2% of parent 
population) (right panel). The resulting cell sub-populations were designated as CD44+/CD24- (P4), 
‘stem-like’, and were collected and compared with the other three sub-populations in further 
functional analyses for differences in malignant and metastatic behavior in vitro. Representative 
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Figure 3.6 Strategy for isolation of CD44+/CD24- cells from Hs578-T human BCC line. FACS 
was used to isolate CD44+ and CD24- sub-population from Hs578-T cells for functional assays (see 
Figure 3.3). Cells were concurrently labelled with DAPI, and the fluorescent antibodies anti-CD44 
APC and anti-CD24 FITC. Cell sub-populations were isolated using a four colour protocol on a 
FACSAria cell sorter (CD44+/CD24-, CD44+/CD24+, CD44-/CD24+ and CD44-/CD24- sub-
populations were collected). (A–C): Representative schematic of a sequentially gated Hs578-T cell 
line sort. (A) Unstained cells (Isotype IgG) were set as a control based on light scatter (left panel) and 
on expression of APC/FITC flurochrome (right panel). (B) Cells were first selected for viability based 
on light scatter (P1, left panel) and for double discrimination (P2, right panel). (C) Cells were then 
selected based on DAPI negativity (P3, left panel) and finally, divided into four sub-populations based 
on expression of CD44 and CD24 expression  phenotype (gated on P4 (CD44+/CD24-) ≈ 36.3% + P5 
(CD44-/CD24+) ≈ 8.0% + P6 (CD44+/CD24+) ≈ 3.8% + P7 (CD44-/CD24-) ≈ 49.5% of parent 
population) (right panel). The resulting cell sub-populations were designated as CD44+/CD24- (P4), 
‘stem-like’, and were collected and compared with the other three sub-populations in further 
functional analyses for differences in malignant and metastatic behavior in vitro. Representative 
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3.5 Human BCSC CD44+/CD24- sub-populations demonstrate enhanced 
viability and cell growth in vitro 
In order to undertake phenotypic characterization of the four sub-populations of BCC 
lines (MDA-MB-231 and Hs578-T) linked with tumor malignancy or aggressiveness, 
they were initially assessed by evaluating their cell viability in vitro. FACS-sorted 
cells were cultured in 24 well plates at a density of 4x104 cells/well and counted after 
trypan blue staining at various time points (24, 48 and 72 hrs). As shown in Figure 
3.7A, B, the viability of all the cell sub-populations was demonstrated, with 
increasing cell proliferation observed over the time points investigated. No 
significant differences in viability were noted at 24 hrs, but after 48 and 72 hrs 
incubation the CD44+/CD24- cells had shown the greatest increase in both MDA-
MB-231 and Hs578-T lines. In some cases these differences were statistically 
significant, in particular the CD44+/CD24- cells compared to CD44-/CD24-, CD44-
/CD24+ and CD44+/CD24+ cell sub-sets (P<0.05, P<0.01, P<0.001) (Figure 3.7A, B).  
To corroborate the results obtained using trypan blue, proliferation assays were also 
was measured in an MTT assay (Figure 3.8).  Results obtained after various time 
points 6, 24, 48 and 72 hrs of incubation were consistent with those using trypan blue 
(Figure 3.7), indicating proliferation MDA-MB-231 and Hs578-T BCCs. In addition, 
these results clearly indicate the enhanced proliferation of CD44+/CD24- cells 
compared to other sub-populations for both MDA-MB-231 and Hs578-T cells, at 24, 
48 and 72 hours (Figure 3.8A, B).  
In MDA-MB-231 and Hs578-T cells, the proliferation rates of cell sub-populations 
were not significantly different after only 6 hrs of incubation, as might be expected at 
this early time point when cells have just become adherent. A significant increase of 
growth rates of these cell sub-populations was detected after 24, 48 and 72 hrs 
(P<0.05, P<0.01, P<0.001) (Figure 3.8).  The CD44+/CD24- cell numbers were 
significantly increased compared to CD44-/CD24- (P<0.001) and CD44+/CD24+ and 
CD44-/CD24+ (P<0.05, P<0.01, P<0.01) at all time points except at 6 hrs, for MDA-
MB-231 (Figure 3.8A). Similarly the CD44+/CD24- sub-population from Hs578-T 
showed significantly increased compared to CD44-/CD24- (P<0.001), and 











Figure 3.7 Relative cell viability potential of BCSCs in vitro. The cell viability of the four 
CD44/CD24 expression sub-populations of (A) MDA-MB-231 and (B) Hs578-T cell lines was 
evaluated by trypan blue staining assay at various time points (24, 48 and 72 hrs). Results are 
expressed as mean value ± S.D from 3 independent experiments (each with duplicate measurements). 













































































Figure 3.8 Cell growth differs between four CD44/CD24 expression sub-populations from MDA-
MB-231 and Hs578-T human BCCs. Four sub-populations (CD44-/CD24-, CD44+/CD24-, 
CD44+/CD24+ and CD44-/CD24+) isolated from the (A) MDA-MB-231 and (B) Hs578-T BCC lines 
were cultured at a density of 4x104 for various time points 6, 24, 48 and 72 hrs and cell number was 
determined by MTT assay. Data shown are the means ± SD, from 2 independent experiments, each 




























































































3.6 Human BCSC CD44+/CD24- sub-populations demonstrate enhanced 
adhesion abilities in vitro 
Cell adhesion assays were performed to further investigate the adhesion properties of 
the two cell types MDA-MB-231 and Hs578-T with the objective of identifying any 
preferential properties of the BCSCs. To assess the total number of adhered cells, 
cells were seeded on 96 well plates coated with fibronectin; after the experimental 
time points (0, 1, 3 and 5 hrs), cells were detached enzymatically using 
trypsin/EDTA and counted using a hemocytometer. 
The number of sorted attached cells at the time points of 0, 1, 3 and 5 hrs is presented 
in Figure 3.9. The results from the four sub-population of MDA-MB-231 cells are 
represented in the Figure 3.9A.  At each time point the CD44+/CD24- cells displayed 
more attached cells compared to the other three sub-populations (CD44-/CD24-, 
CD44+/CD24+ and CD44-/CD24+).  After 1 and 3 hrs incubation, the adhesion of 
CD44+/CD24- cells were only slightly higher than for CD44+/CD24+ cells but this 
difference was not statistically significant. On the other hand, statistically significant 
differences were evident for the higher mean number of attached CD44+/CD24- cells 
at 1 and 3 hrs compared to CD44-/CD24- and CD44-/CD24+ cells (P<0.001) (Figure 
3.9A). However, comparing the sub-populations after 5 hrs incubation it was evident 
that CD44+/CD24- cells showed a significantly higher number of attached MDA-
MB-231 cells compared to all three sub-populations (CD44-/CD24- and CD44-
/CD24+, P<0.001 and CD44+/CD24+, P<0.01) (Figure 3.9A). Overall these data 
indicated that CD44+/CD24- cells show significantly greater adhesive capacity 
compared to other MDA-MB-231 BCC sub-populations. 
The cell adhesion data from Hs578-T cells (mean ± SD, n = 3) is shown in Figure 
3.9B. In general the data were similar to that for the MDA-MB-231 cells. Firstly, the 
CD44+/CD24- cells displayed higher adhesive capacity than CD44-/CD24- cells at all 
time points, and these differences were statistically significant (P<0.001) (Figure 
3.9B). For the CD44-/CD24+ cells adhesion was lower at all time points but was only 
statistically significant at 3 and 5 hrs (P<0.05 and P<0.001 respectively).  Although 
there was a consistent trend for CD44+/CD24+ cells to exhibit lower adhesion than 







significance except only statistically significant at 5 hrs (P<0.01). (Figure 3.9B). 
Overall these data indicated that CD44+/CD24- cells show significantly greater 
adhesive capacity compared to other Hs578T BCC sub-populations, with the 
possible exception of the CD44+/CD24+ cells. 
 
Figure 3.9 CD44+/CD24- CSCs from MDA-MB-231 and Hs578-T human BCCs display elevated 
cell adhesion capacity. CD44-/CD24-, CD44+/CD24-, CD44+/CD24+ and CD44-/CD24+ cells (2×104) 
isolated from the (A) MDA-MB-231 and (B) Hs578-T BCC lines by FACS-sorting were plated in 
triplicate for various time points (0, 1, 3, 5 hrs) onto fibronectin-coated sterile 96-well non-tissue 
culture plates. Non-nadherent cells were removed and adherent cells were quantified by manual 
counting using a hemocytometer at a magnification of ×10. Data are presented as the mean adhesion 








































































3.7 Human BCSC CD44+/CD24- sub-populations demonstrate enhanced 
migratory abilities in vitro  
To further determine whether human BCSCs display traits linked with tumor 
malignancy or aggressiveness, the migration ability of the sorted sub-populations 
from MDA-MB-231 and Hs578-T human BCC lines was investigated. The CD44-
/CD24-, CD44+/CD24-, CD44+/CD24+ and CD44-/CD24+ sorted sub-populations 
were assessed in a Transwell migration assay with FBS as chemoattractant (Figure 
3.10A). 
The numbers of CD44-/CD24-, CD44+/CD24-, CD44+/CD24+, and CD44-/CD24+ 
MDA-MB-231 cells that migrated through the basement membrane were 116 ± 15.5, 
214 ± 15.6, 170 ± 10.1, and 99 ± 7.1 / field) respectively.  The numbers of CD44-
/CD24-, CD44+/CD24-, CD44+/CD24+, and CD44-/CD24+ Hs578-T cells that 
migrated through the basement membrane were 66 ± 7.62, 156 ± 7.55, 81 ± 8.6, and 
118 ± 12.3 / field) respectively (Figure 3.10B). 
We observed that the number of migrating cells in CD44+/CD24- in both cell lines 
(MDA-MB-231 and Hs578-T cells) towards serum was significantly higher than 
respective CD44-/CD24-, CD44+/CD24+ and CD44-/CD24+ sub-populations 
(P<0.001). The migration of CD44-/CD24+ sub-population cells from MDA-MB-231 
was lower than CD44+/CD24+ sub-population (P<0.001) and also CD44-/CD24- cells 
(P<0.05). Similar results were seen for Hs578-T cells, [except that CD44-/CD24+ cell 
migration only showed a strong trend towards higher migration capacity than 
CD44+/CD24+ and CD44-/CD24- cells, (P<0.001) (Figure 3.10B)]. These results 
revealed that CD44+/CD24- cells exhibited elevated migrative capacity compared to 









Figure 3.10 CD44+/CD24- CSCs from MDA-MB-231 and Hs578-T human BCCs display elevated 
migratory capacity. The migration of four sorted sub-population cells CD44-/CD24-, CD44+/CD24-, 
CD44+/CD24+ and CD44-/CD24+ were assessed in Transwell cell culture chambers for 24 hours in 
response to a chemoattractant media (5% FBS) as described in Methods.  (A) Representative photos 
of migration assay in human BCSCs (MDA-MB-231 and Hs578-T) cells. MDA-MB-231 and Hs578-
T CD44+/CD24- sub-population cells show higher more migration capability than CD44-/CD24-, 
CD44+/CD24+ and CD44-/CD24+ cells. Scale bar=400 µm (B) The mean number of FACS-sorted cells 
(12×13 cells/well), n=3 for each cell population migrating through the chamber towards 
chemoattractant was assessed. Migrated cells were quantified by manual counting four fields/well. 
Data from one of three representative experiments shown; mean ± SD, n=2 replicates in each assay.  
***=significantly different than respective population of CD44+/CD24- cells migrating through 










































3.8 Human BCSC CD44+/CD24- sub-populations demonstrate enhanced 
invasive potential in vitro  
In order to establish the cell invasive phenotype of the two human BCC lines (MDA-
MB-231 and Hs578-T) Matrigel invasion assays were performed. Sorted cells were 
seeded onto Matrigel-coated transwell membranes and after 24 hrs cells that invaded 
to the lower side of the filter were counted and shown (Figure 3.11A). Following 
incubation period, the numbers of CD44-/CD24-, CD44+/CD24-, CD44+/CD24+, and 
CD44-/CD24+ of MDA-MB-231 cells that invaded through the basement membrane 
were 105 ± 8.8, 241 ± 16.4, 189 ± 12.1, and 176 ± 12 / field; magnification, ×10) 
respectively.  The equivalent data for Hs578-T cells were 71 ± 10.5, 211 ± 11.1, 194 
± 10.4, and 128 ± 9 / field; magnification, ×10) respectively (Figure 3.11B). 
CD44+/CD24-, CD44+/CD24+ and CD44-/CD24+ subpopulations of MDA-MB-231 
and Hs578-T were observed to be significantly more invasive towards serum through 
Matrigel than the CD44-/CD24- sub-population (P<0.001). The number of invading 
cells from the CD44+/CD24- subset was significantly higher compared to the two 
sub-populations CD44+/CD24+ and CD44-/CD24+ cells in MDA-MB-231 cell line 
(P<0.001). CD44+/CD24- and CD44+/CD24+ cells from Hs578-T cells displayed 
approximately similar levels of invasion, while the level for CD44+/CD24- cells was 
significantly higher than the CD44-/CD24- and CD44-/CD24+ cells (P<0.001) (Figure 
3.11B). These results revealed that CD44+/CD24- cells have a higher metastatic 
capacity, consistent with the hypothesis that CSCs contribute to migration and 










Figure 3.11 CD44+/CD24- CSCs from MDA-MB-231 and Hs578-T human BCCs display high 
invasive potential. Four sub-populations (CD44-/CD24-, CD44+/CD24-, CD44+/CD24+ and CD44-
/CD24+) were isolated from the MDA-MB-231 and Hs578-T BCC lines. Transwells (8µm) were pre-
coated with 10 µg/well Matrigel and FACS-sorted cells (12×103 cells/well), (n=2) for each cell 
population). Cells were allowed to invade through the Matrigel for 24 hrs towards chemoattractant 
media (5% FBS). (A) Representative photos of invasion assay data from each set of cell line sub-
populations from human BCSCs (MDA-MB-231 and Hs578-T). Invasion of the four sorted sub-
population cells CD44-/CD24-, CD44+/CD24, CD44+/CD24+ and CD44-/CD24+ were measured in 
Transwell cell culture chambers following 24 hrs incubation. CD44+/CD24- cells sorted from MDA-
MB-231 and Hs578-T show more invasion capability than the other three sub-populations. The mean 
number of cells invaded to the lower surface was counted. Scale bar=400 µm.   (B) The number of 
invading cells was quantified by manual counting of four fields/well. Data from one of three 
representative experiments shown; mean ± SD, n=2 replicates in each assay. ***=CD44+/CD24- cells 
were significantly different than other sub-populations of MDA-MB-231 and Hs578-T cells invading 






































3.9 Human BCSC CD44+/CD24- sub-populations exhibit higher colony 
forming efficiency compared with other sub-populations 
To further investigate possible functional differences between CD44+/CD24- CSCs 
and other sub-populations from MDA-MB-231 and Hs578-T BCC lines, these cells 
were also FACS-sorted and tested in a colony-formation efficiency assay. After four 
weeks of incubation, colonies were seen in the soft agar and cells were counted. The 
colony-formation capacity of CD44+/CD24- and other respective sub-populations 
indicated that putative CSC CD44+/CD24- cells from the MDA-MB-231 and Hs578-
T cell lines have a significantly higher potential to form colonies compared to the 
other respective sub-populations (P<0.01, P<0.001) (Figure 3.12).  
On average, CD44+/CD24- and CD44+/CD24+ cells from MDA-MB-231 cell line 
gave rise to 28 colonies per 1 × 103 input cells and CD44-/CD24-, CD44-/CD24+ cells 
gave rise to 20 and 17 colonies per 1 × 103 input cells, respectively. The number of 
colonies of CD44+/CD24- cells was significantly higher compared to CD44-/CD24-, 
and CD44-/CD24+ cells (P<0.01, P<0.001), whereas CD44+/CD24- and 
CD44+/CD24+ cells from MDA-MB-231 cells displayed approximately similar levels 
of colony formation efficiency (Figure 13.12). 
Broadly similar results were obtained in experiments performed with sub-
populations from Hs578-T cells (Figure 13.12). On average, CD44+/CD24- cells gave 
rise to 25 colonies per 1 × 103 input cells, CD44+/CD24+ cells gave rise to 17 
colonies per 1 × 103 input cells, and CD44-/CD24-, CD44-/CD24+ cells gave rise to 
16 and 11 colonies per 1 × 103 input cells, respectively. CD44+/CD24- cells were 
observed to be significantly higher in number of colonies than other Hs578-T sub-
populations (P<0.01, P<0.001) (Figure 13.12). Overall the data from both cells lines 
support the view that CD44+/CD24- cells have a more aggressive colony-forming 









Figure 3.12 CD44+/CD24- CSCs from MDA-MB-231 and Hs578-T human BCCs display elevated 
colony forming ability. FACS-sorted cells were grown in soft agar (0.6%) for 4 weeks (1x103 
cells/96 well plate, n=3 wells/cell population). Colonies were quantified and the results represent 
combined data (mean ± SD) from two independent experiments (each with triplicate measurements). 
Statistical analysis was performed using a Student's t-test. **P < 0.01, ***P < 0.001 for CD44+/CD24- 
vs. other respective populations. 
 
3.10 Human BCSC CD44+/CD24- sub-populations display higher 
chemoresistance to chemotherapeutic agents  
Since CSCs have been reported to display higher resistance to chemotherapeutic 
agents, the effect of such agents on apoptosis of cell sub-populations from MDA-
MB-231 and Hs578-T BCC lines was studied, by staining for Annexin V and PI. Cell 
subsets were stained with Annexin V and PI, which can be detected in the early and 
late stage of apoptosis respectively. The use of annexin V along with PI staining 
made it possible to distinguish apoptotic cells from cells with a damaged cell 
membrane. Cells were grown and treated separately with three different agents 
tamoxofin (Tam), doxorubicin (Dox) or cisplatin (Cis) and incubated for 24, 48 and 
72 hrs. After incubation, sorted cells were subjected to Annexin V/PI staining and 
analyzed using flow cytometry. Figure 3.13 and 3.14 show representative data 
analysis of apoptotic cells in CD44+/CD24- and CD44-/CD24- sorted cells from 








































and tamoxifen for 48 hrs and cisplatin for 72 hrs. For comparison data are also 
provided for unsorted cells, since insufficient cells were available for the other 2 
minor cell sub-populations to permit these experiments. Complete FACS datasets are 
provided in Appendix 2.1, 2.2 and 2.3.  
Individual experiments showed that treatment of the CD44-/CD24-, CD44+/CD24- 
sorted and unsorted MDA-MB-231 cells with different doses of doxorubicin after 48 
hrs were affected and the number of apoptotic cells were increased steadily in 
approximately 5% with the increase of doxorubicin concentrations, as compared to 
untreated cells (Figure 3.13 A). 5 µg/ml doxorubicin resulted in the highest 
percentages of apoptotic cells compared to untreated cells (P<0.001). It was shown 
that, no significant differences between CD44-/C24- and CD44+/C24- untreated cells, 
and apoptotic percentage of CD44+/C24- cells were significantly lower compared to 
untreated unsorted cells (P<0.05). CD44-/C24- cells were significantly the highest 
percentage of apoptotic cells compared to unsorted cells and CD44+/C24- cells in cell 
cultures treated with various concentration of doxorubicin (P<0.05, P<0.01, 
P<0.001) (Figure 3.13A). As a proof of principle chemoresistance of cancer 
initiating-like cells, CD44+/C24- sorted cells from MDA-MB-231 were more 
resistant to doxorubicin at various concentrations than other sub-populations cells 
(P<0.05, P<0.001) (Figure 3.13A). 
To determine whether the increase of cell apoptosis observed after treatment with 
different concentrations of other chemotherapeutic agent (cisplatin), MDA-MB-231 
cells were also tested with flow cytometry (Figure 3.13B). After incubation of MDA-
MB-231 cells with various concentrations of cisplatin for 72 hrs, cisplatin treatment 
significantly induced apoptosis compared to untreated cells (P<0.01, P<0.001). 
CD44+/CD24- cells treated with 0.001, 0.01 or 0.1 µM cisplatin for 72 hrs did not 
show increased levels of apoptosis compared with untreated cell groups, but showed 
significantly levels of apoptosis at 1 and 10 µM (P<0.01). The apoptotic percentages 
of CD44+/CD24- cells treated with 0.001, 0.01 or 0.1 µM for 72 hrs were 
significantly lower compared to the other cell populations (P<0.01, P<0.001). In 
contrast, CD44+/CD24- cells treated with 10 µM of cisplatin were significantly 
higher than respective populations (P<0.05, P<0.01). No significant differences were 







cisplatin, while a significant decrease was observed compared to unsorted cells 
(P<0.001) (Figure 3.13B). 
Tamoxifen treatments were also tested on MDA-MB-231 cell populations. Figure 
3.13C shows mean ± SD values of the percentages of apoptotic unsorted and sorted 
cells (CD44-/CD24- and CD44+/CD24-) after 48 hrs incubation with various 
concentrations. Percentages of apoptosis in isolated MDA-MB-231 cells treated with 
low concentrations of tamoxifen for 48 hrs were not detected at all time points. 
Higher concentrations of tamoxifen (1000, 10000 and 100000 nM) were significantly 
higher than in those of untreated cells (P<0.01, P<0.001). Moreover, significant 
differences were not observed between sorted and unsorted cells in most treated 
cells. CD44+/CD24- cells were significantly lower than unsorted cells at 10000 and 
100000 nM tamoxifen (P<0.05, P<0.001). In addition, CD44+/CD24- cells were 
significantly lower than CD44-/CD24- cells at 100000 (P<0.05) and no significant 
effect was observed at 10000 nM tamoxifen Figure 3.13C. 
To further investigate the effect of chemotherapeutic agents on induction of 
apoptosis on CD44+/CD24- of other human BCC (Hs578-T) cells, sorted and 
unsorted cells of Hs578-T cells were also tested with flow cytometry (Figure 3.14A). 
Hs578-T cells treated with various concentrations of doxorubicin at 48 hrs showed a 
significant effect on cell apoptosis compared to untreated cells (P<0.01, P<0.001) 
(Figure 3.14A). Percentages of apoptosis in unsorted Hs578-T cells treated with 
doxorubicin after 48 hrs of incubation was significantly higher than other isolated 
cells (P<0.05, P<0.01, P<0.001). Similar results to MDA-MB-231 cells were 
observed in Hs578-T with CD44+/CD24- sub-population, cells were significantly less 
sensitive to chemoagent doxorubicin in comparison to the other respective unsorted 
and sorted cell subpopulation (P<0.01, P<0.001), but no significant differences were 
observed between them in untreated cells. (Figure 3.14A). CD44+/CD24- isolated 
cells treated with 5 and 10 µg/ml of doxorubicin for 48 hrs showed a significant 








Various concentrations of cisplatin clearly induced significant apoptosis after 72 hrs 
in unsorted and sorted cells from Hs578-T cells compared to untreated cells (P<0.01, 
P<0.001), while no statistical significant was observed at 0.01 µM compared to 
untreated cells (Figure 3.14B). Moreover, significant differences were not detected 
between CD44-/CD24- and CD44+/CD24- sub-population cells at 0.01 and 1 µM, but 
a significant decrease was observed at 0.001, 0.1 and 10 µM (P<0.01, P<0.001). 
CD44+/CD24- cells were observed significantly lower in apoptotic percentages 
compared to unsorted cells at all various concentrations cells (P<0.05, P<0.01, 
P<0.001) except at 0.001 µM. (Figure 3.14B).   
Broadly similar results to MDA-MB-231 cells were obtained in tamoxifen treatments 
performed with sub-populations from Hs578-T cells  (Figure 3.14C). Low 
concentrations of tamoxifen at 1 and 10 nM did not induce apoptosis in Hs578-T 
sub-populations compared to untreated cells. Modulatory concentration of 100 nM 
tamoxifen significantly decreased cell apoptosis (P<0.05) compared to untreated 
cells. In contrast, higher concentrations of tamoxifen (10000, 100000 µM) were 
significantly induced apoptosis than in those of untreated cells (P<0.01, P<0.001). 
Cell apoptosis of CD44+/CD24- cells treated with those high concentrations of 
tamoxifen were significantly lower than unsorted or CD44-/CD24-cells (P<0.05, 
P<0.01, P<0.001) at most of he time points. In addition, untreated cells and cells 
treated with 10 nM tamoxifen showed a significant decrease in CD44+/CD24- 
compared to unsorted cells (P<0.05, P<0.01).  
These results show a significant increase in apoptosis and decrease in survival in 
both unsorted and sorted MDA-MB-231 and Hs578-T cells that were treated with 
various concentrations of three different chemotherapeutic agents compared with the 
untreated groups. These results suggest that the anti-proliferative effect of treatment 
is caused by apoptosis. In addition, CD44+/CD24- human BCCs showed less 
sensitivity to chemotherapeutic agents compared to unsorted and CD44-/CD24- 








Figure 3.13 Comparison of chemosensitivity of MDA-MB-231 unsorted and sorted cells to 
various concentrations of (A) Doxorubicin at 48 hrs, (B) Cisplatin at 72 hrs and (C) Tamoxifen 
at 48 hrs. MDA-MB-231 unsorted and FACS sorted cells were exposed to chemotherapeutic agents 
at increasing concentrations for 48 hrs or 72 hrs. Untreated cells (UT) were used as a control. 
Apoptotis was measured by Annexin V/PI staining and FACS sorting as described in Methods, and 
the percentage of early and late apoptotic cells were calculated. Data from one of two representative 
experiments is shown (mean.±.SD, n=3). Data in inset show statistical significance at *= P<.0.05; **= 





























































































Figure 3.14 Comparison of chemosensitivity of Hs578-T unsorted and sorted cells to various 
concentrations of (A) Doxorubicin at 48 hrs, (B) Cisplatin at 72 hrs and (C) Tamoxifen at 48 
hrs. Hs578-T unsorted and FACS sorted cells were exposed to chemotherapeutic agents at increasing 
concentrations for 48 hrs or 72 hrs. Untreated cells (UT) were used as a control. Apoptotis was 
measured by Annexin V/PI staining and FACS sorting as described in Methods, and the percentage of 
early and late apoptotic cells were calculated. Data from one of two representative experiments is 
shown (mean.±.SD, n=3). Data in inset show statistical significance at *= P<.0.05; **= P<.0.01 and 




































































































3.11 Discussion  
The existence of small sub-populations of CSCs in solid human cancers is widely 
reported, and cancer-derived cell lines have also been described as containing 
putative CSCs with similar characteristics, including a number of BCC lines. Results 
described here confirmed that a number of established BCC lines contain sub-
fractions of CSCs, defined by marker expresson patterns; these cells have been 
reported to be tumor-initiating cells with the capacity to differentiate into 
phenotypically diverse progeny and are thus of significant interest for cancer 
treatment. The findings in this chapter indicated that the MDA-MB-231 and Hs578-T 
BCC lines contain significant CD44+/CD24- cell populations with phenoptypic 
characteristics typical of CSCs, indicating that they would be good models for 
studying effects of HS on CSCs. 
As the various markers identified in previous studies are not sufficient to identify a 
single CSC population, the existence of various lineages of BCSCs, likely leading to 
different types of BC and also coexisting within the same tumour, have been 
suggested (Hwang-Verslues et al., 2009). BCSC characteristics generally associate 
with differential expression of CD44 and CD24, since CD44+/CD24- cells have been 
reported as having higher tumourigenic properties in immunodeficient mice and also 
express EMT markers (Al-Hajj et al., 2003, Mani et al., 2008). When we analysed 
CD44, CD24 and CD133 in human BCC lines (MCF-7-A, T-47D, ZR-75-1, MDA-
MB-231 and Hs578-T), the pattern of CD44 and CD24 expression in different cell 
lines generally corresponded to their previously observed pattern of CSC marker 
expression. For example, in the case of the moderately metastatic MDA-MB-231 and 
Hs578-T cell lines, two distinct subpopulations were also observed with respect to 
CD44 and CD24 expression. Similarly, non-metastatic MCF-7-A, T-47D and ZR-75-
1 cells did not contain a detectable CD44+/CD24− or CD133+ subpopulation. CD133 
marker was found negative labeling for all cell lines, except for T-47D, and was not 
considered to be useful for cell selection in our further studies. In contrast, CD44 and 
CD24 markers displayed staining that was heterogeneous between cell lines but also 
within each cell line (Table 3.1) and is thus useful for selection purposes; 







histological subtype and parallels the classification of MDA-MB-231 and Hs578-T 
cells as a function of tumourigenicity (Table 3.2).  
Here we confirmed that commonly studied human BCC lines contain sub-sets of 
tumour initiating-like cells based on the expression of putative CSC markers CD44 
and CD24. Moreover, cell lines that contain these stem-like cell CD44+/CD24- 
populations at significant levels show a correlation with their previously established 
aggressiveness at tumour formation in vivo in animal models. Our findings 
demonstrated that CD44+/CD24- isolated from the human BCC lines MDA-MB-231 
and Hs578-T display significantly greater characteristics associated with 
malignant/metastatic properties compared to other corresponding sub-populations 
(CD44-/CD24-, CD44-/CD24+, and CD44+/CD24+). These characteristics included 
increased in vitro proliferation (Figure 3.8), adhesion (Figure 3.9), migration (Figure 
3.10), invasion (Figure 3.11) and colony forming ability (Figure 3.12).  
When the in vitro proliferative capacity and viability of CD44+/CD24− cells isolated 
from MDA-MB-231 and Hs578-T cells versus the other corresponding CD44-/CD24-
, CD44-/CD24+, and CD44+/CD24+ sub-populations was compared in this study, it 
was shown that the CD44+/CD24− cells showed enhanced growth. Compared to the 
classic view of stem cell phenotypes, the present proliferation results were initially a 
bit surprising, due to the fact that stem cells typically have a lower proliferation rate 
than that of committed cells (Beckmann et al., 2007). However, in context of the 
CSC concept (Introduction, Figure 1.8), these sub-sets of cells may divide and 
proliferate at very low rate when located in restrictive niche environments. Indeed, 
previous studies showed that ALDH-expressing stem cells in human bone marrow 
and umbilical cord blood has been observed to divide rapidly, and represent a 
progenitor cell population (Nagano et al., 2007); this may also be true in the context 
of some BCCs. The proliferation studies described here are consistent with previous 
studies showing increased proliferative capacity of CD44+/CD24− cells sorted from 
other tumor cells (from MDA-MB-231 and Hs578-T human BCC lines) (Croker et 
al., 2009); it might be that when separated from their niche environments (stromal 
cells, neighboring cells, ECM etc) and without immune interaction, they gain the 
ability to proliferate faster, in contrast to CD44-/CD24- cells (Ghaffari et al., 2015, 







considered that CD44+/CD24- cells were similar to stem cells, being capable of self-
renewal, including extensive proliferative capacity, as well as invasion, migration, 
colony formation and adhesion at potentially greater levels than CD44-/CD24- cells. 
In line with an earlier report (Sheridan et al., 2006, Yan et al., 2013), these results 
indicate that CD44+/CD24- cells have the highest invasion capacity compared to the 
other three sub-populations of MDA-MB-231 and Hs578-T cells and indicated that 
the increase of CSC markers expression selects for BCSCs with enhanced malignant 
and metastatic ability indicating the potential for metastatic activity. 
In the context of the CSC concept, chemotherapeutic agents target most cells in a 
tumor; however, a small sub-set of cells that proliferate slowly become resistant to 
chemotherapeutic agents, potentially providing a pivotal mechanism in the 
development of chemoresistance (Introduction, Figure 1.9). Indeed, CSCs in vitro 
have been shown to be significantly resistant to various types of chemotherapeutic 
agents (Hong et al., 2015, Liu et al., 2015). In agreement with this, findings here 
showed that CD44+/CD24- cells were significantly more resistant to 
chemotherapeutic agents (doxorubicin and cisplatin) than for example CD44-/CD24- 
cells. However, after longer time periods of treatment, the level of apoptotic cells 
increases in all cell populations but remains significantly lower in CD44+/ CD24- 
cells compared to CD44-/CD24- and other sub-populations; this may be observed if 
resistant cells are emerging from the few clones displaying a lower proliferation rate 
or having less susceptibility to the chemotherapy agent. So, CD44+/CD24- cells may 
expand as the progeny of chemoresistant-treated cells. 
In conclusion, we were able to demonstrate and isolate CD44+/CD24- cells and other 
sub-populations from human BCCs by FACS, allowing them to be cultured and 
studied separately in conditioned medium. The CD44+/CD24- cells were 
demonstrated to have expected CSC properties of self-renewal and proliferation, as 
well as high adhesion, migration, invasion and colony formation capacity; they also 
displayed resistance to chemotherapy agents relative to other cell sub-populations. 
This characterization indicated that these BCSCs provide useful models from which 
to gain new insights into how HSs might regulate these important cells, and 







4 Modulatory effects of HS/heparins on the phenotype of BCSCs 
4.1 General introduction and aims 
 As outlined in detail previously, HSPGs are key components of the ECM, which 
have a crucial role in mediating cell proliferation, migration, invasion and cellular 
signaling (Ibrahim et al., 2013, Okolicsanyi et al., 2014). These studies found that the 
siRNA-mediated syndecan-1 silencing resulted in a reduced a side population (SP) of 
MDA-MB-231 and MCF-7 BCC lines, and a reduced ALDH1-positive cell pool 
(Ibrahim et al., 2013). In addition, the knockdown of syndecan-1 in MDA-MB-231 
cells decreased the CD44+/CD24- CSC sub-population and increased the 
CD44+/CD24+ population (Ibrahim et al., 2013).   
The invasive phenotype of the CD44+/CD24- sub-population of MDA-MB-231 
BCCs has been observed to be higher than the CD44+/CD24+ sub-population 
(Sheridan et al., 2006). Another study found that, syndecan-1-depleted MDA-MB-
231 cells displayed increased invasiveness (Ibrahim et al., 2012).  
A well established model of BCSCs is the triple negative, highly invasive and 
metastatic MDA-MB-231 and Hs578-T cell lines. They have been employed in this 
project to investigate a potential role of HS/heparin and chemically modified 
heparins on CSC phenotype, in terms of proliferation, adhesion, migration and 
invasion. After growth in suspension culture, MDA-MB-231 and Hs578-T cells were 
sorted by flow cytometry to isolate CD44-/CD24- and CD44+/CD24- sub-populations, 
and then tested in various cell culture conditions for the above characteristics. Sorted 
cells were then treated with various concentrations of a small library of HS, heparin 
and chemically modified heparins. 
The aims of the work in this chapter were to: 
• Study the role of HS/heparin and chemically modified heparins on BCSC 
phenotype in terms of growth, adhesion, migration and invasion. 









These studies will allow us to determine whether the phenotype of CSCs can be 
modulated to reduce or prevent their tumorigenicity, to regulate the level of the 
renewing CSC population, and possibly to render them more sensitive to 
chemotherapeutic agents. 
4.2 Effect of chlorate treatment on CD44+/CD24- BCSCs  
Since our main objective was to identify whether HS modulates CSC behaviour, 
bright phase microscopy analysis was first used to ask whether CSC-like cells from 
MDA-MB-231 and Hs578-T cell cultures were affected by chlorate treatment to 
prevent HS sulphation. Sodium chlorate inhibits the generation of 3'-
phosphoadenosine-5'-phosphosulfate (PAPS), the sulphate donor used by most of the 
cell sulfotransferase enzymes, including those that mediate transfer of sulphate 
groups onto nascent HS chains (Guimond et al., 1993). Thus, treatment of cell 
cultures with sodium chlorate leads to a general inhibition of sulphation and is a 
method for studying HS function, since distinct HS functions are associated with 
different degrees and patterns of sulphation (Powell et al., 2004, Rudd et al., 2010). 
In order to examine the effects of chlorate on CS-like cells from MDA-MB-231 and 
Hs578-T cells, morphology were examined using bright field light microscopy. 
Briefly, CD44+/CD24- sorted cells were seeded at 20×103 and cultured in 6 well 
tissue culture plates for 24 hrs prior to treatment. Cells were treated with either 10 
mM of sodium chloride (NaCl) as a control or with 10 mM of sodium chlorate 
(NaClO3) and cultured for further 48 hrs. Cell morphology was observed for the 
CD44+/CD24- sub-set of MDA-MB-231 and Hs578-T cell lines cultured in serum-
supplemented medium as control (Figure 4.1). In the presence of chlorate (10 mM) 
(Figure 4.1A), it was evident that cell growth was significantly diminished (P<0.01) 
(Figure 4.1B). This effect was related to the reduced sulphation and not simply ionic 
strength of the added chlorate, since treatment with an equal concentration of sodium 
chloride yielded no major effects (Figure 4.1). This experiment gave an initial 








Figure 4.1 CSCs from MDA-MB-231 and Hs578-T BCCs are affected by chlorate treatment. (A) 
Bright Phase images of CD44+/CD24- sub-population of MDA-MB-231 and Hs578-T cells cultured 
for [48 hrs] either untreated, or in the presence of 10 mM sodium chlorate or sodium chloride (×20 
magnification). Scale bar, 40 µm.  (B) The cell viability of both cell lines was evaluated by trypan 
blue staining assay at 48 hrs. Results are expressed as mean value ± S.D. **P<0.01 vs. untreated cells. 
The experiment was performed three independent experiment, each in duplicate n=2. UT, untreated 
control cells; NaCl, sodium chloride; NaClO3, Sodium chlorate.  
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4.3 Effects of HS/heparins on CSC sub-population levels in BCC lines 
Since our main objective was to identify modulation of CSC proliferation and cell 
fate, flow cytometry was used to assess whether CSC-like cells from MDA-MB-231 
and Hs578-T cell cultures are differentially affected by treatment with various 
concentrations of HS/heparins. As mentioned before, various work showed that BCC 
lines express putative CSC markers, such as CD44 in combination with low/- CD24 
(de Beça et al., 2013, Gong et al., 2010, Velasco-Velázquez et al., 2011). We have 
been able to confirm CD44+/CD24- expression in MDA-MB-231 and Hs578-T cells, 
and focused on this sub-population of cells. When we analyzed HS/heparin-treated 
MDA-MB-231 and Hs578-T cells by flow cytometry to identify the CD44+/CD24- 
sub-population, we observed that some of these treatments, even at very low 
concentrations (sub to low ng/ml), reduced the proportion of CD44+/CD24- cells in 
culture (Figure 4.2; 4.3, and Appendix 3.1- 3.8 for the FACS analyses; quantitative 
data is summarised in Figures 4.4 and 4.5). 
As a first example, porcine mucosal heparin (PMH) caused a significant decrease 
(~25%) in the CSC-like subpopulation of MDA-MB-231 cells treated with a low 
concentration of PMH (1, 10, 100 ng/ml) (P<0.01, P<0.001) for 48 hrs prior to 
sorting, although an exception was an increase of the proportion of CD44+/CD24- 
observed at the lowest concentration (0.001 ng/ml). The biggest decreases were 
observed at 1-100 ng/ml, whereas higher concentrations of PMH (1 µg/ml and 
above) caused a less significant reduction in the CSC population (Figures 4.2 and 
4.4). PMH treatment gave similar effects on the CSC-like subpopulation of Hs578-T 
cells, causing a reduction of ~ 40 to 50% in the CD44+/CD24- proportion at all 
various concentrations (Figures 4.2 and 4.5). 
PMHS also induced significant reduction in the CSC sub-population from MDA-
MB-231 cells, with the statistically significant and strongest reductions noted in the 
concentration range 0.001, 0.01, 1, 10, 100 ng/ml (P<0.05, P<0.01), and also at high 
concentrations at 1 µg/ml (P<0.05) (with the exception of an increase observed at 10 
and 100 µg/ml (P<0.01) (Figure 4.3 and 4.4). Similar reductions in the CD44+/CD24- 
sub-population were also observed after PMHS treatment of Hs587-T cells at all 







The various modified heparins were also tested at a wide range of concentrations for 
their effects on the levels of CD44+/CD24- cells in MDA-MB-231 and Hs578-T 
cells. The results are summarised as follows: 
Compound 1 – Persulfated heparin (PerS H): MDA-MB-231 cells showed a 
significant decrease in the proportion of CD44+/CD24- cells when treated with PerS 
H (Figure 4.4; Appendix 3.1). The maximal effect was at 10 ng/ml (reduction to 
~2.5% of total cells, compared to ~15% in untreated cells). Effects at some 
concentrations were not significant due to experimental variation, and the data 
suggested decreased loss of CD44+/CD24- cells at the higher concentration (100 
ng/ml and 100 µg/ml; Figure 4.4; Appendix 3.1). Similar results were seen in Hs578-
T cells subjected to PerS H treatment, with maximal effect at ~1-10 ng/ml, and loss 
of this effect at the highest concentrations (100 µg/ml)  (Figure 4.5; Appendix 3.1).  
Compound 2 – N-acetylated heparin (NAc H): Treatment with this modified 
heparin resulted in a significant reduction of the proportion of CD44+/CD24- cells 
from MDA-MB-231 compared to untreated control cells at concentrations in the 
range 1-100 ng/ml and 1-10 µg/ml (P<0.05, P<0.01); low doses (0.001, 0.01 and 0.1 
ng/ml) and the highest dose (100 µg/ml) were apparently inneffective due to large 
experimental variation) (Figure 4.4; Appendix 3.2). In contrast, more pronounced 
reductions in the CD44+/CD24- sub-population were observed in Hs587-T cells 
treated with NAc H, with this effect occurring with all doses range (P<0.01) (Figure 
4.5; Appendix 3.2). 
Compound 3 – 2-deS, N-sulphated heparin (2 deS-NS H): at low concentrations in 
the range 0.001 to 100 ng/ml this compound produced a significant decrease in the 
CD44+/CD24- population of MDA-MB-231 cells (P<0.01, P<0.001), but not at 
higher doses except 10 µg/ml (P<0.05). (Figure 4.4; Appendix 3.3). Similar results 
were seen in Hs578-T cells, this compound did produce a significant reduction (25 to 
50%) in the CD44+/CD24- population at doses in the range 0.001 to 100 ng/ml 
(P<0.05, P<0.01). This effect was lost at 1 and 10 µg/ml treatments except 100 µg/ml 








Compound 4 – 6-deS, N-sulphated heparin (6 deS-NS H): produced a significant 
reduction (~30-50%) in the CD44+/CD24- population of MDA-MB-231 cells 
(P<0.01, P<0.001), but with a very flat dose response, and the effects at 0.01 ng/ml 
and 1 µg/ml were not statistically significant (Figure 4.4 and Appendix 3.4). Effects 
on reduction of the CD44+/CD24- population in Hs578-T cells were less clear, and 
only observed at 0.001, 0.01, 100 ng/ml and 1 µg/ml (P<0.01) (Figure 4.5; Appendix 
3.4) 
Compound 5 – 2-deS, N-acetylated heparin (2 deS-NAc H):  This compound 
produced more divergent effects. No significant effect on the level of the 
CD44+/CD24- population in MD-MBA-231 at most doses, except that doses of 
0.001, 10 ng/ml and 1 µg/ml showed a significant increase in the proportion of these 
cells compared to untreated cells (P<0.001) (Figure 4.4; Appendix 3.5). The 
CD44+/CD24- sub-population of Hs578-T cells was not significantly decreased by 
treatment with 2 deS-NAc H, most prominently at 0.001, 0.01 ng/ml and 1 µg/ml, 
but with significant effect at most other concentrations (P<0.05, P<0.01, P<0.001) 
(Figure 4.5; Appendix 3.5). 
Compound 6 – 6-deS, N-acetylated heparin (6 deS-NAc H): Similar results were 
seen with this compound caused a large decrease in the proportion of CD44+/CD24- 
cells from MDA-MB-231 at 0.1 ng/ml to 1 µg/ml (P<0.05, P<0.01). No significant 
effect was observed at low dose 0.001 ng/ml and high doses 10 and 100 µg/ml 
(Figure 4.4; Appendix 3.6).  In marked contrast to the MDA-MB-231 cells, this 
compound did not produce a significant effect on CD44+/CD24- cell numbers from 
Hs578-T cells at most doses range, except at 10 and 100 ng/ml (P<0.05, P<0.01) 
(Figure 4.5; Appendix 3.6). This compound at lower dose 0.01 ng/ml caused a large 
increase in the proportion of CD44+/CD24- cells from both MDA-MB-231 (Figure 
4.4; Appendix 3.6) and Hs578-T cell line (Figure 4.5; Appendix 3.6) cell lines.   
Compound 7 – 2,6-deS, N-sulphated heparin (2,6 deS-NS H): Low concentration of 
compound 7 (0.001 ng/ml) did not show any significant effect on the CD44+/CD24- 
cell population of the MDA-MB-231 cell line, but significant reductions were 
observed at 0.01 ng/ml and higher, with maximal effects (~75% reduction) at 10 







effects on the CSC-like subpopulation of Hs578-T cells, but with a more U-shape 
dose response with maximal effect at 10 ng/ml (P<0.05, P<0.01), and no effect at 
100 µg/ml (Figure 4.5; Appendix 3.7).   
Compound 8 – 2,6-deS, N-acetylated heparin (2,6 deS-NAc H): This compound 
produced a significant reduction in the CD44+/CD24- population of MDA-MB-231 
cells at all doses in the range 0.001 ng/ml to 100 µg/ml (P<0.05, P<0.01, P<0.001) 
(Figure 4.4; Appendix 3.8). However, 2,6 deS-NAc H did not produce a significant 
effect on CD44+/CD24- cell numbers from Hs578-T cells except at 10 ng/ml and 
1µg/ml (P<0.05, P<0.01) (Figure 4.5; Appendix 3.8).  
It can be concluded that addition of exogenous HS, heparin and modified heparins 
have significant effects on the level of the CSC sub-population in BCC lines. These 
effects were dose responsive, with some occurring at remarkably low concentrations 
(in the low ng/ml range), and in some cases the effects are lost at high 
concentrations. Some of the compounds exert effects which vary with the cell-type. 
Further investigation is warranted to examine the effects of heparin and other 
modified heparin compounds on MDA-MB-231 and Hs578-T BCCs and the 
phenotype of their CSC sub-populations. For these studies PMH, and PMHS, along 
with the modified heparins PerS H, 2,6 deS-NS H and NAc H were selected since 
they were the most potent at inducing reductions in the CD44+/CD24- population, in 









Figure 4.2 Treatment with 
porcine mucosal heparin (PMH) 
reduces the CD44+/CD24- 
subpopulation in BCC lines.  
Following 48 hrs treatment with 
PMH at various concentrations 
flow cytometry was used to 
measure the CD44+/CD24- 
subpopulation. MDA-MB-231 (A) 
and Hs578-T (B) cell lines were 
maintained in DMEM 
supplemented with 10% FBS, 
10µg/ml insulin, 0.5 µg/ml 
hydrocortisone and 2 mmol/l L-
glutamine, in a humidified 
atmosphere containing 5% CO2 at 
37oC. Cells were treated with 1, 
10, 100 ng/ml, 1,10, 100 µg/ml of 
PMH for 48 hrs. 105 single-cell 
suspensions of MDA-MB-231 and 
Hs578-T were double stained with 
anti-human CD44 and CD24. Cells 
in red region corresponding to 
CD44+/CD24- Isotype controls 
corresponding to MD-MB-231 and 
Hs578-T cells are shown. 
Representative data from one of 
four experiments are shown. 
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Figure 4.3 Treatment with 
porcine mucosal heparin 
sulphate  (PMHS) reduces the 
CD44+/CD24- subpopulation in 
BCC lines.  Following 48 hrs 
treatment with PMHS at various 
concentrations, flow cytometry 
was used to measure the 
CD44+/CD24- subpopulation. 
MDA-MB-231 (A) and Hs578-T 
(B) cell lines were maintained in 
DMEM supplemented with 10% 
FBS, 10µg/ml insulin, 0.5 µg/ml 
hydrocortisone and 2 mmol/l L-
glutamine, in a humidified 
atmosphere containing 5% CO2 
at 37oC. Cells were treated with 
1, 10, 100 ng/ml, 1,10, 100 
µg/ml of PMHS for 48 hrs. 105 
single-cell suspensions of MDA-
MB-231 and Hs578-T were 
double stained with anti-human 
CD44 and CD24. Cells in red 
region corresponding to 
CD44+/CD24- Isotype controls 
corresponding to MD-MB-231 
and Hs578-T cells are shown. 
Representative data from one of 
four experiments are shown. 
 
 




































































































































0.01 ng/ml PMHS 
0.1 ng/ml PMHS 




































































































10 ng/ml PMHS 
100 ng/ml PMHS 


























10 µg/ml PMHS 






























Figure 4.4 Quantification of the inhibitory effects of HS/heparin and chemically modified 
heparins on the CSC sub-population from MDA-MB-231 BCCs. Flow cytometric analysis of 
CD44+/CD24- expression in MDA-MB-231 cells following 48 hours treatment with compounds 1-8, 
PMHS or PMH (at 0.001, 0.01 0.1, 1, 10, 100 ng/ml, and 1, 10 100 µg/ml) for 48 hrs. Values 
expressed as isotype control APC/FITC.  Error bars correspond to SD from the total of four 
independent experiments. *P<0.05, **P<0.01, ***P<0.001=significantly different than respective 

































































































































































































































































































































































































































































































































































































































































































Figure 4.5 Quantification of the inhibitory effects of HS/heparin and chemically modified 
heparin on the CSC sub-population from Hs578-T BCCs. Flow cytometric analysis of 
CD44+/CD24- expression in Hs578-T cells following 48 hrs treatment with compounds 1-8, PMHS or 
PMH  (at 0.001, 0.01 0.1, 1, 10, 100 ng/ml, and 1, 10 100 µg/ml) for 48h. Values expressed as isotype 
control APC/FITC. Error bars correspond to SD from the total of four independent experiments. 


























































































































































































































































































































































































































































































































































































































































































































4.4 Effects of selected HS/heparins on proliferation of CSCs from BCC lines 
HSPGs are well known to have a role in cell growth, so the effects of the heparins on 
proliferation was examined in CD44+/CD24- cells sorted from human MDA-MB-231 
and Hs578-T BCC lines. Proliferation was measured using the MTT assay over 3 
days and compared with the corresponding untreated cells (Figure 4.6). A dose of 10 
ng/ml was chosen since this was a typical effective dose for the previously observed 
effects on the CD44+/CD24- sub-population levels. 
Untreated CD44+/CD24- cells sorted from MDA-MB-231 cells proliferated over a 
period of 3 days, with a steady increase observed between days 1-3 (Figure 4.6A). 
Treatment with NAc H resulted in a significantly higher apparent rate of growth 
(P<0.001), However, all the other compounds tested (PMH, PMHS and 2,6 deS-NS 
H) had no significant effect on cell growth over day, but thereafter resulted in a 
marked slowing of cell growth, such that cell growth was greatly diminished by day 
3 (P<0.05, P<0.01, P<0.001). Treatment with PerS H resulted in a significantly 
higher apparent rate of growth at day 1 (P<0.001), but thereafter, significant changes 
were not detected at day 2 and 3 (Figure 4.6A).  
In the case of CD44+/CD24- cells sorted from Hs578-T cells, NAc H again appeared 
to significantly increase the proliferation rate, though day 1-3 time points (P<0.001) 
(Figure 4.6B). For the other compounds there was no difference from the control 
untreated cells at days 1, but they all appeared to decrease proliferation at days 2 and 
3, particularly in the case of PMHS, PMH and 2,6 deS-NS H for MDA-MB-231, 
PMHS, PMH and PerS H for Hs578-T cells. Treatment with 2,6 deS-NS H resulted 
in a significantly lower apparent rate of growth at day 2 and 3.  Thus overall the 
selected heparins have broadly similar effects on the proliferation of CSCs from 
these two BCC lines. NAc H tends to promote growth, whereas PMH, PMHS, PerSH 








Figure 4.6 Effect of HS, heparin and selected chemically modified heparins on proliferation of 
the CD44+/CD24- sub-population from MDA-MB-231 and Hs578-T cells. An MTT assay was used 
to test cell proliferation: CD44+/CD24- of (A) MDA-MB-231 and (B) Hs578-T cells were treated or 
not with10 ng/ml of PerS H, 2, 6 deS-NS H, NAc H, PMHS and PMH and maintained over a period 
of 3 days. Cells were harvested each day for MTT reduction colorimetric assay. Data are shown as 



















































































4.5 Effects of HS/heparins on adhesion of CSCs from BCC lines  
Since HSPGs have a crucial role in tumour cell adhesion, the activity of soluble HS, 
heparin and modified heparin were evaluated here on adhesion of BCSCs. Briefly, 
unsorted and sorted cells (CD44-/CD24- and CD44+/CD24-) from MDA-MB-231 and 
Hs587-T BCC lines were treated with 10 ng/ml HS/heparin and modified heparins 
(PerS H, 2,6 deS-NS H, PMH and PMHS) for 48 hrs before the assay was 
performed. The cells were seeded into pre-coated 24-well plate with 15 µg/ml of 
fibronectin (FN) at a density of approximately 2x104 cells/well and allowed to adhere 
3 hrs. After incubation period, non-adherent cells were removed and washed twice 
with PBS and adherent cells were counted. For each replicate (n=3), the mean 
numbers of adherent cells in triplicate were counted using a hemocytometer by light 
microscope at a magnification of ten high-powered fields (10x) by using four 
independent fields. 
Cell adhesion to substrata coated with 15 µg/ml of FN was significantly inhibited in 
the presence of 10 ng/ml levels of soluble 2,6 deS-NS H, PMHS and PMH in 
CD44+/CD24- sub-population isolated from both MDA-MB-231 and Hs578-T cells 
(P<0.001), while PerS H induced no change in cell adhesion in all sub-populations in 
both cell lines compared to untreated cells (Figure 4.7). In addition, cell adhesion to 
FN of CD44-/CD24- of MDA-MB-231 and Hs578-T cells was not induce to the 
effects of 2,6 deS-NS H and heparin treatments compared to untreated cells (Figure 
4.7). Unsorted cells from MDA-MB-231 cell line treated with 2,6 deS-NS H, PMH 
and PMHS showed a significant decrease in cell adhesion (P<0.001) (Figure 4.7A). 
PMHS/heparin and selected chemically modified heparins did not show any 
significant change on cell adhesion in parental Hs578-T cells compared to untreated 
control cells. Only PMHS treatment significantly increased cell adhesion in all sub-
population in Hs578-T cells (P<0.01, P<0.001) (Figure 4.7B). PMHS treatment was 
significantly increased negative cell population to CD44 and CD24 markers in 
MDA-MB-231. In contrast, PMHS treatments were significantly decreased cell 








Figure 4.7 Effect of HS, heparin and selected chemically modified heparins on cell adhesion of 
the CD44+/CD24- sub-population from MDA-MB-231 and Hs578-T cells. (A) MDA-MB-231 and 
(B) Hs578-T treated with 10 ng/ml of PerS H, 2,6 deS-NS H, PMH and PMH for 48 hrs. Cell 
adhesion after 3 hrs on plastic coated with fibronectin were washed and adhered cells were counted 
with light microscope (magnification, ×10). Black bars denote unsorted cells, dark grey bars denote 
CD44-/CD24- and light grey bars denote CD44+/CD24-. Graphs represent mean ± SD. Data are 
expressed as mean ± SD/microscopic field. Data from one of three representative experiments shown; 








































































































4.6 Effects of selected HS/heparins on migration of CSCs from BCC lines 
In order to evaluate whether HS/heparin and selected chemically modified heparins 
inhibited cancer cell migration, a classical migration assay in Boyden chambers was 
performed with sorted and unsorted MDA-MB-231 and Hs578-T BCCs (Fig 4.17). 
Cells were initially plated and incubated for 24 hrs, followed by exposure to a 48 hr 
treatment with 10 ng/ml of HS/heparin and selected modified heparins (PerS H, 2,6 
deS-NS H, PMH and PMHS). Upon expansion, cells were plated on collagen IV-
coated upper wells for 24 hrs and migrated cells were then counted. The untreated 
CD44+/CD24- cells displayed higher migration than CD44-/CD24- cells (MDA-MB-
231, Figure 4.8A; Hs578-T, Figure 4.8B) as observed previously (Chapter 3, Figure 
3.10).  For MDA-MB-231 the results in Figure 4.8A show that 10 ng/ml pre-
treatment with PMHS or PerS H caused a significant reduction in migration of the 
CD44+/CD24- cells to levels comparable to untreated unsorted cells Figure 4.8A.  
Treatment with PMH or 2,6 deS-NS H caused an even greater reduction in migration 
of CD44+/CD24- cells (Figure 4.8A). Treatments with the compounds also caused 
small but significant reductions in migration of unsorted and CD44-/CD24- cells 
compared to their untreated counterparts, especially with PMH and 2,6 deS-NS H 
(Figure 4.8A).  
Figure 4.8B shows that PerS H and 2,6 deS-NS H (but not PMHS or PMH) caused a 
reduction on migration of CD44+/CD24- cells from Hs578-T cells. In addition, all the 
compounds caused significant reductions in migration of unsorted and CD44-/CD24- 
cells  (Figure 4.8B).  Thus there are some cell type dependent effects of the 
compounds on migration, but for both cells lines at least some of the compounds can 









Figure 4.8 Effect of HS, heparin and selected chemically modified heparins on migration of the 
CD44+/CD24- sub-population from MDA-MB-231 and Hs578-T cells. Boyden chamber assays 
were used to compare the migration of unsorted and sorted (A) MDA-MB-231 and (B) Hs578-T cells 
pre-treated or not with 10 ng/ml of PerS H, 2,6 deS-NS H, PMH and PMHS for 48 hrs. Equal 
numbers of treated MDA-MB-231 and Hs578-T cells were subjected to cell migration and incubated 
for 24 hrs. Then, migrated cells were detected on the membrane after stating with Diff-Quik solution. 
Data are expressed as mean ± SD/microscopic field. Data from one of three representative 
experiments shown; n=2 replicates in each assay, with (*P<0.05, **P<0.01, ***P<0.001 vs control). 


















































































































4.7 Effects of selected HS/heparins on invasiveness of CSCs from BCC lines 
HS play an important role in regulating metastatic behaviors in tumor cells. Since 
HSPGs is known to inhibit and promote cell invasion, with their function being 
determined by their location (cell surface or ECM) (Sanderson, 2001), it was 
important to establish whether the effects of HS/heparin and selected chemically 
modified heparins on BCSC invasion. The malignant breast carcinoma cell lines 
MDA-MB-231 and Hs578-T were sorted to CD44-/CD24- and CD44+/CD24- sub-
populations as described in methods (see section 2.2.2.3). Unsorted and sorted cells 
were treated with various HS/heparin and chemically modified heparins at low does 
10 ng/ml of (PerS H, 2,6 deS-NS H, PMH and PMHS). Cells then were plated in 
Matrigel invasion chambers for 24 hrs and invaded cell number was counted. (Figure 
4.9) represents the quantification of cell invasion. The untreated CD44+/CD24- cells 
displayed higher matrix invasion than CD44-/CD24- cells (MDA-MB-231, Figure 
4.9A) as observed previously (Chapter 3, Figure 3.10).  For MDA-MB-231 the 
results in Figure 4.9A show that pre-treatment with 10 ng/ml of PMHS, PM heparin 
and also two chemically modified heparins (PerS H and 2,6 deS-NS H) caused a 
marked reduction in invasion of the CD44+/CD24- cells to levels comparable to 
untreated unsorted cells (P<0.001).  2,6 deS-NS H also caused a small decrease in 
invasion of the unsorted cells, and possibly minor decreases for the CD44-/CD24- 
cells (Fig 4.9A). For Hs578-T cells the effects on invasiveness were less pronounced. 
The untreated CD44+/CD24- cells displayed higher matrix invasion than CD44-
/CD24- cells (Figure 4.9B) as observed previously (Chapter 3, Figure 3.10). For the 
CD44+/CD24- cells decreases were noted upon treatment with PMH, PerS H and 2,6 
deS-NS (P<0.05), but not PMHS.  Similarly, small decreases were also noted for 
unsorted and CD44-/CD24- cells from Hs578-T BCSC treated with PMH, PerS H 








Figure 4.9 Effect of HS, heparin and selected chemically modified heparins on invasion by the 
CD44+/CD24- sub-population from MDA-MB-231 and Hs578-T cells. Unsorted and sorted (A) 
MDA-MB-231 and (B) Hs578-T cells were treated (or not) with 10 ng/ml of PerS H, 2,6 deS-NS H, 
PMH or PMHS for 48 hrs and plated on Matrigel-coated champers, and the number of cells that 
invaded through the membrane after 24 hrs was counted for statistical analysis and expressed as the 
mean ± SD/microscopic field. Data from one of three representative experiments shown; n=2 
replicates in each assay. Significantly lower invasion was observed for cells treated with HS, heparin 










































































































4.8 Effects of selected HS/heparins on chemoresistance of CD44+/CD24- CSCs 
from BCC lines 
To investigate whether the treatments with HS and other compounds impact 
apoptosis CD44+/CD24- cells, unsorted and FACS sorted MDA-MB-231 and Hs578-
T cells (based on CD44 and CD24 expression) were grown and treated with optimum 
doses of either 5 µg/ml doxorubicin, 0.1 µM cisplatin or 1000 nM tamoxifen, in 
combination with 10 ng/ml of PMHS, PMH and selected chemical modified heparins 
(PerS H, NAc H and 2,6 deS-NS H) for 48 hrs; cell apoptosis was then assessed by 
flow cytometry.  
Figures 4.10 and 4.11 show dot plots of fluorescence intensities of cells labeled with 
annexin V/PI, showing the effects of HS/heparin and selected chemically modified 
heparins on BCSCs treated with the different chemotherapy agents. This allows 
comparison with the early and late apoptosis rates in non-treated and agent treated 
cells (CD44-/CD24- and CD44+/CD24- sorted cells). Quantitation of the data is 
shown in Figures 4.12 and 4.13.   
For MDA-MB-231 cells it was evident that doxorubicin induced early and late 
apoptosis in CD44-/CD24-, but not in CD44+/CD24- cells compared to untreated 
controls (CD44-/CD24-, 12.4 ± 1.25 vs 7.48% UT (P<0.001); and CD44+/CD24-, 
8.43 ± 1.07 vs 8.14% UT) (Figure 4.12A). In contrast, simultaneous treatment with 
selected chemically modified heparins PerS H, NAc H, 2,6 deS-NS H, PMH or 
PMHS induced marked increases in early and late apoptosis in CD44+/CD24- cells 
(to 10.56 ± 1.1, 11.76 ± 1.12, 14.34 ± 1.08, 14.78 ± 1.19, 8.87 ± 0.95 respectively, 
P<0.05, P<0.01, P<0.001) (Figure 4.12A). For CD44-/CD24- cells treatment with the 
combination of doxorubicin with PerS H and NAc H did not alter the sensitivity to 
doxorubicin treatment (11.95 ± 1.27, 13.76 ± 0.71 respectively vs 12.4% for 
doxorubicin alone), while 2,6 deS-NS H, PMH and PMHS treatment all caused 
significant increases in CD44-/CD24- cell apoptosis compared to doxorubicin 
treatment alone (18.98 ± 0.90, 20.75.20 ± 0.95, 16.17 ± 1.29 vs 12.4% Dox alone, 







Figure 4.12B shows comparison data between CD44-/CD24- and CD44+/CD24- 
sorted cells from MDA-MB-231 treated with the chemotherapeutic agent cisplatin. 
Compared with the untreated control groups, cisplatin alone induced increased 
apoptosis in CD44-/CD24-  (10.47 ± 1.29 vs 7.07% in UT; P<0.001) and also a 
smaller increase for CD44+/CD24- cells (7.84 ± 1.34 vs 6.29% in UT; P<0.05) 
(Figure 4.12B). Notable increases in apoptosis were induced when cells were treated 
with the modified heparins PerS H, NAc H and 2,6 deS-NS H in the presence of 
cisplatin: CD44-/CD24- (19.87 ± 1.38, 20 ± 1.20, 14.48 ± 1.20 respectively vs 7.07% 
Cis alone), and CD44+/CD24- (17.12 ± 1.18, 18.45 ± 1.39, 10.35 ± 1.07 respectively 
vs 6.29% Cis alone) (all P<0.001). In addition PMH with cisplatin were significantly 
decreased cell apoptosis in CD44+/CD2- cells (6.01 ± 1.11 vs 7.84% Cis alone; 
P<0.05) but not in CD44-/CD24- cells (10.28 ± 1.52 vs. 10.42% Cis alone).  In 
addition a combination of PMHS with cisplatin had no significant effect on both 
types of sorted cells CD44-/CD24- and CD44+/CD24- compared to cisplatin alone 
(11.04 ± 1.52 vs 10.47% Cis alone and 9.04 ± 1.11 vs 8.25% Cis alone, respectively) 
(Figure 4.12B). 
The effects of HS/heparin and chemically modified heparins on sensitivity of BCCs 
to tamoxifen was also tested (Figure 4.12C). Both CD44-/CD24- and CD44+/CD24- 
sorted cells from the MDA-MB-231 cell line were significantly sensitive to 
tamoxifen treatment alone, with increased apoptosis compared to untreated cell 
group (17.20 ± 1.4 vs 10% UT alone, and 12.05 ± 1.72 vs 7.54% UT alone, 
respectively; P<0.001). For CD44-/CD24- cells only 2,6 deS-NS H, PMH and PMHS 
significantly increased cell apoptosis compared to similar sub-population treated 
with tamoxifen alone (20.23 ± 1.68, 28.24 ± 1.88, 21.76 ± 1.91 respectively vs 
17.2% for Tam alone; P<0.001). For CD44+/CD24- cells all of the compounds 
induced significant increases in apoptosis compared to tamoxifen alone (P<0.01, 
P<0.001).  (Figure 4.12C); Overall, it is thus clear that CSCs from MDA-MB-231 
cells can be sensitized to induction of apoptosis via a number of chemotherapeutic 
agents if treated with heparin-based compounds. 
To determine whether Hs578-T BCC lines share similar enhanced chemosensitivity 
in response to treatment with the compounds, sorted cells were cultured with 







tamoxifen, alone or in combination with 10 ng/ml of HS/heparin and selected 
modified heparin (PerS H and 2,6 deS-NS H) for 48 hrs, with cell apoptosis was 
assessed by flow cytometry (Figure 4.13). As shown in Figure 4.13A,C, 
combinations of any of the compounds with the anticancer agents doxorubicin or 
tamoxifen induced increased apoptosis for both CD44-/CD24- and CD44+/CD24- 
Hs578-T cells compared to untreated control cells (P<0.01, P<0.001), the only 
exception being 2,6 deS-NS H treatment in combination with doxorubicin for 
CD44+/CD24- cells (13.12 ± 1.22 vs 10.58% UT alone), (Figure 4.13A). The largest 
increases were noted with the combination of PerS H with doxorubicin (28.1 ± 1.53 
vs 14.42% Dox alone, P<0.001) or  (tamoxifen with PMH or PMHS) (27.79 ± 1.77, 
30.72 ± 1 respectively vs 13.02% Tam alone, P<0.001) compared to single agent 
groups alone. In marked contrast, although a significant increase in apoptosis was 
observed in CD44+/CD24- cells treated with cisplatin (14.73 ± 1.02 vs 11.5% UT, 
P<0.001), addition of the various compounds did induce significant decreases in 
apoptosis compared cisplatin alone (P<0.05, P<0.001); (Figure 4.13B). Cisplatin 
alone did not induce increased apoptosis in the CD44-/CD44- sub-population, but 
each of the compounds (PerS H, 2,6 deS-NS H, PMH or PMHS) induced significant 
decreases in the apoptotic percentage in these cells compared to cisplatin alone (7.05 
± 1.28, 11.32 ± 2.15, 7.86 ± 1.11, 7.06 ± 1.12 respectively vs 15.09% Cis alone, 
P<0.001) (Figure 4.13C).  Thus Hs578-T cells also displayed enhanced 
chemosensitivity in response to treatment with exogenous HS/heparins, though there 
were some differences compared to MDA-MB-231 cells in terms of responses to 










Figure 4.10 Apoptosis analysis in CSCs from MDA-MB-231 cells by flow cytometry. 
CD44+/CD24- sub-population of MDA-MB-231 human BCC line were treated with optimum 
concentrations of chemotherapeutic drugs (1 µg/ml Dox, 0.1 µM Cis, 1 µM Tam) alone or 
combination with of PMHS, PMH or modified heparin (perS H, NAc H and 2,6 deS-NS H) for 48 hrs. 
Cells then stained with Annexin V-Alexa Fluor® 488 and PI staining. Representative cytograms of 
apoptosis in CD44+/CD24- sub-population in the absence or presence of agents and HSPGs and the 
positive stained cells were counted using the Guava Viacount flow cytometer. Within a cytogram, Q1 
represents necrotic cells; Q2 and Q4 represent late and early apoptotic cells, respectively and Q3 
represents viable cells. Both early and late apoptotic cells were calculated. Data shows a 
representative example from two independent experiment. 
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Figure 4.11 Apoptosis analysis in CSCs from Hs578-T cells by flow cytometry. CD44+/CD24- 
sub-population of Hs578-T human BCC line were treated with optimum concentrations of 
chemotherapeutic drugs (1 µg/ml Dox, 0.1 µM Cis, 1 µM Tam) alone or combination with of PMHS, 
PMH or modified heparin (perS H, NAc H and 2,6 deS-NS H) for 48 hrs. Cells then stained with 
Annexin V-Alexa Fluor® 488 and PI staining. Representative cytograms of apoptosis in 
CD44+/CD24- sub-population in the absence or presence of agents and HSPGs and the positive 
stained cells were counted using the Guava Viacount flow cytometer. Within a cytogram, Q1 
represents necrotic cells; Q2 and Q4 represent late and early apoptotic cells, respectively and Q3 
represents viable cells. Both early and late apoptotic cells were calculated. Data shows a 
representative example from two independent experiments. 
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Figure 4.12 Effect selected HS, heparin and modified heparins on the induction of early and late 
apoptosis by chemotherapeutic agents in CSCs from MDA-MB-231 cells. After exposure to the 
different treatments for 48 hrs, the proportion of early and late apoptotic cells was analysed by flow 
cytometry using annexin V-FITC and PI. MDA-MB-231 treated cells with optimum concentrations of 
chemotherapeutic drugs alone or combination with 10 ng/ml of PMHS, PMH or modified heparin 
(perS H, NAc H and 2,6 deS-NS H) for 48 hrs. (A) 5 µg/ml Dox, (B) 0.1 µM Cis, (C) 1 µM Tam. 
Differences in drug resistance between CD44-/CD24- and CD24+/CD44- cells were calculated. Data 
represent the average of the early and apoptotic cells and shown as mean.±.SD. Data in inset show 
statistical significance at ≠P<0.05, ≠≠≠P<0.001 vs. untreated cell group. *P<0.05, **P<0.01; 
***P<0.001 for all treatment compared with single chemotherapy agent group. Data from one of two 































































































































































Figure 4.13 Effect selected HS, heparin and modified heparins on the induction of early and late 
apoptosis by chemotherapeutic agents in CSCs from Hs578-T cells. After exposure to the different 
treatments for 48 hrs, the proportion of early and late apoptotic cells was analysed by flow cytometry 
using annexin V-FITC and PI. Hs578-T treated cells with optimum concentrations of 
chemotherapeutic drugs alone or combination with 10 ng/ml of PMHS, PMH or modified heparin 
(perS H, NAc H and 2,6 deS-NS H) for 48 hrs. (A) 5 µg/ml Dox, (B) 0.1 µM Cis, (C) 1 µM Tam. 
Differences in drug resistance between CD44-/CD24- and CD24+/CD44- cells were calculated. Data 
represent the average of the early and apoptotic cells and shown as mean.±.SD. Data in inset show 
statistical significance at ≠P<0.05, ≠≠≠P<0.001 vs. untreated cell group. *P<0.05, **P<0.01; 
***P<0.001 for all treatment compared with single chemotherapy agent group. Data from one of two 




















































































































































HS is a multifunctional regulator of different biological processes (Turnbull et al., 
2001), including aspects important to cancer cell behaviour such as proliferation and 
differentiation. HS plays important roles in cell growth and development, tissue 
homeostasis and cell migration, through interactions with a wide variety of proteins 
such as chemokines, enzymes and growth factors (Powell et al., 2010). These 
activities represent novel targets for therapeutic or diagnostic approaches. For that 
reason, a targeted modulation of HS expression or function in CSCs may be a 
promising approach, leading to either reduced proliferation or apoptosis, or loss of 
malignant properties of the cells. To study HS involvement in CSCs, the present 
studies aimed to use model BCSCs in culture. 
A wide range of commonly available BCC lines were investigated (see Chapter 3); 
some lines such as MDA-MB-231 and Hs578-T were found to express appropriate 
markers (CD44+/CD24-) indicating the expected sub-populations, based on previous 
studies (Hwang-Verslues et al., 2009, Sheridan et al., 2006). The potential 
differential effects of differently modified heparins was undertaken, along with dose-
response experiments to determine the minimal concentrations required for the 
observed effects. Low concentrations of chemically modified heparin (as low as 1-
100 ng/ml) were found to induce a reduction of 40-50% in the CD44+/CD24- CSC 
sub-population in both cell lines, indicating the potential to interfere with this aspect 
of BC tumour phenotype. Further studies are now needed to investigate whether this 
effect might be due to specific effects of the heparin on the CSC sub-population (eg. 
reduced proliferation or increased apoptosis), and the mechanisms involved (see 
Chapter 5). 
Removal of overall HS sulphation through cell treatment with a low concentration of 
chlorate (NaClO3) did appear to exert a specific effect on CD44+/CD24- sub-
population of MDA-MB-231 and Hs578-T BCC in terms of reduced cell 
proliferation.  
Another possible mechanism by which cell surface HSPGs may be involved in 







the MDA-MB-231 and Hs578-T cell lines showed a significant reduction of cell 
proliferation after treatment by HS and selected chemically modified heparins and a 
significant increase of cell multiplication, if NAc H treatment was applied on both 
cell lines, suggesting an important contribution of HS and chemically modified 
heparin in the proliferative response of BCSCs.  
HSPGs play an important role in regulating tumour cell metastasis. Previous work 
has demonstrated that HSPGs mediate the activities of growth and motility factors, 
control cell adhesion (Laterra et al., 1983), migration (Moon et al., 2005, Yenigun et 
al., 2013) and invasion (Sanderson, 2001). HSPGs inhibit or promote cell invasion, 
migration and adhesion with their function being determined by the HSPGs location 
(ECM or cell surface), the heparin-binding molecules they can interact with, 
modifying enzymes such as heparanases, and the precise structural characteristics of 
the HSPGs (Sanderson, 2001). 
Previous experiments examined the role of cell surface levels of syndecan-2 using 
knockdown of syndecan-2 by siRNA. FACS analysis confirmed that syndecan-2 
level was reduced to near background; a crucial role in focal adhesion was observed 
due to loss of the PG, whereas focal adhesion was enhanced by HS treatment (Lim et 
al., 2015). These data demonstrate a considerable impact of depletion of the HSPGs 
syndecan-1 and syndecan-2 on the CSC SP and invasiveness. Consistent with this, 
the present study shows that HS/heparin and chemically modified heparin (PerS H, 
2,6 deS-NS H) are all regulators of CD44+/CD24- stem-like cells in terms of their 
invasiveness and ability to migrate. In terms of adhesion, some HS/heparins were 
found to regulate the invasiveness and migration in non-cancer stem-like cell sub-
population of MDA-MB-231. Matrigel cell invasion and collagen migration were 
remarkably inhibited [after HSPGs for CSCs and normal cancer cells of MDA-MB-
231 cell line].  
Hs578-T cells showed a significant reduction of migrating cells when treated with 
HSPGs, while a small affect in invasive BCSCs treated with HSPGs. Small 
significant effect of HSPGs on invaded unsorted and CD44+/CD24- sorted cells of 
Hs578-T cells was reported in this study. Heparin and chemically modified heparin 







cells in Hs578-T breast carcinoma. 
HS chains associate with various heparin binding growth factors and ligands such as 
fibronectin (Bernfield et al., 1999). Syndecans are the most well-characterized 
HSPGs in terms of regulating ECM adhesion via interactions with fibronectin 
(Tumova et al., 2000). The current study showed that HS, heparin and chemically 
modified heparin 2,6 deS-NS H significantly reduced the CD44+/CD24- sub-
population of MDA-MB-231 and Hs578-T BCCs. In contrast, PerS H has no impact 
on adhesion of BCSCs and normal BCCs in both cell line.  
Cisplatin, tamoxifen and doxorubicin are used for treatment of a wide range of 
tumours, including breast tumours (Prabhakaran et al., 2013, Smith et al., 2006, 
Yenigun et al., 2013). Although these kinds of drugs have been used for 
chemotherapeutic treatment of patients with breast tumours, many patients are 
intrinsically resistant to them, resulting in poor responses and/or recurrence of 
tumours after therapy (McDermott and Wicha, 2010). Moreover, previous studies 
demonstrated that cells which overexpress heparanase were found to be more 
resistant to chemotherapeutic agents; these studies identified a role for heparanase in 
modulating autophagy in cancer and normal cells, conferring growth advantages 
under stress as well as chemoresistance (Shteingauz et al., 2015).  
Of particular interest is that CSCs have been reported to be resistant to chemotherapy 
agents compared to the bulk tumour population (Olsson et al., 2011). Here I 
hypothesised that heparin may alter the chemosensitivity of CSCs, and in agreement 
with this idea it has recently been reported that cancer cells are sensitised to 
chemotherapeutic agents by treatment with low molecular weight heparin (Phillips et 
al., 2011). Thus it was of interest to explore the structure-activity relationships which 
might underlay this activity by using a library of differently modified heparins (Yates 
et al., 2004) in combination with chemotherapeutic agents. Here I found that HS/ 
heparin and chemically modified heparin in combination with chemotherapeutic 
(cisplatin, or doxorubicin) and anti-oestrogen agents (tamoxifen) have significant 
effects on normal BCCs and BCSCs through inducing apoptosis in two cell line 
models (MDA-MB-231 and Hs578-T cells). However, cisplatin with these modified 







cells. Low molecular weight heparin (LMWH) has recently been shown to cause 
reversal of cisplatin resistance, likely by interfering with function of endogenous 
GAGs/cell surface HSPGs (Pfankuchen et al., 2015). In addition, syndecan-1 is 
correlated with higher resistance to radiation of BCCs (Pfankuchen et al., 2015). The 
data presented here and summarized in Tables 4.1 and 4.2 are consistent with these 
observations, and support the idea that HSPGs have roles in regulating breast tumor 
progression. These insights could be used to develop strategies employing modified 
heparins to reduce chemoresistance, which could be used in combination with 
chemotherapy regimes. 
Table 4.1 Summary table of effects of HS/heparin and modified heparins in 
MDA-MB-231 BCSC phenotype 
 Proliferation Adhesion Migration Invasion Chemosinsitivity  
     Dox Cis Tam 
PerS H No effect No effect Sig - Sig - Sig +  Sig + Sig + 
NAc H Sig + - - - Sig + Sig + Sig + 
2,6 deS-
NS H 
Sig - Sig - Sig - Sig - Sig + Sig + Sig + 
PMHS Sig + Sig - Sig - Sig - Sig + Sig + Sig + 
PMH Sig - Sig - Sig - Sig - Sig + Sig + Sig + 
*Sig, statistically significant.   
Table 4.2 Summary table of effects of HS/heparin and modified heparins in 
Hs578-T BCSC phenotype 
 Proliferation Adhesion Migration Invasion Chemosinsitivity  
     Dox Cis Tam 
PerS H No effect No effect Sig - Sig - Sig + Sig - Sig + 
NAc H  - - - - - - 
2,6 deS-
NS H 
Sig + Sig - Sig - Sig - No 
effect 
Sig - Sig + 
PMHS Sig  - Sig - Sig - Sig - Sig + Sig - Sig + 
PMH Sig  - Sig - Sign - No effect Sig + Sig - Sig + 









5 HS/Heparin and modified heparins mediate angiogenesis and 
molecular signaling in BCSCs 
!
5.1 General introduction 
BCSCs are being intensely investigated largely owing to their contributions towards 
heterogeneity and chemotherapy resistance in breast tumorigenesis. In this regard, 
CSCs are considered as a target to treat or cure breast tumorigenesis; however, 
understanding of BCSC biology, including their critical regulatory pathways, 
remains incompletely understood. 
CD44 and ABCG2: The expression of CD44 glycoprotein is found in multiple 
isoforms on different types of cells where it functions as a receptor for hyaluronan-
mediated motility. Recently, interest has centered on the expression of CD44 in 
human malignancies due to CD44 acting as a metastasis-related molecule with 
multiple functions including promoting cell migration, invasion, adhesion and 
presentation of growth factors and cytokines (Kuniyasu et al., 2001). Multiple studies 
demonstrated that tumorigenic CD44+/CD24− BCC populations have tumour-
initiating abilities (Al-Hajj et al., 2003, Ponti et al., 2005). This tumorigenic property 
has been associated with display of stem cell–like properties (Ponti et al., 2005), 
enhanced metastasis (Ratajczak et al., 2010), invasive properties (Zhang et al., 2012), 
and chemo/radio resistance (Arima et al., 2012).  
High expression of the ATP binding cassets (ABC) transporter protein ABCG2 has 
also been identified in various cancer samples from patients such as breast cancer 
(Mao and Unadkat, 2015). In addition, it has been shown that there is a correlation 
between the expression of ABCG2 and the response to many types of 
chemotherapeutic agents as well as a reduction in survival rate, and  ABCG2 
expression levels may be used as a reliable indicator of prognosis in cancer patients 
(Natarajan et al., 2012). The ABC transporter family is primarily responsible for the 
phenotype of CSC-like populations identified in some stem cell derived organs and 







lines side-populations; and significantly this is an efflux transporter implicated in 
broad-spectrum chemoresistance (Sicchieri et al., 2015). 
Angiogenic molecules: Angiogenesis is also a master event in tumour growth. This 
event is mediated by pro- and anti-angiogenic factors balanced secreted by multiple 
cell types in the tumour niche. Different cell types can enhance angiogenesis by 
secreting vascular endothelial growth factor (VEGF) family that form new blood 
vessels. However, direct evidence that BCSCs can contribute to angiogenesis 
properties is still lacking (Byrne et al., 2005). 
Several lines of evidence implicate the importance of VEGFA and VEGFB in breast 
cancer (Gasparini, 2000). VEGF was found to be overexpressed in BC tissue when 
compared to normal breast tissue and VEGF levels in these tissues have been 
associated with disease-free and overall survival (Byrne et al., 2007, Dent, 2009).  
HS polysaccharide chains bind to wide range of protein ligands, such as, serine 
proteases, growth factors and their receptors. These chains can mediate angiogenesis 
driven by a number of growth factors including all but one splice variant of VEGF 
(Chen et al., 2004, Ruhrberg et al., 2002). A number of in vivo and in vitro studies 
have examined the roles of HSPGs in VEGF activity: most importantly, HS seems to 
be essential to spatially restrict VEGF to create the appropriate gradient to allow 
blood vessel branching to occur (Ruhrberg et al., 2002). HS proteoglycans can also 
re-activate oxidation-damaged forms of VEGF, a function that may be essential in 
hypoxic sites where new vessels are required (Gengrinovitch et al., 1999). They 
potentiate VEGF binding to its two specific signal-transducing receptors (Gitay-
Goren et al., 1992) and may interact directly with the receptors (Chiang and 
Flanagan, 1995, Cohen et al., 1995, Dougher et al., 1997) analogous to the widely 
studied HS–FGF-2–FGF receptor signaling complex (Delehedde et al., 2000, Lundin 
et al., 2000). 
Angiopoietins are ligands for the receptor tyrosine kinase (Tie2), which is expressed 
by endothelial cells and their precursors, and these molecules are also important for 
regulation of angiogenesis. Three angiopoietins have been identified, including Ang-
1, Ang-2 and Ang-3 (Xu et al., 2004). Studies have shown that, Ang-2 and Ang-3 are 







It is believed that both Angiopoietins 2 and 3 compete with Ang-1 for binding to Tie-
2, and block Tie-2 phosphorylation induced by Ang-1 (Holash et al., 1999, 
Maisonpierre et al., 1997, Valenzuela et al., 1999). 
Other signaling pathway molecules: Chemokines are important molecules in 
regulating cancer cell phenotype. The C-X-C chemokine receptor type 4 (CXCR4) is 
one of the most common studied cell surface chemokine receptors expressed on 
many different types of tumour cells. It was reported that, CXCR4 signalling 
correlates with aggressiveness and metastasis promotion. Previous studies reported 
that CXCR4/CXCL12 signalling regulates BC metastases in vivo and in vitro 
respectively (Kucia et al., 2005). The expression of CXCR4 has been detected in the 
stem cell population of brain tumours and breast cancer (Dontu et al., 2003, Reya et 
al., 2001, Singh et al., 2004).     
It is thought that the metastasis of BCSCs is stimulated by the interaction between 
CXCL12 and CXCR4 presented by HS on the ECM and vascular endothelium. This 
induces. The activation and expressing of CXCR4 causes cell migration followed by 
angiogenesis resulting the metastasis in secondary tumours (Harvey et al., 2007, 
Luker and Luker, 2006, Mellor et al., 2007, Müller et al., 2001, Würth et al., 2015).  
Previous studies have also emphasized the upregulated role of the proinflammatory 
cytokine IL-8 in a wide variety of solid tumors, including, bladder, gastric prostate, 
lung, ovarian and melanoma. It has been reported that IL-8 contributes to multiple 
hallmarks of cancer, including, increased angiogenesis, proliferation, invasion, and 
metastases (Singh et al., 2013). 
Several other signaling pathways including ERK1/2 MAPK (Wang et al., 2010), 
STAT3 (Fouse and Costello, 2013), Wnt/β-catenin and Notch signaling pathways 
help in maintaining the normal and cancer stem cell program (Karamboulas and 
Ailles, 2013). In addition, these pathways support EMT of cancer cells as well as 
multiple drug transporter expression. Cells that have undergone EMT are known as 
progenitor cells and have chemoresistance properties. Thus, stem cell properties, 
drug resistance and induction of EMT programs appear to be interlinked (Kotiyal and 







The signaling pathway through ERK is considered as one of the main determinants 
in the control of diverse cellular process including maintenance of CSCs, due to its 
an important role in EGFR signaling. ERK signaling is significantly upregulated in 
CSCs (Wang et al., 2010). Recent reports have revealed a requirement for Notch 
signaling for the maintenance of BCSCs (Mittal et al., 2014, Sharma et al., 2012). 
Furthermore, the inhibition of Notch and Ras/MAPK signaling may be beneficial for 
BC treatment and results in a significant decrease in the BCSC population (Jung et 
al., 2016, Mittal et al., 2014, Sharma et al., 2012). ERK1/2 are widely expressed and 
involved in regulation of cell functions, via protein phosphorylation, such as, 
regulation of apoptosis, downstream kinases and several transcription factors. 
Different stimulation such as cytokines, growth factors, virus infection and other 
stimuli also activate the ERK1 and ERK2 pathways (Chua et al., 2004, Johnson and 
Lapadat, 2002). 
Fibroblast growth factor-2 (FGF2) is one of the prototypic  members of the fibroblast 
growth factor family. It plays an important role in the regulation of cell survival, 
angiogenesis, differentiation and migration. (Chua et al., 2004).  It has been 
demonstrated that FGF2 binds to its cell-surface tyrosine kinase FGF receptor 
(FGFRs), triggering receptor dimerization and autophosphorylation of tyrosine 
residues, resulting in modulaiton of intracellular docking sites for downstream 
proteins leading to cell responses (Chua et al., 2004). HS has been demonstrated to 
be an important requirement for the binding of FGF-2 to its receptor (Chan et al., 
2015). In addition, it has been reported that both the 2-O-sulfate groups of IdoUA 
and the 6-O-sulfate groups of N-sulfated GlcN are required for this FGF-2 mitogenic 
activity (Guimond et al., 1993). HSPGs modulate the activity of FGF2 via 
functioning as coreceptors to enhance the binding of FGF2 to its receptors.  
However, FGF2 might also signal directly through HSPG via inducing aggregation 
of syndecan-4 and activation of protein kinase Cα. Previous studies demonstrated 
that the syndecan-4 cytoplasmic tail is phosphorylated on Ser138. Indeed, FGF2 can 
reduce the phosphorylation 2 to 3 fold, inducing multimerization and activation of 
protein kinase Cα (Horowitz and Simons, 1998). FGF2-mediated signaling via 
syndecan-4 proceeds to downstream signal transduction, such as ERK1/2, to regulate 
cell activity independent of FGFRs. The biological response mediated by ERK1/2 is 







a site of convergence for FGF2-mediated signaling through HSPG and FGFR (Chua 
et al., 2004, Horowitz and Simons, 1998). 
STAT3 also plays an important role in maintenance of BCSCs (Xiong et al., 2014). 
Accumulating evidence indicates that, Wnt and IL-6/JAK2/STAT3 pathways were 
found to be active in CD44+/CD24− sub-populations isolated from BCCs, and 
xenograft tumours growth can be supressed due to blocking this pathway via specific 
inhibitors. In addition, normal cancer cell populations can be converted to CSC 
populations through activation of the IL-6/JAK2/STAT3 signalling pathway via 
upregulation of OCT-4 (Kim et al., 2013). Many different inhibitors of STAT3, such 
as niclosamide, have been found to prevent the production of OCT-4, thus, these 
studies support that STAT3 plays a plays a prominent role in regulating BCSC self-
renewal(Kim et al., 2013). Recent studies have shown that Syndecan-1 (CD138), a 
heparan sulfate proteoglycan, was found to modulate all of these pathways in BC. 
High Syndecan-1 expression in breast carcinomas is related to an aggressive 
phenotype (Barbareschi et al., 2003), and reduced BC-specific overall survival 
(Leivonen et al., 2004). Both Wnt signaling and Syndecan-1 modulate the mammary 
progenitor population growth and differentiation in BCSCs, (Ibrahim et al., 2013), 
demonstrating a pivotal role for Syndecan-1 in CSC function. 
Aims of this chapter:  To explore mechanisms by which exogenous HS/heparins 
may influence the phenotype of BC CSCs, more specifically: 
• To evaluate the effect of exogenous HS/heparins on stem cell and drug resistance 
genes in BCSCs. The relative mRNA expression of CSC markers, including CD44 
and EpCAM and drug resistance genes ABCG2 has been tested in CD44-/CD24- and 
CD44+/CD24- sub-populations from MDA-MB-231 and Hs578-T untreated and 
treated cells.  
• To identify whether a CD44+/CD24- phenotype might induce angiogenesis via 
HSPGs; CD44+/CD24- BCCs from cultures of MDA-MB-231 and Hs578-T cells 
were examined to determine the effect of HS/heparins as enhancers or supressors of 
expression of VEGFA, VEGFB, Ang-1, Ang-2, CXCR4 and IL-8 by qRT-PCR. 
• To study the potential role of HS in FGF2-mediated ERK1/2 activation in CSCs. The 







the CD44+/CD24- CSC-like sub-population was assessed using MDA-MB-231 and 
Hs578-T human BCC lines as a model. 
• To investigate the regulatory role of HSPGs on inflammatory signaling pathways in 
BCSCs. qRT-PCR and western blot technologies were employed in MDA-MB-231 
and Hs578-T BCSCs to assess the effects of HS/heparins. The functional impact of 
HS and highly sulphated chemically modified heparin on the expression of effectors 
of the stemness-related IL-6/STAT3 and signaling pathways, was also analyzed.  
• To elucidate the regulatory role of HS/heparin and chemically modified heparin on 
signalling molecules mediated by FGF2 in in MDA-MB-231 and Hs578-T BCSCs. 
The phosphorylation of 18 well-characterized signalling molecules was examined by 
PathScan analysis.  
• To study the possibility that HS/heparins might affect on HSPG’s biological function 
in BCSCs.  Study was undertaken by analyzing effect of HS/heparins on the 
expression patterns of the genes involved in HSPG biosynthesis and comparing them 
with untreated cell group. 
5.2 CSC and drug resistance genes are highly expressed in CD44+/CD24- BCC 
lines 
In order to investigate the relative mRNA expression of CSC and drug resistance 
genes between CD44+/CD24- and CD44-/CD24- BCC lines, quantitative RT-PCR 
assay was performed. Briefly, CD44+/CD24- and CD44-/CD24- sorted cells from 
MDA-MB-231 and Hs578-T cells were cultured for three days. Cells were harvested 
and total RNA was extracted followed by cDNA synthesis. qRT-PCR analysis was 
performed and measurements were normalized against GAPDH using 2−ΔCT. 
The BCSC marker (CD44) has been shown to regulate invasion and metastasis of 
BCCs either positively or negatively. The results showed that CD44, commonly used 
to isolate a sub-set with CSC-like characteristics, was as expected highly expressed 
in CD44+/CD24- cells from MDA-MB-231 and Hs578-T (Figure 5.1A, B; 
CD44+/CD24- vs. CD44-/CD24-: 7.22 ± 0.74 and 6.17 ± 0.24 fold respectively [mean 
± SD] (P<0.001)) relative to CD44-/CD24-. Another marker of CSCs, epithelial cell 
adhesion molecule (EpCAM), was not detectable after 40 cycles in the CD44+/CD24- 







CD44+/CD24- vs. CD44-/CD24-: 1.12 ± 0.14 and 1.23 ± 0.15 fold respectively [mean 
± SD]). Over-expression of BCRP/ABCG2 is an essential mechanism of drug 
resistance. Results showed that CD44+/CD24- cells isolated from MDA-MB-231 and 
Hs587-T cells expressed significantly increased levels of ABCG2 (Figure 5.1A, B; 
CD44+/CD24- vs. CD44-/CD24-: 5.08 ± 0.27 and 5.01 ± 0.64 fold respectively [mean 
± SD] (P<0.001)), compared with 1% in CD44-/CD24- cells. These data 
demonstrated that some CSC and drug resistance genes are increased in 
CD44+/CD24- sub-population of some BCC lines compared with CD44-/CD24- cells. 
!
Figure 5.1 The relative mRNA expression of CSC and drug resistance markers in CD44-/CD24- 
and CD44+/CD24- BCCs. (A) MDA-MB-231 and (B) Hs578-T BCC lines were maintained as 
described in the Methods section. CD44, ABCG2 and EpCAM mRNA levels (measured by qRT-
PCR) were found to be significantly higher in CD44+/CD24- cells than in CD44-/CD24- sub-
populations (***P<0.001). GAPDH mRNA served as a control. All the results are presented as the 






























































5.3 Angiogenic markers are highly expressed in CD44+/CD24- BCC lines 
Angiogenesis plays an important role in the growth and metastasis of BC (Sun et al., 
2013). Hence the expression of angiogenic genes was tested by qRT-PCR. As shown 
in Figure 5.2A, B, the expression of various proangiogenesis genes were analyzed in 
CD44-/CD24- and CD44+/CD24- BCCs, including VEGFA, VEGFB, Ang-1, Ang-2, 
the chemokine CXCL8 (IL-8) and the chemokine receptor CXCR4. The results 
showed that CD44+/CD24- sub-population isolated from MDA-MB-231 and Hs578-
T cells expressed high levels of the panel of proangiogenic genes mentioned above 
compared to CD44-/CD24- cells. In detail, as shown in Figure 5.2A, proangiogenic 
factors VEGFA, VEGFB, IL-8, CXCR4, Ang-1 and Ang-2 were highly expressed in 
the CD44+/CD24- MDA-MB-231 cells (fold expression CD44+/CD24- vs. CD44-
/CD24-: 3.48 ± 0.54, 3.33 ± 0.21, 5.06 ± 0.39, 5.62 ± 0.39, 5.58, ± 0.25 and 2.77 ± 
0.38 respectively [mean ± SD] P<0.001, P<0.01). Figure 5.2B shows that 
proangiogenic factors VEGFB, IL-8, CXCR4 and Ang-1 were highly expressed in 
the highly invasive and metastatic CD44+/CD24- Hs578-T cells (fold expression 
CD44+/CD24- vs. CD44-/CD24-: 3.17 ± 0.25, 2.88 ± 0.21, 3.57 ± 0.15 and 2.72 ± 
0.23 respectively [mean ± SD] P<0.001). VEGFA and Ang-2 mRNA expression 
were not significantly different between the CD44+/CD24- and CD44-/CD24- cells 










Figure 5.2 Analysis of angiogenic genes in CD44+/CD24- vs CD44-/CD24- BCCs by qRT-PCR. 
Proangiogenic mRNA levels after 48 hrs cell culture incubation of (A) MDA-MB-231 cell line, and 
(B) Hs578-T cell lines. ‘Control’ represents CD44-/CD24- cells. Proangiogenic mRNA levels were 
determined using qRT-PCR and the relative expression was calculated by normalizing the 
amplification of DNA samples to GAPDH and compared with the CD44-/CD24- expression levels. 
Error bars indicate SD of data (n=2) and obtained in three independent experiments. **P<0.01, 












































































5.4 Determination of the effects of HS/heparin and chemically modified 
heparins on CSC markers in BCCs  
To characterize the potential mechanisms involved in the effect of 
HS/heparin/modified heparins on human BCSCs from the CD44+/CD24- side 
population isolated from MDA-MB-231 and Hs578-T cells, the expression of CSC 
markers was analysed by qRT-PCR in response to treatment conditions. In this study, 
HS, heparin and two highly sulphated modified heparin derivatives, PerS H and 2,6 
deS-NS H, were added to the CD44+/CD24- sub-population isolated from both 
MDA-MB-231 and Hs578-T cells, following by culturing for 48 hrs. An untreated 
group was defined as the control calibrator for the 2−ΔCT analysis after performing 
qRT-PCR for selected marker genes.  
As shown in Figure 5.3, results showed that both CD44 and ABCG2 genes in both 
cell lines (MDA-MB-231 and Hs578-T) showed changes in levels of mRNA 
expression in all analysed treatments in CD44+/CD24- compared to calibrator 
untreated cells (Figure 5.3A).  The CD44+/CD24- sub-population in both MDA-MB-
231 and Hs578-T cells that were treated with PerS H, 2,6 deS-NS H and PMHS 
showed down-regulation of expression of CD44 (P<0.001) (Figure 5.3A; (MDA-
MB-231 fold changes: -0.75 ± 0.13, -1.34 ± 0.13 and -1.10 ± 0.16 respectively [mean 
± SD]; Hs578-T fold changes: -0.65 ± 0.16, -0.84 ± 0.13 and -1.29 ± 0.09 
respectively [mean ± SD]). No change in CD44 expression was detectable in both 
cell lines (MDA-MB-231 and Hs578-T) treated with PMH (expression 1.23 ± 0.19 
and 1.13 ± 0.47 respectively [mean ± SD]) compared to untreated cells, as a 
calibrator. 
As shown in Figure 5.3B, ABCG2 mRNA expression was found to be increased 
compared to the untreated control in MDA-MB-231 and Hs578-T cultures. MDA-
MB-231 treated cells with PMH and PMHS showed significant increases in ABCG2 
expression (2.20 ± 0.17 and 1.53 ± 0.2 respectively [mean ± SD] P<0.05, P<0.001). 
MDA-MB-231 and Hs578-T cells treated with PerS H also showed an increase in 
expression of ABCG2 by approximately 50% compared to untreated cells (mean 
1.50 ± 0.11, 1.60 ± 0.11 respectively [mean ± SD], P<0.01). Hs578-T treated cells 







(expression 2.75 ± 0.30 and 2.16 ± 0.09 respectively [mean ± SD], P<0.01, P<0.001). 
In contrast, no significant change in expression of ABCG-2 could be detected in 
MDA-MB-231 cells treated with 2,6 deS-NS H and Hs578-T cells treated with PMH 
compared to untreated cells (expression 1.26 ± 0.22 and 1.36 ± 0.16 respectively 
[mean ± SD]) (Figure 5.3B). 
The expression of EpCAM mRNA was found to be largely unchanged with most 
treatments of the CSC sub-population in both MDA-MB-231 and Hs578-T cells 
(Figure 5.3C). Changes in expression of EpCAM genes in MDA-MB-231 cells were 
not detected in cells treated with all compounds, except PMHS which induced a 
small increase by approximately 45% (1.45 ± 0.2, P<0.05) compared to untreated 
control cells. Similarity, significant changes in EpCAM expression were not 
observed in Hs578-T cells treated with PerS H or 2,6 deS-NS H, whereas PMH 
treatment showed a significant increase in EpCAM (2.17 ± 0.32, -0.78 ± 0.16 [mean 
± SD]  (P<0.01). Interestingly, the expression of EpCAM mRNA was found to be 
strongly down-regulated in the CSC sub-population from Hs578-T cells treated with 








Figure 5.3 CD44, ABCG2 and EpCAM expression in BCCs treated with HS and modified 
heparins. (A) CD44, (B) ABCG-2 and (C) EpCAM expression in CD44+/CD24- sub-population 
isolated from MDA-MB-231 and Hs578-T BCCs, relative to untreated group (UT), treated with 10 
ng/ml of PerS H, 2,6 deS-NS H, PMH or PMHS for 48 hrs. Expression was assessed using qRT-PCR 
normalized to human GAPDH. Data are representative of two measurements per sample of two 

















































































































































5.5 Determination of the effects of HS/heparin and modified heparin on 
angiogenesis cell markers in BCCs  
As described above, angiogenesis leads to the formation of blood vessels from pre-
existing ones, allowing tumour growth. VEGFA, VEGFB and Angiopoietins (Ang-1, 
Ang-2) have important roles in tumour angiogenesis (Samples et al., 2013), but few 
data regarding their role in BCSCs phenotype are available. The expression of these 
markers of the angiogenic phenotype (VEGFA, VEGFB and Angiopoietins (Ang-1, 
Ang-2) was noted in BCSCs in section 5.3 above.  We next examined whether 
treatment of these cells with HS, heparin or modified heparins might alter their 
expression. In addition, both the expression of CXCR4 and IL-8 were examined 
using qRT-PCR to assess similar questions regarding effects of heparins on 
chemokines. In this study, HS, heparin and two highly sulphated modified heparin 
derivatives (PerS H and 2,6 deS-NS H) were added to the CD44+/CD24- sub-
population isolated from both MDA-MB-231 and Hs587-T cells following by 
culturing for 48 hrs. Quantitative PCR analysis was performed as described in 
Methods. 
The effect of HS, heparin and modified heparins on the expression of VEGFA 
(Figure 5.4A), VEGFB (Figure 5.4B), Ang-1 (Figure 5.4C), Ang-2 (Figure 5.4D), 
CXCR4 (Figure 5.4E) and IL-8 (Figure 5.4F), on the CD44+/CD24- sub-population 
of MDA-MB-231 and Hs578-T cells is shown in Figure 5.4.  
The expression of VEGFA increased in MDA-MB-231 CD44+/CD24- cells treated 
with HS, heparin, 2,6 deS-NS H and PerS H (fold change, 1.14 ± 0.12, 1.57 ± 0.10, 
2.01 ± 0.16 and 2.25 ± 0.14 respectively [mean ± SD],  (P<0.05, p<0.001) (Figure 
5.4A). Significant up-regulation of VEGFA expression in the CD44+/CD24- sub-
population in Hs578-T cells was observed with PerS H and PMH (P<0.01, P<0.001) 
compared to untreated cells (fold change 2.22 ± 0.21 and 1.56 ± 0.10 respectively,  
[mean ± SD]). No changes in expression level of VEGFA was found to be detectable 
in CD44+/CD24- sub-set of Hs578-T treated cells with 2,6 deS-NS H or PMHS 







Changes in VEGFB expression were undetectable in both MDA-MB-231 and Hs78-
T CSC sub-population cells treated with PerS H or PMH, while increases were 
detected with PMHS treatment (fold expression 1.48 ± 0.08, 1.19 ± 0.09 
respectively, [mean ± SD]  (P<0.05, P<0.01)). MDA-MB-231 cells treated with 2,6 
deS-NS H showed a significant increase in VEGFB expression compared to 
untreated cells (1.28 ± 0.12, [mean ± SD]  (P<0.05)). In contrast Hs578-T cells did 
not show a significant change in expression to VEGFB in response to 2,6 deS-NS H 
(Figure 5.4B). 
Ang-1 expression (Figure 5.4C) was strongly down-regulated in the CD44+/CD24- 
Hs578-T cells exposed to PerS H, 2,6 deS-NS H or PMH (fold change, -1.66 ± 0.21, 
-1.52 ± 0.12, -1.06 ± 0.07 respectively, [mean ± SD] (P<0.001), and was found to be 
up-regulated in cells treated with PMHS (fold 1.57 ± 0.19 [mean ± SD]) (P<0.01). In 
contrast, the CD44+/CD24- cells sorted from the MDA-MB-231 line showed 
significant up-regulation in cells treated with 2,6 deS-NS H or PMHS compared to 
control (fold 1.98 ± 0.15 and 2.51 ± 0.33 respectively, [mean ± SD], P<0.01, 
P<0.001). Cells treated with PerS H and PMHS did not significantly change in 
expression of Ang-1 (1.22 ± 0.16, 1.24 ± 0.31 respectively) (Figure 5.4C). 
Ang-2 expression was found to be downregulated in the CD44+/CD24- sub-
population isolated from MDA-MB-231 and Hs578-T treated with PerS H, or 2,6 
deS-NS H (MDA-MB-231 fold changes: -1.01 ± 0.13, -1.09 ± 0.07 respectively, 
[mean ± SD], P<0.001; and Hs578-T fold changes: 1.45 ± 0.22 and 1.09 ± 0.15 
respectively [mean ± SD], P<0.001). In contrast both cell lines treated with PMH or 
PMHS expressed higher levels of Ang-2 compared to untreated controls (MDA-MB-
231 expression, 1.82 ± 0.07 and 3.31 ± 0.28, respectively, [mean ± SD], P<0.001; 
and Hs578-T expression, 2.31 ± 0.37 and 3.22 ± 0.17 respectively, [mean ± SD], 
P<0.001) (Figure 5.4D). 
The expression of CXCR4 mRNA was found to be strongly down-regulated in 
response to all analysed treatments, for both MDA-MB-231 and Hs578-T cells with 
approximately 1-1.5 fold decreases compared to untreated cells (Figure 5.4E; MDA-
MB-231 treated with PerS H, 2,6 deS-NS H, PMH or PMHS, fold changes: -0.97 ± 







Hs578-T with same treatments, fold expression: -1.18 ± 0.19, -1.09 ± 0.19, -0.85 ± 
0.17, -1.14 ± 0.14 respectively, [mean ± SD], P<0.001).  
As for the Ang-1 and Ang-2 expression results (Figure 5.4C, D), the expression 
levels of IL-8 (Figure 5.4F) displayed significant differences amongst the different 
treatments evaluated.  As shown in Figure 5.4F, the modified heparins PerS H and 
2,6 deS-NS H significantly reduced the expression of IL-8 in CD44+/CD24- cells 
isolated from MDA-MB-231 cells (fold change -0.35 ± 0.13 and 0.98 ± 0.16 
respectively, mean ± SD) and Hs578-T cells (fold change: -1.1 ± 0.14 and -1.01 ± 
0.18 respectively, mean ± SD; P<0.001)). PMH reduced the expression of IL-8 in 
CD44+/CD24- cells from Hs578-T (fold change -0.66 ± 0.22 [mean ± SD]; P<0.001) 
while MDA-MB-231 cells showed no significant change in expression of IL-8 
(expression 1.17 ± 0.12 [mean ± SD]) compared to controls. PMHS significantly 
increased the expression of IL-8 in both cell lines compared to untreated controls 
(expression 1.27 ± 0.01 and 1.32 ± 0.15 respectively, [mean ± SD]) (P<0.05). 
5.6 HS, heparin and modified heparins differentially effect FGF2 activation of 
ERK1/2 in MDA-MB-231 and Hs578-T BCSCs  
Given that ERK/MAPK is an important pathway that can be activated by FGF2 in 
some cell types, the effects of HS/heparin/modified heparins on FGF2 mediated 
ERK1/2 expression in CD44+/CD24- MDA-MB-231 or Hs578-T cells was analyzed 
by Western blot. Cells were starved for 6 hrs, then treated with or without 20 ng/ml 
FGF2 combined with either 10 ng/ml PerS H, 2,6 deS-NS H, PMH or PMHS for 15 
and 60 min. Figure 5.5A shows representative results from stimulated CD44+/CD24- 
sub-population from MDA-MB-231 cells, and Figures 5.5B and C represent the 
quantitated levels of FGF2-activated p-ERK1/2 and t-ERK1/2 to α-tubulin ratios 
under the various HS and chemically modified heparin treatments. Figure 5.5D 
represents the quantitated level of p-ERK1/2 to t-ERK1/2 ratio. 
When cells were stimulated with FGF2, a shift in the activation pattern was 
observed. After FGF2 stimulation, levels of phosphorylated ERK1/2 were 
significantly increased in FGF2 stimulated CD44+/CD24- cells compared to 
unstimulated cells (P<0.001) (Figure 5.5A). HS/heparin and chemically modified 







control (FGF2 alone) cells (P<0.01, P<0.001) at all time points, in some cases back 
to the control (no FGF2) level. Some variations in the ratio of t-ERK1/2 to α-tubulin 
in CD44+/CD24- cells was noted; for example 2,6 deS-NS H significantly lower 
levels than cells stimulated with FGF2 alone at 15 and 60 min (P<0.05, P<0.001) 
(Figure 5.5C). A small increase of t-ERK1/2 was noted in cells treated with PerS H, 
PMHS and PMH at 15 min (P<0.05), whereas, no significant changes were detected 
in cells treated with the same compounds at 60 min compared to untreated stimulated 
cells with FGF2 (Figure 5.5C). Figure 5.15D shows the ratios of p-ERK1/2 to t-
ERK1/2 expression levels; although the ratios vary due to altered t-ERK1/2 levels, in 
most cases the compounds caused a reduction in this ratio compared to FGF2 alone, 
with the notable exception of 2,6 deS-NS H. 
Similar experiments were carried out in CD44+/CD24- cells isolated from the Hs578-
T line. Figure 5.6A,B shows that p-ERK1/2 levels are elevated in response to 
stimulation with FGF2 (P<0.01). Once again, p-ERK levels were generally lowered 
significantly by treatment with the compounds (P<0.05, P<0.01, P<0.001) (Figure 
5.6B). When cells were stimulated with FGF2, no significant change in the t-ERK 
activation pattern was observed. After FGF2 stimulation, a significant reduction of t-
ERK1/2 was noted in cells treated with 2,6 deS-NS H, PMHS and PMH at 15 min 
(P<0.05, P<0.01, P<0.001), whereas, no significant changes were detected in cells 
treated with the same compounds at 60 min compared to untreated stimulated cells 
with FGF2 (Figure 5.6C) After FGF2 stimulation, the compounds induced significant 
reductions in p-ERK/t-ERK ratios compared to FGF2 alone at both time points, 
except PerS H, which only caused a reduction at 60 min. However, there was an 
anomaly since FGF2 treatment unexpectedly induced a reduction in the p-ERK/t-
ERK ratio.  In general there may be a problem with measurement of t-ERK in these 
experiments, and measurement of p-ERK alone may be the best guide to effects of 
the compounds on ERK phosphorylation. Nevertheless, overall the data supported 
the view that the compounds can act to attenuate FGF2 signals transduced via the 
MAPK pathway in BCCs, and this signaling pathway is thus implicated at least in 











Figure 5.4 Effects of HS/heparin and modified heparins on the expression of angiogenic markers 
in BCCs. CD44+/CD24- sub-population cells isolated from BCC line MDA-MB-231 and Hs578-T 
were treated with 10 ng/ml of PerS H, 2,6 deS-NS H, PMH or PMHS for 48 hrs. mRNA was extracted 
and subjected to qRT-PCR analysis to ascertain levels of  (A) VEGFA, (B) VEGFB, (C) Ang-1, (D) 
Ang-2, (E) CXCR4 and (F) IL-8 mRNA expression levels. Expression values were normalised to 













































































































































































































































































Figure 5.5 Effects of heparins on FGF2-stimulated ERK1/2 activation in BCSCs from MDA-
MB-231. The CD44+/CD24- sub-populations isolated from MDA-MB-231 BCCs were treated with or 
without FGF2 (20 ng/ml) in the presence or absence of 10 ng/ml PerS H, 2,6 deS-NS H, PMH or 
PMHS for 15 or 60 min. Western blots from cell protein extracts were probed with anti-phospho and 
anti-total ERK1/2 antibodies. The blots were scanned using and quantified using ImageStudioLite 
software. ERK1/2 activation is represented by the amount of ERK1/2 phosphorylation normalized to 
the total amount of ERK1/2. (A) Representative western blot analysis showing effects of various 
compounds on FGF2-activation of ERK1/2. (B) Densitometric measurements converted to ratios of p-
ERK1/2 to α-tubulin. (C) Densitometric measurements converted to ratios of t-ERK1/2 to α-tubulin. 
(D) Densitometric measurements converted to ratios of p-ERK1/2 to t-ERK1/2.  Values are presented 
as the means ± SD of two independent experiments in duplicate expressed as ratio of the values 
measured in MDA-MB-231 cells (≠≠P<0.01, versus to untreated unstimulated cells), (*P<0.05, 
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Figure 5.6 Effects of heparins on FGF2-stimulated ERK1/2 activation in BCSCs from Hs578-T 
cells. The CD44+/CD24- sub-populations isolated from Hs578-T BCCs were treated with or without 
FGF2 (20 ng/ml) in the presence or absence of 10 ng/ml PerS H, 2,6 deS-NS H, PMH or PMHS for 
15 or 60 min. Western blots from cell protein extracts were probed with anti-phospho and anti-total 
ERK1/2 antibodies. The blots were scanned using and quantified using ImageStudioLite software. 
ERK1/2 activation is represented by the amount of ERK1/2 phosphorylation normalized to the total 
amount of ERK1/2. (A) Representative western blot analysis showing effects of various compounds 
on FGF2-activation of ERK1/2. (B) Densitometric measurements converted to ratios of p-ERK1/2 to 
α-tubulin. (C) Densitometric measurements converted to ratios of t-ERK1/2 to α-tubulin. (D) 
Densitometric measurements converted to ratios of p-ERK1/2 to total ERK1/2.  Values are presented 
as the means ± SD of two independent experiments in duplicate expressed as ratio of the values 
measured in MDA-MB-231 cells (≠≠P<0.01, versus to untreated unstimulated cells), (*P<0.05, 
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5.7 HS and modified heparins induce downregulation of components of the 
IL-6 signaling pathway in BCSs  
To investigate whether HS and modified heparins might affect expression of IL-6 
and the STAT3 signaling pathway in MDA-MB-231 and Hs578-T BCCs qRT-PCR 
(Figure 5.7) and western blotting (Figure 5.8;9) were used respectively. The 
CD44+/CD24- sub-population isolated from MDA-MB-231 and Hs578-T human 
BCCs was pre-treated with 10 ng/ml PerS H, 2,6 deS-NS H, PMH or PMHS for 48 
hrs and mRNA extracted. Compared to untreated controls the expression level of IL-
6 mRNA was significantly suppressed by treatment with 2,6 deS-NS H or PMHS in 
both cell lines. PMH treatment differentially affected on IL-6 expression levels in 
MDA-MB-231 and Hs578-T cells. CD44+/CD24- of MDA-MB-231 significantly 
reduced the expression of IL-6 whereas significant increased was detected in Hs578-
T cells treated with PMH compared to untreated control cells (Figure 5.7). 
Figure 5.7 qRT–PCR analysis of IL-6 expression in BCSCs subjected to treatment with HS or 
chemically modified heparins. Total RNA was extracted from CD44+/CD24- cells from MDA-MB-
231 and Hs578-T BCSCs after treatment with 10 ng/ml PerS H, 2,6 deS-NS H, PMH or PMHS for 48 
hrs. Expression levels of IL-6 mRNA were measured using RT–PCR (relative to untreated control). 
Comparisons between groups were analyzed using t-test analysis. **P<0.01 and ***P<0.001 denote 
significant differences compared with the untreated control. Error bars represent mean ± SD; n= 2 
independent preparations, each assay performed in duplicate. The relative expression levels of IL-6 







































5.8 HS, heparin and modified heparins differentially affect IL-6 activation of 
STAT3 in MDA-MB-231 and Hs578-T BCSCs  
IL-6 is known to signal via activation of transcription factor including STAT3. The 
functional impact of HS and modified heparins on STAT3 activation status was thus 
investigated by western blotting using phosphorylation-specific antibodies (Figure 
5.8A). CD44+/CD24- MDA-MB-231 and Hs578-T BCCs were starved for 6 hrs, and 
then treated with 10 ng/ml IL-6 in the absence or presence of 10 ng/ml PerS H, 2,6 
deS-NS H, PMH or PMHS for different time intervals (15, 30 and 60 min). Levels of 
phosphorylated and total STAT3 were assessed by quantitating the densities of the 
respective immunoreactive bands. Results showed that Tyr705 in STAT3 is 
phosphorylated after cell stimulation with IL-6 at all time points compared to 
unstimulated cells (P<0.001) (Figure 5.8A). 2,6 deS-NS H, PMH or PMHS 
treatments significantly decreased STAT3 phosphorylation after stimulation with IL-
6 at all time points (P<0.001). No significant effect on STAT3 phosphorylation was 
observed in cells treated with PerS H at 15 and 30 min, though a significant decrease 
was observed at 60 min for this compound (P<0.01) (Figure 5.8A). The expression 
of t-STAT3 level was not significantly affected by IL-6 treatment or additional 
treatment with HS or chemically modified heparins, except for a minor decrease with 
2,6 deS-NH or PMHS treatment at 15 and 60 min respectively (P<0.01) (Figure 
5.8B). 
Representative data from Hs578-T cells is shown in Figure 5.9. IL-6 triggers a rapid 
increase in phosphorylation of Tyr705 on STAT3 compared to unstimulated cells 
(P<0.001). CD44+/CD24- Hs578-T stimulated cells treated with HS/heparin and 
chemically modified heparins displayed significantly decreased STAT3 
phosphorylation levels and this response was observed at all time points (with the 
exception of PerS H at 15 and 30 min) (P<0.01, P<0.001), compared to untreated 
stimulated cells (Figure 5.9B). The expression of t-STAT3 was not altered in cells 










Figure 5.8 Effects of HS/heparins on IL-6-stimulated STAT3 activation in BCSCs from MDA-
MB-231 cells. The CD44+/CD24- sub-populations isolated from MDA-MB-231 BCCs were treated 
with or without IL-6 (10 ng/ml) in the presence or absence of 10 ng/ml PerS H, 2,6 deS-NS H, PMH 
or PMHS for 15, 30 or 60 min. Western blots from cell protein extracts were probed with anti-
phospho and anti-total STAT3 antibodies. The blots were scanned using and quantified using 
ImageStudioLite software. STAT3 activation is represented by the amount of STAT3 phosphorylation 
normalized to the total amount of STAT3. (A) Representative western blot analysis showing effects of 
various compounds on IL-6-activation of STAT3. (B) Densitometric measurements converted to 
ratios of p-STAT3 to histone 3. (C) Densitometric measurements converted to ratios of t-STAT3 to 
histone 3. (D) Densitometric measurements converted to ratios of p-STAT3 to t-STAT3.  Values are 
presented as the means ± SD of two independent experiments in duplicate expressed as ratio of the 
values measured in MDA-MB-231 cells (≠≠≠P<0.001, versus to untreated unstimulated cells), 
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Figure 5.9 Effects of HS/heparins on IL-6-stimulated STAT3 activation in BCSCs from Hs578-T 
cells. The CD44+/CD24- sub-populations isolated from Hs578-T BCCs were treated with or without 
IL-6 (10 ng/ml) in the presence or absence of 10 ng/ml PerS H, 2,6 deS-NS H, PMH or PMHS for 15, 
30 or 60 min. Western blots from cell protein extracts were probed with anti-phospho and anti-total 
STAT3 antibodies. The blots were scanned using and quantified using ImageStudioLite software. 
STAT3 activation is represented by the amount of STAT3 phosphorylation normalized to the total 
amount of STAT3. (A) Representative western blot analysis showing effects of various compounds on 
IL-6-activation of STAT3. (B) Densitometric measurements converted to ratios of p-STAT3 to 
histone 3. (C) Densitometric measurements converted to ratios of t-STAT3 to histone 3. (D) 
Densitometric measurements converted to ratios of p-STAT3 to t-STAT3.  Values are presented as the 
means ± SD of two independent experiments in duplicate expressed as ratio of the values measured in 
MDA-MB-231 cells (≠≠P<0.01, ≠≠≠P<0.001, versus to untreated unstimulated cells), (*P<0.05, 
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5.9 Effects of HS and chemically modified heparin mechanism on cell 
signaling in CD44+/CD24- sub-populations from MDA-MB-231 and 
Hs578-T BCC lines. 
One hypothesis for the mechanisms underlying the effects of treatment BCSCs with 
HS/heparin and chemically modified heparins is that they cause activation and/or 
inactivation of signalling pathways.  To investigate this hypothesis, protein extracts 
were examined using a PathScan® Intracellular Signaling Array (a slide-based 
antibody array that uses sandwich immunoassay to detect phosphorylation status of 
18 well-characterized signaling molecules).  Attention was focused on the activation 
and inhibition of multiple signaling pathways in the CD44+/CD24- sub-populations 
from MDA-MB-231 and Hs578-T cell lines. CD44+/CD24- sub-population sorted 
from MDA-MB-231 and Hs578-Tcells were treated with 10 ng/ml of various 
compounds (PerS H, NAc H, 2 deS-NS H, 6 deS-NS H, 2,6 deS-NS H, PMHS and 
PMH) and incubated for 48 hrs (Figure 5.10). Complete PathScan intracellular 
signalling datasets are provided in Appendix 4.1 and 4.2.  
As shown in a quantitative graphical summary (Figure 5.11), significant decreases in 
phosphorylation of multiple signaling molecules, including S6 Ribosomal, mTOR 
and PRAS40 in MDA-MB-231 and Hs578-T cells, were detected in response to HS 
and chemically modified heparins compared to untreated control cells (P<0.001). 
Interestingly, although 10 ng/ml of compounds, including PerS H, NAc H, 2 deS-NS 
H, 6 deS-NS H and 2,6 deS-NS H, did not affect the phosphorylation level of 
ERK1/2, there was an 86% increase in ERK1/2 phosphorylation with 10 ng/ml 
PMHS or PM heparin treatment, for both MDA-MB-231 and Hs578-Tcells 
(P<0.001), while NAc H, 2,6 deS-NS H, PMHS and PMH induced a significant 
expression compared to untreated cells; this suggests the possibility that the growth-
inhibitory and apoptotic mechanisms of PMHS and PMH may be mediated at least in 
part through the activation of ERK1/2. In addition, for MDA-MB-231 cells, some of 
the modified heparins (PerS H, NAc H, 2 deS-NS H and 6 deS-NS H) broadly 
induced AMPKα activation, while all except 2 deS-NS H caused a significant 







In contrast, for Hs578-T cells no effects on AMPKα or PRAS40 were noted, whilst 
NAc H, PMHS and PMH induced activation of STAT3 (which was unaffected in 
MDA-MB-231 cells) (Figure 5.11). ERK1/2 activation also was noted in 
CD44+/CD24- cells, treated with NAc H, 2,6 deS-NS H, PMHS and PMH (P<0.001) 
(Figure 5.11). 
Strong inhibition of phosphorylation of two tested signaling molecules, S6 ribosomal 
protein and mTOR, were also noted for Hs578-T cells treated with PerS H, NAc H or 
2 deS-NS H (Figure 5.11).  
Overall, the compounds induced changes in multiple signaling pathways, with both 
activation and inhibition noted; furthermore, interesting cell type differences were 
noted in the cell responses to the different compounds. 
5.10 Effects of treatments with HS/modified heparins on FGF2 stimulation of 
the CD44+/CD24- sub-populations from MDA-MB-231 and Hs578-T BCCs  
Since changes in ERK1/2 phosphorylation were noted in response to some of the 
compounds (section 5.6), and FGF2 is a HS-dependent growth factor known to 
activate this pathway, FGF2 stimulation alone or in combination with HS/chemically 
modified heparins in BCSCs was measured using the PathScan intracellular signaling 
array kit (Figure 5.12). The corresponding complete PathScan intracellular signaling 
datasets are provided in Appendix 4.3 and 4.4.  
As shown quantitatively in Figure 5.13, there were significant increases in 
phosphorylation of ERK1/2 (as expected) and also STAT3 (P<0.001) in both cell 
types; in contrast, mTOR activation was inhibited by FGF2. Many of the pathways 
were not significantly affected by FGF2 treatment or additional treatment with HS or 
chemically modified heparins (P<0.001) (Figure 5.13 and Appendix 4.3 and 4.4). 
Although PMHS and PMH did not affect the phosphorylation of ERK1/2 after 
stimulation with FGF2, there was a 25 to 50% decrease in ERK1/2 phosphorylation 
with 10 ng/ml of PerS H, NAc H, 2, deS-NS H and 2,6 deS-NS H compared to 
FGF2-stimulated MDA-MB-231 CSCs untreated cells. This was not observed for 
Hs578-T CSCs, but these demonstrated inhibition of p-ERK1/2 upon treatment with 









Figure 5.10 PathScan intracellular signalling array analysis. The CD44+/CD24- sub-population 
sorted from MDA-MB-231 and Hs578-T BCCs were treated (or not) with 10 ng/ml of HS compounds  
(PerS H, NAc H, 2 deS-NS H, 6 deS-NS H, 2,6 deS-NS H, PMHS and PMH) for 48 hrs. Following 
treatments, cell extracts were prepared and analyzed using the PathScan® intracellular signalling 
array kit, according to the manufacturer's protocol. The slide was incubated with Lumi-GLO/peroxide 
reagent and exposed in an ImageQuant™ LAS 4000 Biomolecular Imager (with exposure for a length 






















Figure 5.11 Quantitative analysis of intracellular signalling array data from HS and chemically 
modified heparin treatment of CD44+/CD24- sorted cells from MDA-MB-231 and Hs578-T 
BCCs. Cells were treated, and cell extracts prepared and analyzed using the PathScan® intracellular 
signalling array kit as described in Figure 5.10. The results are representative of two experiments, 





decrease of phosphorylation level when MDA-MB-231 CSCs were treated with NAc 


























































































































































































































































cells (P<0.001).  2 deS-NS H, PMHS and PMH induced a reduction in activation of 
STAT3 in Hs578T CSCs. Stimulation of MDA-MB-231 CSCs with FGF2 resulted in 
strongly decreased Bad and p38 signaling (P<0.001), but no significant effects were 
observed in these pathways with additional treatment with HS or chemically 
modified heparins. Stimulation of Hs578-T CSCs with FGF2 was not detected 
compared to untreated cells, but significant reductions were observed in Bad 
pathway with additional treatment with HS or chemically modified heparins 
(P<0.001).  
AMPKα phosphorylation in MDA-MB-231 CSCs was not increased by FGF2 
stimulation, but was decreased by treatments with 2,6 deS-NS H, PMHS or PMH 
(P<0.05, P<0.001), whereas Hs578T CSCs were largely unaffected.  
Akt/Thr473, S6 ribosomal protein, mTOR and p53 were all significantly activated in 
untreated Hs578-T CSCs, whereas significant reductions in all their phosphorylation 
levels were noted in FGF2 stimulated cells (p<0.001); however, the additional 
treatment with compounds did not significantly alter the levels of these pathways. 
Although no marked difference of Bad activation was evident in Hs578T CSCs 
stimulated with FGF2 relative to the unstimulated cells, a significant decreased of 
Bad phosphorylation levels were noted with additional treatment with the 
compounds (p<0.001). Analysis of the PathScan results indicated that there was no 
alteration in the phosphorylation of the other 12 signalling molecules in Hs578-T 
CSCs under the experimental conditions tested (Figure 5.13).   
Overall the results suggest selectivity in the action of the various compounds for 
targets in CSCs, with effects on a number of signaling pathways (both upregulation 
and downregulation). The most notable effects were on ERK1/2, STAT3 and mTOR 
pathways, making them prime candidates for mediating the growth-inhibitory and 












Figure 5.12 PathScan® Intracellular Array analysis. CD44+/CD24- sub-population sorted from 
MDA-MB-231 and Hs578-T BCCs were stimulated with 20 ng/ml FGF2 and treated (or not) with 10 
ng/ml of HS compounds  (PerS H, NAc H, 2 deS-NS H, 6 deS-NS H, 2,6 deS-NS H, PMHS and 
PMH) for 60 min. Following treatments, cell extracts were prepared and analyzed using the 
PathScan® intracellular signalling array kit, according to the manufacturer's protocol. The slide was 
incubated with Lumi-GLO/peroxide reagent and exposed in an ImageQuant™ LAS 4000 
Biomolecular Imager (with exposure for a length of time dependent on the signal intensity). The result 
is representative of two experiments, each run in duplicate. 
 
 









Figure 5.13 Pathscan quantitative analysis of CD44+/CD24- sorted cells from MDA-MB-231 and 
Hs578-T BCCs with FGF2 stimulation of signaling molecules.  Cells were stimulated with 20 
ng/ml FGF2 and treated  (or not) with 10 ng/ml of HS compounds (PerS H, NAc H, 2 deS-NS H, 6 
deS-NS H, 2,6 deS-NS H, PMHS and PMH) for 60 min. cell extracts were prepared and analyzed 
using the PathScan® intracellular signalling array kit as described in Figure 5.12. The results are 
representative of two experiments, each run in duplicate. Normalized mean luminescence intensity ± 
SD, n=2. ≠≠≠P<0.001 relative to untrteated cells.  (*P<0.05, **P<0.01, ***P<0.001 versus to 




























































































































































































































































































































































































































5.11 Effects of HS/heparin and chemically modified heparins on specific genes 
involved in synthesis and editing of HSPGs in BCSCs 
5.11.1 Effects of HS/heparin derivatives on the expression of genes encoding 
core proteins carrying HS chains 
About 11 HSPG core proteins encoded genes were demonstrated in present study 
The most cell surface HSPGs gene families including syndecans and glypicans. 
These families comprise 4 syndecans (SDC1-4) and 6 glypicans  (GPC1-6) 
respectively. The other remaining gene is an ECM HSPG, (AGRN) (Iozzo, 2001, 
Park et al., 2000).  
MDA-MB-231 CSCs: For the agrin protein, PMHS and 2,6 deS-NS H significantly 
decreased agrin levels (P<0.05, P<0.001), while heparin significantly increased agrin 
levels in CD44+/CD24- sorted cells from the MDA-MB-231 line (Figure 5.14; Table 
5.1). Within the syndecan and glypican groups, a down regulation was observed in 
the transcript levels of CD44+/CD24- cells treated with PMHS, however, SDC-2 and 
GPC-3 and 4 displayed up-regulation. 2,6 deS-NS H and heparin significantly 
increases the expression of SDC1-4 (P<0.05), wherase, 2,6 deS-NS H and heparin 
significantly decreased the expression of the GPC group; however, GPC-1 displayed 
up-regulation with both treatments (Figure 5.14; Table 5.1). 
Hs578-T CSCs: No significant differences in the transcript levels of CD44+/CD24- 
cells from Hs578-T treated with heparin and 2,6 deS-NS H were noted for agrin; 
however, a significant increase and decrease was shown in cells treated with PMHS 
and PMH, respectively (P<0.05) (Figure 5.15; Table 5.2). PMHS significantly 
increased the GPC group in CD44+/CD24- cells; however only GPC-3 displayed a 
decrease in these cells. Within the SDC group, SDC-1 was not detected in cells 
treated with PMHS, whereas, SDC-2 and 4 showed a significant down-regulation 
and SDC-3 showed a significant up-regulation in cells treated with PMHS (P<0.01). 
For SDC-1 no significant differences in the transcript levels of CD44+/CD24- cells 
could be detected. For heparin treatment, no significant changes were noted for SDC-
2 and 4 compared to untreated cells and increases were noted for SDC-1 and 3 
respectively. GPC-2 and 5 displayed a significant decrease, while GPC-1 and 6 







showed no significant differences compared to untreated cells and GPC-3 and 4 were 
not detected at all in cells treated with heparin (Figure 5.15; Table 5.2).  
HS chains are synthesized by biosynthetic enzymes in the Golgi apparatus (Presto et 
al., 2008). The present study examined the glycosyltransferases (GTs) encoding 
genes which are involved in HS chain polymerization, including EXTL1-3 
(responsible for HS initiating and possessing the first GlcNAc residue), and EXT1 
and 2 polymerase complex (responsible for chain extension). The transcript level of 
EXTs and EXTLs groups were significantly higher in CD44+/CD24- sup-population 
of MDA-MB-231 treated with heparin and Hs578-T cells treated with PMHS (Figure 
5.14; Table 5.1) and (Figure 5.15; Table 5.2). These gene groups did not show clear 
alteration patterns in CD44+/CD24- sorted from MDA-MB-231 cells treated with 
PMHS and 2,6 deS-NS H; however, EXTL1 and 2 showed increased with 2,6 deS-
NS H treatment, although its high expression did not allow for definitive conclusions 
to be drawn (Figure 5.14; Table 5.1). EXTL2 and 3 showed a decrease with PMHS 
(P<0.05, P<0.001). 2,6 deS-NS H and heparin showed an increased in EXTs and 
EXTLs groups, whereas heparin different effects of EXTs and EXTLs group in 
CD44+/CD24- sup-population of Hs578-T cells (Figure 5.15; Table 5.2).  
The above GT activities are involved in HS chain synthesis resulting in an 
unmodified HS chain (GlcA-GlcNAc repeating units). NDSTs clearly have a crucial 
role in the modification of HS chains by removing acetyl groups from GlcNAc 
residues and creating sulphation of the amino group. This is catalyzed by four 
different isoforms of N-deacetylase/N-sulfotransferases, (NDST1-4) (Esko and 
Lindahl, 2001, Lindahl et al., 1998). Transcripts of all these isoforms, NDST1-4 
showed up regulation and down regulation in the CD44+/CD24- sup-population of 
MDA-MB-231 treated with PMHS. The NDST group showed an increase in the 
transcript level in CD44+/CD24- cells treated with 2,6 deS-NS H; however, NDST2 
showed a decrease in the transcript levels, while a significant increase in NDST3 and 
4 was noted (Figure 5.14; Table 5.1). When the analysis was conducted in the 
CD44+/CD24- sub-population of Hs578-T cells, transcripts of all these isoforms, 
NDST1-4, were significantly increased in cells treated with PMHS (P<0.01, 
P<0.001); however, only NDST3 showed a decrease in cells treated with PMH. None 







treated with heparin or 2,6 deS-NS-H (Figure 5.15; Table 5.2).  
In biosynthesis epimerization of GlcA is the next step, mediated by glucuronosyl C5-
epimerase. The C5-GlcA epimerase enzyme (GLCE) catalyzes the conversion of 
GlcA into IdoA. The addition of 2-O-sulphation is at C2 to IdoA or GlcA residues by 
HS 2-O- sulphotransferase (HS2ST1), and the addition of 6-O-sulphation at the C6 
position of GlcNAc and GlcNS residues is catalyzed by HS 6-O-sulphotransferase 
isoforms 1–3 (HS6ST1, HS6ST2 and HS6ST3) (Esko and Lindahl, 2001, Lindahl et 
al., 1998, Turnbull et al., 2001, Whitelock and Iozzo, 2005) After that, the 
modification step of HS chain involves the final addition of rare 3-O-sulphates at the 
C3 position of GlcNS residues. This step is catalyzed by HS 3-O-sulphotransferase 
isoforms 1–6 (HS3ST1, HS3ST2, HS3ST3A1, HS3ST3B1, HS3ST4, HS3ST5 and 
HS3ST6) (Turnbull et al., 2001, Whitelock and Iozzo, 2005). None of these enzymes 
showed statistically significant alterations in transcriptional level in CD44+/CD24- 
sorted cells from MDA-MB-231 cells treated with 2,6 deS-NS H compared to 
untreated cells; however, adding 2,6 deS-NS H to the cells significantly increased the 
HS3ST3A1 expression level and significantly decreased the expression level of 
HS3ST3B1 (P<0.01, P<0.001). In addition, these enzymes showed a significant 
decrease with PMHS treatment and a significant increase with heparin treatment 
(Figure 5.14; Table 5.1). When the analysis was conducted in CD44+/CD24- sorted 
cells from Hs578-T cells treated with heparin, no significant differences of transcript 
levels of these enzymes were detected.  Adding PMHS to the cells significantly 
increased the expression of these enzymes; however only HS3ST2, HS3ST3A1, 
HS3ST4, HS3ST5 and HS6ST2 showed a significant decrease in cells treated with 
HS. Adding 2,6 deS-NS H to the cells significantly increased the expression of 
(HS2ST2, HS3ST2, HS2ST3A1, HS2ST3B1 and HS2ST4) enzymes; however only 
HS3ST2, HS3ST3A1, HS3ST4, HS3ST5 and HS6ST2 showed a significant decrease 
in cells treated with HS (Figure 5.15; Table 5.2).  
The last step of HS chain modification during biosynthesis is carried out at the cell 
surface by two sulphatase enzymes (Sulf1 and Sulf2). Theses enzymes remove 
GlcN-6S from specific regions of HS chain (Taylor and Gallo, 2006). Interestingly, 
the transcript of Sulf1 in CD44+/CD24- sorted cells from MDA-MB-231 cells was 







addition the Sulf2 enzyme did not show clear alteration patterns in HS/heparin and 
2,6 deS-NS H treated cells (Figure 5.14; Table 5.1). Sulf1 enzyme was not detected 
in CD44+/CD24- sorted cells from the Hs578-T line treated with heparin or 2,6 deS-
NS H. PMHS increased the transcript level of Sulf2 enzyme in CD44+/CD24- sorted 
cells from the Hs578-T line. Adding heparin or 2,6 deS-NS H to the cells resulted in 
a decreased transcript level of the Sulf2 enzyme (Figure 5.15; Table 5.2).  
5.11.2 Effects of HS/heparin and chemically modified heparins on the 
expression of heparanases 
Heparanase (HPSE) is an endo-β-D-glucuronidase enzyme that degrades polymeric 
HS into shorter length HS oligosaccharides, generating biologically active 
molecules. This enzyme, along with Sulf1 and Sulf2 were analyzed in relation to 
addition of HS/ heparin and chemically modified heparins to BCSCs. Heparanase 2 
(HPSE2) is another related molecule which lacks HS-degrading activity, but it is still 
able to interact with HS with high affinity (Arvatz et al., 2011). Performing Taqman 
assays we failed to detect significant changes in HPSE2 transcript levels either in 
CD44+/CD24- of MDA-MB-231 cells with PMHS, heparin or 2,6 deS-NS H. The 
transcript level of HPSE1 in MDA-MB-231 cell line showed a significant increase 
with PMHS and a significant decrease with heparin. No significant changes were 
detected with 2,6 deS-NS H (Figure 5.14; Table 5.1). When the analysis was 
conducted in the CD44+/CD24- sub-population of Hs578-T cells, the transcript levels 
of both enzymes were increased upon treatment with HS/heparin and the selected 





















Figure 5.14 Heat map depicting changes in expression of HS associated genes induced by 
HS/heparin and selected chemically modified heparins in CD44+/CD24- cells sorted from the 
MDA-MB-231 line.  RNA isolated from the CD44+/CD24- cells was analysed after treatment for 48 
hrs with either HS/heparin or selective modified heparins  (2,6 deS-NS H) at 10 ng/ml. The mRNA 
expression of MDA-MB-231 cells was analyzed by Taqman real time PCR relative to the house 
keeping genes 18S and GAPDH using the 2−ΔΔCt method. Expression changes were compared 
relative to untreated cells. Red: significantly increased expression; blue; significantly decreased 
expression; green: non-significant change; white; not detected. UT 1 and UT 2 represent biological 
replicates in untreated cells, while PMHS 1 and PMHS 2 represent biological replicates in cells 
treated with PMHS; PMH 1 and PMH 2 indicate biological replicates in cells treated with PMH; 2,6 





















































Table 5.1 Summary of quantitative analysis of changes in expression of genes 
involved in synthesis and editing of HS induced by HS/heparin and selected 
















Mean%log    Mean%log    Mean%log       
Up/Down t/test  Up/Down t/test  (fold%change) Up/Down t/test     





PMH p/value in%2,6%deS/NS%H%± reg.%in%AD p/value 
 
in%PMHS%±%S.E.M in%PMH%±%S.E.M    






(n=3)  (n=3)              
(n=3)                        
                   
 
18S Hs99999901_s1 !0.100 ± 0.131 DOWN 0.485  !0.213+± 0.079 DOWN 0.054  !0.314+± 0.025 DOWN 0.000 *** 
 
GAPDH Hs99999905_m1 0.032 ± 0.262 UP 0.910  0.548 ± 0.261 UP 0.104  0.607 ± 0.246 UP 0.069  
 
AGRN Hs00394748_m1 !2.445 ± 0.155 DOWN 0.000 *** !0.295+± 0.219 DOWN 0.249  !1.306+± 0.396 DOWN 0.030 * 
 
EXT1 Hs00609162_m1 !0.060 ± 0.133 DOWN 0.674  1.370 ± 0.212 UP 0.003 ** 0.282 ± 0.199 UP 0.229  
 
EXT2 Hs00181158_m1 !0.355 ± 0.301 DOWN 0.303  0.779 ± 0.318 UP 0.071  0.286 ± 0.211 UP 0.247  
 
EXTL1 Hs00184929_m1 28.708 ± 1.395 UP 0.000 *** 20.304 ± 9.432 UP 0.098  1.430 ± 1.202 UP 0.300  
 
EXTL2 Hs01018237_m1 !0.168 ± 0.126 DOWN 0.255  0.417 ± 0.095 UP 0.012 * 0.280 ± 0.166 UP 0.167  
 
EXTL3 Hs00918601_m1 !0.869 ± 0.175 DOWN 0.008 ** 0.745 ± 0.152 UP 0.008 ** !0.119+± 0.020 DOWN 0.004 ** 
 
GPC1 Hs00892476_m1 !0.534 ± 0.112 DOWN 0.009 ** 0.498 ± 0.205 UP 0.072  0.155 ± 0.368 UP 0.695  
 
GPC2 Hs00415099_m1 !4.269 ± 0.569 DOWN 0.002 ** !1.618+± 0.583 DOWN 0.050  !2.674+± 0.106 DOWN 0.000 *** 
 
GPC3 Hs01018936_m1 8.224 ± 8.834 UP 0.405  !18.508+± 8.609 DOWN 0.098  !17.451+± 8.893 DOWN 0.121  
 
GPC4 Hs00155059_m1 11.141 ±+11.752 UP 0.397  !9.848+± 11.237 DOWN 0.430  !23.482+± 11.542 DOWN 0.112  
 
GPC5 Hs00270114_m1 !1.288 ± 0.788 DOWN 0.177  !0.166+± 0.365 DOWN 0.672  !1.001+± 0.232 DOWN 0.013 * 
 
GPC6 Hs00170677_m1 !1.286 ± 0.066 DOWN 0.000 *** 0.830 ± 0.174 UP 0.009 ** !0.003+± 0.050 DOWN 0.962  
 
HPSE Hs00935036_m1 !1.311 ± 0.115 DOWN 0.000 *** 0.550 ± 0.107 UP 0.007 ** !0.265+± 0.039 DOWN 0.003 ** 
 
HPSE2 Hs00222435_m1 !1.257 ± 0.763 DOWN 0.175  0.710 ± 1.258 UP 0.603  !0.076+± 0.522 DOWN 0.891  
 
HS2ST1 Hs00202138_m1 !0.292 ± 0.395 DOWN 0.501  1.319 ± 0.399 UP 0.030 * 0.678 ± 0.441 UP 0.199  
 
HS3ST1 Hs00245421_s1 !1.394 ± 0.643 DOWN 0.096  0.772 ± 0.145 UP 0.006 ** !0.059+± 0.330 DOWN 0.868  
 
HS3ST2 Hs00428644_m1 21.055 ±+10.574 UP 0.117  !2.835+± 10.294 DOWN 0.797  !3.756+± 11.903 DOWN 0.768  
 
HS3ST3A1 Hs00925624_s1 18.403 ±+11.768 UP 0.193  3.350 ± 0.470 UP 0.002 ** 30.389 ± 0.601 UP 0.000 *** 
 
HS3ST3B1 Hs00797512_s1 !1.140 ± 0.158 DOWN 0.002 ** 0.975 ± 0.081 UP 0.000 *** !0.351+± 0.050 DOWN 0.002 ** 
 
HS3ST4 Hs00901124_s1 !3.640 ± 0.505 DOWN 0.002 ** 3.650 ± 1.016 UP 0.023 * 6.088 ± 11.553 UP 0.626  
 
HS3ST5 Hs00999394_m1 10.829 ±+11.440 UP 0.397  !24.541+± 10.601 DOWN 0.082  !11.282+± 22.641 DOWN 0.644  
 
HS3ST6 Hs03007244_m1 9.404 ±+17.811 UP 0.625  !0.671+± 16.357 DOWN 0.969  !7.675+± 9.667 DOWN 0.472  
 
HS6ST1 Hs00757137_m1 !0.661 ± 0.216 DOWN 0.038 * 1.361 ± 0.445 UP 0.038 * 0.319 ± 0.459 UP 0.525  
 
HS6ST2 Hs02925656_m1 1.598 ± 0.845 UP 0.132  !7.216+± 10.169 DOWN 0.517  !4.473+± 9.820 DOWN 0.672  
 
HS6ST3 Hs00542178_m1 !1.530 ± 0.037 DOWN 0.000 *** 0.843 ± 0.043 UP 0.000 *** 0.249 ± 0.141 UP 0.153  
 
NDST1 Hs00925442_m1 0.315 ± 0.440 UP 0.514  1.457 ± 0.638 UP 0.084  1.010 ± 0.596 UP 0.165  
 
NDST2 Hs00234335_m1 !1.963 ± 0.011 DOWN 0.000 *** 0.725 ± 0.244 UP 0.041 * !0.978+± 0.169 DOWN 0.004 ** 
 
NDST3 Hs01128584_m1 !0.716 ± 0.437 DOWN 0.177  1.504 ± 0.345 UP 0.012 * 1.983 ± 0.605 UP 0.031 * 
 
NDST4 Hs00224024_m1 0.845 ± 0.890 UP 0.396  2.685 ± 2.114 UP 0.273  1.490 ± 0.718 UP 0.107  
 
SDC1 Hs00896423_m1 !0.264 ± 0.286 DOWN 0.409  1.314 ± 0.304 UP 0.012 * 0.973 ± 0.587 UP 0.173  
 
SDC2 Hs00299807_m1 0.239 ± 0.592 UP 0.707  1.397 ± 0.399 UP 0.025 * 0.994 ± 0.740 UP 0.251  
 
SDC3 Hs01568665_m1 !0.427 ± 0.310 DOWN 0.241  1.018 ± 0.339 UP 0.040 * 0.121 ± 0.296 UP 0.702  
 
SDC4 Hs00161617_m1 !1.221 ± 0.586 DOWN 0.105  0.236 ± 0.543 UP 0.686  0.267 ± 0.492 UP 0.616  
 
SULF1 Hs00290918_m1 18.872 ±+11.506 UP 0.176  0.094 ± 0.959 UP 0.927  20.459 ± 10.739 UP 0.129  
 












Figure 5.15 Heat map depicting changes in expression of HS associated genes induced by 
HS/heparin and selected chemically modified heparins in CD44+/CD24- cells sorted from the 
Hs578-T line.  RNA isolated from the CD44+/CD24- cells was analysed after treatment for 48 hrs 
with either HS/heparin or selective modified heparins  (2,6 deS-NS H) at 10 ng/ml. The mRNA 
expression of MDA-MB-231 cells was analyzed by Taqman real time PCR relative to the house 
keeping genes 18S and GAPDH using the 2−ΔΔCt method. Expression changes were compared 
relative to untreated cells. Red: significantly increased expression; blue; significantly decreased 
expression; green: non-significant change; white; not detected. UT 1 and UT 2 represent biological 
replicates in untreated cells, while PMHS 1 and PMHS 2 represent biological replicates in cells 
treated with PMHS; PMH 1 and PMH 2 indicate biological replicates in cells treated with PMH; 2,6 
























































Table 5.2 Summary of quantitative analysis of changes in expression of genes 
involved in synthesis and editing of HS induced by HS/heparin and selected 











  Mean%log 













(n=3)  vs.%UT P<0.05* (n=3)  vs.%UT P<0.05* (n=3)  vs.%UT P<0.05*                
 
                  
 
18S Hs99999901_s1 0.032 ± 0.069 UP 0.671 *0.011+± 0.066 DOWN 0.875 *0.215+± 0.025 DOWN 0.001 *** 
 
GAPDH Hs99999905_m1 0.042 ± 0.065 UP 0.555 0.103 ± 0.117 UP 0.429 0.488 ± 0.091 UP 0.006 ** 
 
AGRN Hs00394748_m1 0.553 ± 0.177 UP 0.035 * *0.266+± 0.073 DOWN 0.022 * 0.075 ± 0.058 UP 0.269 
 
EXT1 Hs00609162_m1 0.525 ± 0.138 UP 0.019 * *0.182+± 0.183 DOWN 0.375 0.025 ± 0.151 UP 0.875 
 
EXT2 Hs00181158_m1 0.622 ± 0.086 UP 0.002 ** 0.325 ± 0.254 UP 0.270 0.490 ± 0.104 UP 0.009 ** 
 
EXTL1 Hs00184929_m1 10.792 ± 9.005 UP 0.297 8.270 ± 10.131 UP 0.460 10.353 ± 9.231 UP 0.325 
 
EXTL2 Hs01018237_m1 0.884 ± 0.167 UP 0.006 ** 0.128 ± 0.032 UP 0.017 * 0.234 ± 0.120 UP 0.123 
 
EXTL3 Hs00918601_m1 0.262 ± 0.242 UP 0.340 0.053 ± 0.161 UP 0.760 *0.494+± 0.126 DOWN 0.017 * 
 
GPC1 Hs00892476_m1 0.506 ± 0.172 UP 0.042 * 0.173 ± 0.037 UP 0.010 ** 0.250 ± 0.128 UP 0.123  
 
GPC2 Hs00415099_m1 1.114 ± 0.380 UP 0.043 * *1.227+± 0.165 DOWN 0.002 ** *1.294+± 0.323 DOWN 0.016 * 
 
GPC3 Hs01018936_m1 *1.710+± 0.797 DOWN 0.098 26.954 ± 0.790 UP 0.000 *** 17.055 ± 10.475 UP 0.179 
 
GPC4 Hs00155059_m1 1.252 ± 1.414 UP 0.426 10.879 ± 13.191 UP 0.456 12.364 ± 12.664 UP 0.384 
 
GPC5 Hs00270114_m1 0.814 ± 0.233 UP 0.025 * *0.150+± 0.571 DOWN 0.805 *0.431+± 0.280 DOWN 0.198 
 
GPC6 Hs00170677_m1 0.750 ± 0.075 UP 0.001 *** 0.214 ± 0.027 UP 0.001 ** 0.265 ± 0.055 UP 0.008 ** 
 
HPSE Hs00935036_m1 1.023 ± 0.016 UP 0.000 *** 0.258 ± 0.160 UP 0.183 0.402 ± 0.030 UP 0.000 *** 
 
HPSE2 Hs00222435_m1 *20.619+± 11.325 DOWN 0.143 *10.367+± 11.658 DOWN 0.424 *21.982+± 11.473 DOWN 0.128 
 
HS2ST1 Hs00202138_m1 0.653 ± 0.158 UP 0.014 * 0.258 ± 0.105 UP 0.071 0.248 ± 0.024 UP 0.000 *** 
 
HS3ST1 Hs00245421_s1 1.251 ± 0.114 UP 0.000 *** 0.048 ± 0.035 UP 0.243 *0.251+± 0.106 DOWN 0.076 
 
HS3ST2 Hs00428644_m1 *1.400+± 0.612 DOWN 0.084  *4.361+± 0.875 DOWN 0.008 ** *4.596+± 1.040 DOWN 0.012 * 
 
HS3ST3A1 Hs00925624_s1 *27.008+± 0.056 DOWN 0.000 *** *0.026+± 0.082 DOWN 0.771 0.256 ± 0.090 UP 0.047 * 
 
HS3ST3B1 Hs00797512_s1 2.140 ± 0.135 UP 0.000 *** 0.390 ± 0.206 UP 0.131 0.536 ± 0.154 UP 0.025 * 
 
HS3ST4 Hs00901124_s1 *28.245+± 0.127 DOWN 0.000 *** *0.026+± 0.082 DOWN 0.771 0.256 ± 0.090 UP 0.047 * 
 
HS3ST5 Hs00999394_m1 *33.885+± 0.041 DOWN 0.000 *** *0.026+± 0.082 DOWN 0.771 0.256 ± 0.090 UP 0.047 * 
 
HS3ST6 Hs03007244_m1 17.581 ± 8.784 UP 0.116 0.064 ± 0.172 UP 0.729 *3.353+± 16.738 DOWN 0.851 
 
HS6ST1 Hs00757137_m1 1.035 ± 0.110 UP 0.001 *** 0.045 ± 0.121 UP 0.730 *0.095+± 0.040 DOWN 0.076 
 
HS6ST2 Hs02925656_m1 *0.498+± 1.451 DOWN 0.749 0.746 ± 0.774 UP 0.390 *0.295+± 1.680 DOWN 0.869 
 
HS6ST3 Hs00542178_m1 1.361 ± 0.197 UP 0.002 ** *0.150+± 0.177 DOWN 0.444 0.036 ± 0.234 UP 0.886 
 
NDST1 Hs00925442_m1 0.824 ± 0.122 UP 0.003 ** 0.091 ± 0.007 UP 0.000 *** 0.188 ± 0.072 UP 0.059 
 
NDST2 Hs00234335_m1 1.255 ± 0.044 UP 0.000 *** 0.073 ± 0.110 UP 0.544 *0.121+± 0.062 DOWN 0.125 
 
NDST3 Hs01128584_m1 *1.402+± 0.740 DOWN 0.131 *6.375+± 3.114 DOWN 0.110 *3.692+± 1.364 DOWN 0.054 
 
NDST4 Hs00224024_m1 1.318 ± 0.024 UP 0.000 *** 0.242 ± 0.177 UP 0.244 0.956 ± 0.298 UP 0.033 * 
 
SDC1 Hs00896423_m1 0.233 ± 0.113 UP 0.110 0.143 ± 0.269 UP 0.624 0.292 ± 0.117 UP 0.067 
 
SDC2 Hs00299807_m1 0.099 ± 0.223 UP 0.681  *0.563+± 0.573 DOWN 0.381  *0.230+± 0.273 DOWN 0.447  
 
SDC3 Hs01568665_m1 1.051 ± 0.141 UP 0.002 ** 0.151 ± 0.242 UP 0.567 0.085 ± 0.163 UP 0.629 
 
SDC4 Hs00161617_m1 *0.120+± 0.343 DOWN 0.744 *0.253+± 0.156 DOWN 0.179 0.586 ± 0.315 UP 0.136 
 
SULF1 Hs00290918_m1 2.555 ± 1.607 UP 0.187 35.389 ± 1.431 UP 0.000 *** 34.157 ± 1.439 UP 0.000 *** 
 










Expression of a number of markers associated with BCSCs, including CD44, 
EpCAM and ABCG2, and the effect of HS/heparin and chemically modified heparin 
on theses markers were studied in the CD44+/CD24− population from MDA-MB-231 
and Hs578-T cell lines and summarized in Tables 5.3 and 5.4. Multiple previous 
studies have demonstrated that the CD44+/CD24− population from BCC have tumor-
initiating abilities (Al-Hajj et al., 2003, Ponti et al., 2005). These tumorigenic 
properties have been identified as stem cell–like properties (Al-Hajj et al., 2003), 
enhanced metastasis, invasive properties (Sheridan et al., 2006), and chemo/radio 
resistance (Kim et al., 2009). As expected from the FACS selection, CD44 was 
highly expressed in our studies. Interestingly, treatment with a number of HS/heparin 
compounds resulted in down-regulation of CD44, and thus would produce CD44low 
and/or CD44- cells which have reduced tumorigenicity. This mechanism may be in 
part responsible for the altered phenotype of the cells in terms of reduced adhesion, 
invasion and migration.  In contrast, previous experiments examined the role of 
CD44 variant exon 3 (CD44v3), a HS-binding isoform of CD44, in invasion and 
metastasis associated with HS in colon cancer cell lines (Kuniyasu et al., 2001). It 
was found that CD44v3 expression correlated with increased cell invasion after 
human colon cancer cells are treated with HS. However HS treatment did not show 
any effect on cell growth. In addition, these cells that express CD44v3 were found to 
be stimulated by free HS to invade, which also correlated with poor prognosis 
(Kuniyasu et al., 2001). The CD44+ phenotype is also positively corresponded with 
breast, prostate, colon, and pancreatic cancer initiator cells (Yan et al., 2015). 
Variants of CD44 isoforms are differentially expressed during pregnancy and 
involution, indicating a role in normal breast epithelial homeostasis (Fillmore and 
Kuperwasser, 2007). In future studies is may be of interest to examine the exact 
CD44 variants expressed in the MDA-MB-231 and Hs578-T cell lines, and to see 
whether these vary upon treatment with HS/heparins, since these effects may be 
dynamic. 
(Al-Hajj et al., 2003) demonstrated that the frequency of CSCs was >10-fold higher 







is considered as one of the cell surface markers of several types of CSCs. However, 
some available immortalized human BCC lines lack EpCAM expression. Here we 
found that MDA-MB-231 and Hs578-T BCCs expressed none or only very little 
EpCAM mRNA and protein compared to the other established and well 
characterized BCC lines such as SK-BR-3 or MCF-7 (Prang et al., 2005). Our 
findings are in line with the previous studies by (Prang et al., 2005) regarding  MDA-
MB-231 and Hs578-T human BCCs, so it appears that this marker is not involved in 
the aggressive phenotype of these two BCC lines, and is not related to the responses 
we observed to HS/heparin treatments. 
In further experiments, the expression of ABCG2 was characterised. Previous studies 
showed that MDA-MB-231 cells treated with heparin at relatively low 
concentrations (0.25–32 IU/ml) exhibited inhibition of the ATPase activity of 
ABCG2 (Chen et al., 2014). Thus, HS/heparin compounds may inhibit the efflux 
activity of ABCG2 transporter which otherwise confers higher drug resistance to 
CSCs which express higher levels of this transporter. In contrast, our results showed 
that MDA-MB-231 treated cells with PerS H, PMH and PMHS at low concentration 
(10 ng/ml)  exhibit higher levels of expression of ABCG2, while no significant affect 
was observed in cells treated with 2,6 deS-NS H. The CD44+/CD24- sub-population 
of Hs578-T treated with PerS H, 2,6 deS-NS H and PMHS also showed a significant 
increase in ABCG2 expression, though no significant increase was detected in cells 
treated with heparin. Thus, a number of the compounds can induce increased 
expression of ABCG2 which is counter to the observation here that they induce 
increased chemoresistance in CSCs, presumably via increased cytotoxicity of ABC 
transporter substrates such as doxorubicin and cisplatin; chapter 4.8). It can be 
concluded that the HS/heparin compounds do not enhance chemoresistance of the 
CD44+/CD24- sub-population of MDA-MB-231 and Hs578-T cells via reducing 
expression of the ABCG2 transporter proteins. Rather, since the ATPase activity of 
ABC transporters is essential to their efflux transport activity, and heparin has 
previously been reported to inhibit this activity (Chen et al., 2014), it is reasonable to 
hypothesise that the compounds may be acting via inhibition of ABCG2 and possibly 
other drug transporters. This would result in increased chemosensitivity of BCCs, via 
reducing drug efflux and enhacing drug retention and thus cytotoxicity. Indeed, this 







ABCG2 as the cells attempt to increae drug efflux. Future experiments should thus 
focus on testing the effects of the compounds on the activity of the ABCG2 
transporter to test this hypothesis.   
Previous studies have shown that CSCs consistently secrete markedly elevated levels 
of a panel of angiogenic factors that increase endothelial cell migration and tube 
formation (Bao et al., 2006). Angiogenesis is an essential process for tumour 
formation and maintenance, while anti-angiogenic therapies may effectively target 
and reduce CSCs self-renewal (Bao et al., 2006). However, the roles of angiogenic 
molecules in BCSCs and their contribution to tumor angiogenesis remained largely 
unknown. In the current study, CD44+/CD24- sub-population cells isolated from 
MDA-MB-231 and Hs578-T were used as a model of CSCs to study links between 
CSCs, drug resistance genes and angiogenesis. The expression levels of pro-
angiogenic genes and chemokines that we detected in the CD44+/CD24- cells were 
similar to those described in recent reports in other BC cell lines such as MCF-7A 
(Sun et al., 2013). The data presented here showed that the expression of pro-
angiogenic genes, such as VEGFA, VEGFB, IL-8, Ang-1, and Ang-2 were higher in 
CD44+/CD24− sub-population compared with CD44-/CD24- sub-population isolated 
from MDA-MB-231 and Hs578-T human BCCs. Previous studies reported that, 
chemokines and their receptors are involved in the CSC-mediated production of 
angiogenic factors (Cojoc et al., 2013). Chemokine receptor CXCR4 is known to 
play an important role in tumor angiogenesis and has been shown to be preferentially 
expressed by glioblastoma stem cells (Ehtesham et al., 2009). Previous studies found 
that CXCR4 was highly expressed in the CD44+/CD24− sub-set compared with the 
CD44-/CD24+ sub-set isolated from MCF-7 human BCCs (Sun et al., 2013). Here we 
confirmed similar findings in 2 other human BCC lines (MDA-MB-231 and Hs578-
T); the results showed that the expression of CXCR4 was also higher in 
CD44+/CD24− cells compared with CD44-/CD24+ cells. Multiple studies have 
demonstrated evidence of angiogenesis related to a CD44- phenotype in BCCs 
(Jeyapalan et al., 2011). Reduced expression of CD44 was noted with some 
compound treatments here, suggesting the possibility that this may result in reduction 
of the CD44+/CD24− angiogenic properties with a switch towards a CD44-/CD24- 
phenotype.  On the other hand, CD24 has been shown to either inhibit (Schabath et 







CD44+/CD24- sub-population of MDA-MB-231 and Hs578-T cells appeared to 
correlate more with expression of increased levels of angiogenic factors than the 
CD44-/CD24- sub-population of the same cell line. The relationship between the 
CD44+/CD24- phenotype and enhanced expression of angiogenic molecules 
demonstrated in this study may not be directly linked to the function of these 
individual genes. Nevertheless, increased angiogenic properties seem to be intrinsic 
to cells with a CD44+/CD24- phenotype and can apparently be differentially 
modulated by treatment with HS/heparins.  
Previous studies have shown that soluble heparin or HS can inhibit the interaction 
between CXCL12 chemokine and its receptor CXCR4, preventing the adhesion, 
invasion and migration of CXCR4-expressing T-cells (Dowsland et al., 2003, Hecht 
et al., 2004, Kuschert et al., 1999). The work presented here has shown that HS and 
highly sulphated modified heparins are capable of inhibiting CXCR4 expression in 
CD44+/CD24- cells sorted from both MDA-MB-231 and Hs578-T cell lines. Thus, 
reducing CXCR4 expression may represent a plausible mechanism for reducing the 
angiogenic properties of BCSCs, though direct effects on inhibiting chemokine-
receptor functions cannot be ruled out as an additional mechanism. The present study 
demonstrated that CSC-like cells contribute to a greater pro-angiogenic potential of 
BCCs, and may present targets for effective anti-angiogenic therapies which could 
include heparins. However, the usefulness of heparin itself, having high 
anticoagulant activity, might limited its applicability for treating BC patients. On the 
other hand, PMHS or modified heparins, with intrinsically much lower anticoagulant 
activities, might be candidates for such applications. 
Previous evidence demonstrated that IL-8 binds to GAGs, especially heparin/HS and 
it has been reported that HSPGs on endothelial cell surfaces localize and present 
chemokines to selectin-bound leukocytes (Dowsland et al., 2003). Other studies 
suggest that chemokines bind to cell-surface HS in vitro, and that HS may promote 
IL-8-dependent transmigration of neutrophils and enhance IL-8 activity (Dowsland 
et al., 2003). In addition, IL-8 was found to be highly expressed in breast cancer 
compared to normal breast tissue. IL-8 may also promote breast cancer initiation and 
progression via the IL-8 signaling pathway, and there is evidence indicates that IL-8 







potential candidate molecule for mediating the effects of exogenous HS/heparins on 
BCSCs. The findings here indicated that some modified heparin (PerS H and 2,6 
deS-NS H), but not heparin, did significantly inhibit IL-8 expression in 
CD44+/CD24- cells from the MDA-MB-231 cell line. On the other hand PMHS 
treatment enhanced IL8 expression in these cells. Hs578-T cells showed a significant 
downregulation of IL-8 expression when treated with heparin and modified heparins 
(PerS H and 2,6 deS-NS H), and PMHS treatment again showed a significant 
upregulation of IL-8 expression. Thus modulation of IL-8 expression could be an 
additional mechanism of action of at least some of the compounds in reducing CSC 
tumorigenic properties.     
Binding of HS/heparin to growth factors is modulated by differential sulphation of 
the polysaccharide backbone, creating a multitude of protein binding domains 
(Kreuger et al., 2005) . One of the aims of the present study was to define whether 
exogenous HS/heparin might influence VEGF functions. Data presented here showed 
that VEGFA expression was increased 1.5- 2 fold in MDA-MB-231 and Hs578-T 
cells treated with HS and modified heparin compared to untreated cells. In contrast, 
VEGFB expression was not detected in either MDA-MB-231 or Hs578-T cells 
treated with heparin and modified heparins compared to untreated control cells. 
However, PMHS treatment induced a significant increase in VEGFB expression. The 
lack of response of CD44+/CD24- cells treated with HS and modified heparin in 
terms of VEGFB expression may relate to the fact that VEGF-A165 is a heparin 
binding growth factor (Ruhrberg et al., 2002). 
Angiopoietin activities are differentially regulated by the ECM and HSPGs. This 
might provide the basis for modulating activities of angiopoietins in vivo and thereby 
angiogenesis regulation in physiologic and pathologic situations (Xu et al., 2004). In 
the present study it was found that Ang-1 is downregulated in CSC-like cells in 
MDA-MB-231 cell culture treated with PerS H, 2,6 deS-NS H and PMH, but 
upregulated in cells treated with PMHS. On the contrary, Ang-1 was found to be 
upregulated in CSC-like cells from Hs578-T cells treated with HS, heparin, and 
modified heparin, whereas PerS H and 2,6 deS-NS H treatment downregulated Ang-
2 expression. PMH and PMHS upregulated Ang2 expression in both cells. Role of 







Tables 5.3 and 5.4. 
Table 5.3 Summary table of effect of HS/heparin and modified heparins effects 
on CSC, drug resistance and angiogenic markers in MDA-MB-231 BCSCs 
 CSC markers Angiogenesis 















Sig - No No Sig + Sig + Sig + Sig - Sig - Sig - 
PMHS No  Sig + No Sig + No No Sig + Sig - No 
PMH Sig - Sig + Sig + Sig + Sig + Sig + Sig + Sig - Sig + 
*Sig, statistically significant. 
Table 5.4 Summary table of effect of HS/heparin and modified heparins effects 
on CSC, drug resistance and angiogenic markers in Hs578-T BCSCs 
 CSC markers Angiogenesis 















Sig - Sig + No No No Sig - Sig - Sig - Sig - 
PMHS No  No Sig + No No Sig - Sig + Sig - No 
PMH Sig - Sig + Sig - Sig + Sig + Sig + Sig + Sig - Sig + 
*Sig, statistically significant. 
HSPGs are known to be involved in several biological functions of heparin-binding 
growth factors (GFs) (Chua et al., 2004), including the prototypical FGF family 
members. FGF-2 signaling mediated by HSPGs activates the ERK1/2 signaling 
pathway to regulate cell activity. Several studies have revealed that HSPGs regulate 
the activity of growth factors due to either HSPGs playing an important roles as co-
receptors in binding FGF ligands to their FGFRs (Ornitz, 2000), or indirectly as 
FGF2 receptors (Mundhenke et al., 2002). Several indirect ERK-specific inhibitors 
have been revealed by targeting the upstream kinases, including Raf and MEKs 
(Jung et al., 2016, Lee et al., 2013). However, studies with these inhibitors of ERK 
on CSCs have not been reported. The present results suggest that HS and some 







activation, suggesting that FGF mediate ERK1/2 activation through HSPGs in CSCs. 
These investigations suggest the possibility that HS or specific chemically modified 
heparins could potentially be used to target CSCs functions including signaling that 
supports their growth. 
BCCs stimulated with or without FGF2 and treated with different compounds of 
HSPGs. As expected FGF2 was able to stimulate ERK1/2 phosphorylation, 
presumably dependent on endogenous cell surface HSPGs. The kinetics of FGFR-
mediated ERK1/2 activation the CD44+/CD24- sub-population isolated from MDA-
MB-231 and Hs578-T human BCCs was altered significantly by FGF stimulation, 
HS and chemically modified heparin treatments were observed to prevent FGF2 
from stimulating and activating ERK1/2 signaling, seen as a significant decrease in 
FGF2-induced ERK1/2 phosphorylation. CD44+/CD24- of MDA-MB-231 cells 
expressed significantly less total ERK1/2 and showed a greater response to 2,6 deS-
NS H and HS treatments. In contrast with the other modified heparin compounds 
(PerS H and HS) there was no effect on decreasing the expression levels of ERK1/2. 
These results indicated that 2,6 deS-NS H and HS treatments showed a greater 
overall effect on the FGF2 mediated ERK1/2 signaling pathway. CD44+/CD24- of 
Hs578-T cells expressed significantly less total ERK1/2 and showed a greater 
dependence on 2,6 deS-NS H, heparin and HS treatments. In contrast the other 
modified heparin compound, PerS H, showed no effect on decreasing the expression 
levels of ERK1/2.  
In addition, CD44+/CD24- cells treated with HS and modified heparin for different 
time point in both cell lines expressed significantly less ERK1/2 and showed a 
greater dependence on FGF2 stimulation;  compound treatments alone in 
unstimulated cells showed undetectable activation of ERK1/2, suggesting that adding 
HS and modified heparin on cells alone did not activate ERK1/2. Overall, ERK1/2 
activation via FGF2 stimulation has been shown to be sensitive to a number of the 
compounds, but these responses alone could not predict all the altered biological 
responses noted in the CSC cells. Thus, alteration of activation of ERK1/2 most 
likely represents one component of a complex system of responses that CSCs make 







It is well established that inflammatory signals that come from the tumour 
microenvironment enhance tumour growth and progression (Bromberg and Wang, 
2009, Grivennikov and Karin, 2008). It has been found that IL-6 promotes cell 
proliferation in prostate cancer in vitro (Malinowska et al., 2009) and promotes 
tumour growth in breast and prostate cancer in vivo (Knüpfer and Preiß, 2007, 
Malinowska et al., 2009). Previous studies reported that inflammatory response 
pathways have been linked to BCSCs. Of particular interest in this respect is STAT3, 
one of the common transcription factors, which acts as a key modulator in the 
inflammatory signaling pathway, leading to cancer when inflammation becomes 
chronic. STAT3 acts by regulating the expression of inflammatory cytokines 
including IL-6 that are inflammatory mediators. A growing body of evidence has 
shown that the IL-6/STAT3 inflammatory cytokine signaling pathway is involved in 
a wide range of human tumors and impacts cell adhesion and migration. In 
particular, and most relevant to our mechanistic studies, the IL-6/STAT-3 pathway is 
recognized as an important  signaling pathway in the regulation and maintenance of 
the CD44+/CD24- BCSC phenotype (Hernandez-Vargas et al., 2011, Xie et al., 
2012). A similar link between IL-6 and STAT3 have been demonstrated in the 
survival of intestinal epithelial cells in colitis-associated cancer and in mammary 
epithelial cells (Ibrahim et al., 2013). Based on these results, we hypothesized that 
IL-6 would promote survival of BCSCs via STAT3 and that this signaling axis might 
be susceptible to HS/heparin treatments.  
Indeed we found firstly that the endogenous levels of IL-6 in CD44+/CD24- sorted 
cells from MDA-MB-231 and Hs578-T BCCs was downregulated upon treatment 
with HS/heparins compared to untreated cells. Interestingly, PMH treatment 
significantly upregulated IL-6 expression in Hs578-T cells, and PerS H treatment 
upregulated IL-6 expression in both MDA-MB-231 and Hs578-T cell lines.  
MDA-MB-231 and Hs578-T BCCs reacted rapidly on treatment with HS and 
modified heparin by increased phosphorylation of STAT3 and also total STAT3 at 
comparable intensities and kinetics. The phosphorylation and total STAT3 activation 
could be blocked by low concentrations of 10 ng/ml of PerS H, 2,6 deS-NS H or 
PMHS in stimulated cells, which presumably competes with cell surface HSPGs for 







were found to also inhibit STAT3 phosphorylation in Hs578-T cells, whereas these 
compounds did not effect total STAT3 expression. In agreement with our findings, it 
was previously reported that syndecan-1 silencing in MDA-MB-231 BCCs resulted 
in dysregulation of IL-6-induced NFkB and STAT3 activation (Götte et al., 2007). 
Our findings showed that exogenous HS and sulphated chemically modified heparin 
treatments inhibit proinflammatory signaling through downregulation of IL-6 which 
was linked to reduced constitutive activation of STAT3. These effects of the  
compounds could be a significant factor in their ability to reduce the CD44+/CD24- 
sub-population in MDA-MB-231 and Hs578-T BCCs, and also to alteration in their 
metastatic phenotype. These studies emphasize the importance of HSPGs in 
underpinning a number of biological processes essential for maintenance of the BC 
CSC-like cell phenotypes, and the potential to exploit HS and modified heparins to 
interefere with BC CSCs in novel treatments, perhaps in combination with existing 
drug treatment regimes.  
MAPK/ERK and STAT3 are well known to be activated by various extracellular 
stimuli such as cytokines, growth factors and hormones. MAPK/ERK and STAT3 
signalling are involved in a wide range of cellular processes including proliferation 
and apoptosis, and inflammation and immunity, respectively (Katz et al., 2007, 
Kijima et al., 2002, Mebratu and Tesfaigzi, 2009, Zhang et al., 2005). The results 
from the PathScan intracellular signaling array performed in the current study 
indicated that ERK1/2 and STAT3 were activated in both MDA-MB-231 and Hs578-
T cell lines after stimulation with FGF2, and were altered by additional treatment 
with HS/heparin derivatives. This suggesting a potential role for these pathways in 
mediating the effects of the compounds on BCSC phenotype.  
Moreover, previous studies have demonstrated that AMPKα signaling has an 
important role in the regulation of cancer cell invasion and pharmacological 
activation of AMPK was observed to reduce cancer cell invasion (Fitzgerald et al., 
2012).  In the present study some chemically modified heparins activated AMPKα 
phosphorylation in CD44+/CD24- cells from the MDA-MB-231 cell line (although 
this effect was not observed in Hs578-T cells). Thus, the activation of AMPKα by 







the invasive properties of MDA-MB-231 CSCs, and further studies are warranted to 
investigate the exact role of AMPKα in these effects. 
The present study also demonstrated that HS derivatives significantly reduced S6 
ribosomal protein phosphorylation levels in CD44+/CD24- cells from MDA-MB-231 
and Hs578-T cells. This protein is found downstream of the effector mTOR (a 
protein that has a pivotal role in cell growth and homeostasis), and predicts cell cycle 
progression (Ruvinsky and Meyuhas, 2006). Phosphorylation of S6 ribosomal is 
required in the regulation of mRNA expression during the G1 phase of the cell cycle 
(Thomas et al., 1979). As anticipated, the phosphorylation level of S6 ribosomal 
protein was decreased by treatment with heparin derivatives, and the mTOR 
signaling pathway was inhibited in a similar manner (Figure 5.10). Thus, the findings 
here revealed for the first time, to the best of our knowledge, that the activation of 
AMPKα and inhibition of mTOR and S6 ribosomal by HS and chemically modified 
heparins may play a key role in inhibiting the invasive and cell proliferative capacity 
of CSCs. Future studies should be performed to investigate the exact roles of 
AMPKα, S6 ribosomal protein and mTOR signaling in BCSCs, and their responses 
to treatment of the cells with chemically modified heparins. This could include using 
chemical inhibitors or activators of these pathways to establish whether rescue or 
antagonism of the effects of the modified heparins is possible. 
 
 
HSPGs expression is markedly changed during the tumour transformation and 
progression, leading to affects on both the PG core proteins and the GAG chains 
(Raman and Kuberan, 2010). The fine structure of HS can be determined by the 
expression in cells of HS biosynthetic enzymes, some of which have multiple 
isoforms; the existence in some specific cases of regulation at translation level or 
enzymatic catalysis has been noted (Grobe and Esko, 2002, Theocharis et al., 2010). 
In the present work the expression of genes involved in the biosynthesis of HSPGs 
has been tested in CD44+/CD24- human BCCs (MDA-MB-231 and Hs578-T) treated 
with HS/heparin or a selected modified heparin 2,6 deS-NS H, compared to those of 







there are 13 full-time HSPGs encoding genes in human cells. It was found that only 
syndecan1 was overexpressed in metastatic and non metastatic tumors. In addition, 
the upregulation of SDC-1 has been previously reported in BC (Löfgren et al., 2007). 
Further studies reported that SDC-1 expression shifts from epithelial to stromal cells 
during breast tumour progression, suggesting involvement in the stimulation of 
tumour growth and angiogenesis (Maeda et al., 2006, Yang et al., 2011). 
Upregulation of SDC-1 has also been reported in other tumors including, lung, 
pancreatic and brain cancer, indicating that SDC-1 may play a crucial role in 
promoting growth factor signaling in cancer cells (Raman and Kuberan, 2010). In 
contrast, SDC-1 has been found to be a downregulated in various tumours, such as 
colorectal cancer, suggesting that this HSPG may play a key role as a prognostic 
marker in a cancer-type-specific manner (Raman and Kuberan, 2010).  
In this study, adding HS to CD44+/CD24- cells was found to downregulate the SDC 
isoforms in BCC lines MDA-MB-231 and Hs578-T cells, compared to untreated 
cells. In contrast, adding heparin to those cells was found to upregulate the 
expression of SDCs in MDA-MB-231 and did not significantly affect changes in 
Hs578-T cells. Selected modified heparin 2,6 deS-NS H showed significant 
differences on expression of syndecans in both cell lines. Upregulation of SDCs has 
been previously reported in an estrogen receptor-negative highly proliferative breast 
carcinoma subtype (Baba et al., 2006). Consistent with this result, cell lines analyzed 
in this study displayed a claudin-low phenotype, which constitutes a common late 
stage of breast cancer where tumors have negative levels of estrogen and 
progesterone receptors. 
Members of the GPC group of HSPGs are modulators of cell adhesion and growth 
factor signaling. Over or lower expression of GPCs has been related to malignant 
progression (Stigliano et al., 2009). A previous study found that, GPC-3 has negative 
effect on cell proliferation, and its depletion may contribute to cancer progression 
(Theocharis et al., 2010). 6 members of the GPC family have been analyzed in this 
study.  PMHS and 2,6 deS-NS H down regulated the GPC group in CD44+/CD24- 
sub-population sorted from MDA-MB-231 cells; however, PMHS did not affect 
GPC-3 and 4, whereas 2,6 deS-NS H did not affect on GPC-6, compared to untreated 







contrast GPC-4, 5 and 6 showed a significant increase in their expression. PMHS 
upregulated most of GPC isoforms, whereas only isoform 3 showed a 
downregulation in CD44+/CD24- sub-population cells sorted from the Hs578-T line. 
In addition heparin did not affect GPC-3 and 4 at all compared to untreated samples. 
As for the SDC group, 2,6 deS-NS H treatment showed significant differences on 
expression of GPC in the CSCs from the Hs578-T cell line.  
GAG chain generation requires the action of multiple GTs and regulation of their 
expression in the golgi apparatus (Esko and Lindahl, 2001). Analysis of biosynthetic 
enzymes of HS chains (EXT1, 2 and EXTL1, 2, 3) did not show any significant 
changes with PMHS in the CD44+/CD24- sub-population sorted from the MDA-MB-
231 line, whereas a significant increase was shown in Hs578-T cells. Heparin 
significantly increased these biosynthetic enzymes in MDA-MB-231 and variations 
in the levels of these enzymes was shown in Hs578-T cells (both increases and 
decreases). High and low levels of theses enzymes has been observed in both cell 
lines treated with 2,6 deS-NS H, suggesting that adding PMHS/heparin and the 
selective modified heparin 2,6 deS-NS H induce regulation of the relative levels of 
GTs in BCSCs.  
Our results showed no significant differences of transcript levels in CSCs. In 
contrast, NDST3 and 4 are expressed during embryonic development (Grobe and 
Esko, 2002). In the present study expression of NDSTs was highly detected in 
CD44+/CD24- sorted cells from Hs578-T cells treated with PMHS, and was 
significantly decreased in MDA-MB-231 cells. Although no significant changes of 
NDSTs enzymes was detected in Hs578-T cells with heparin, these enzymes were 
highly detected in MDA-MB-231 cells.  NDST3 was only detected at low and high 
levels in both cell lines, making it difficult to draw conclusions.  
HS3ST2 gene silencing via methylation has been demonstrated in various type of 
cancers, including breast tumours (Bui et al., 2010, Miyamoto et al., 2003). The last 
group of enzymes, which is involved in the modification of HS chain, was 
downregulated in CD44+/CD24- sorted cells from the MDA-MB-231 line. However, 
in this study, adding PMHS to MDA-MB-231 cells appeared to upregulate HS3STs  







of those enzymes in Hs578-T cells treated with heparin, while a significant increase 
was shown in MDA-MB-231 cells. HS2ST1, HS6ST1, 2, 3 and HS3ST1, 2, 3A1, 
3B1, 4, 5, 6 all displayed significant differences in MDA-MB-231 and Hs578-T cells 
treated with 2,6 deS-NS H compared to untreated cells. Whilst the implications of 3-
O-sulfation decrease in tumors are not yet known, it has been suggested that certain 
patterns of 3-O-sulfation could impart cancerous phenotypic changes (Raman and 
Kuberan, 2010).  
HS 6-O-endosulfatases are localized at the cell surface. Analysis of expression of 
both HS 6-O-endosulfatase genes Sulf1 and Sulf2 did not showed significant 
differences in MDA-MB-231 and Hs578-T cells treated with PMHS/heparin and the 
selected modified heparin 2,6 deS-NS H. Previous studies showed that both genes 
were overexpressed in pancreatic cancer (Raman and Kuberan, 2010). With regard to 
breast cancer, downregulation of sulf1 has been previously reported, while sulf2 has 
been indicated to be upregulated in some breast cancer cell lines. Another study 
suggested that alterations in sulfation patterns in tumors may relate to protecting the 
cancer cell from Natural Killer (NK) recognition (Raman and Kuberan, 2010). Our 
data here suggests that HS/heparin and chemically modified heparin treatments could 
potentially be used to modulate HS biosynthesis and thereby the sulfation patterns in 
BCSCs, and thereby alter their phenotype and susceptibility to biological or 
therapeutic control.  
The expression of HPSE has been reported in various types of human cancer. In 
addition, its expression was found to be linked with the reduction of patient survival 
and increased tumor metastasis (Arvatz et al., 2011). Here, adding PMHS to 
CD44+/CD24- sorted cells from the MDA-MB-231 line produced a significant 
reduction in the transcription level of HPSE, while heparin increased the HPSE level. 
No significant effect was observed in cells treated with 2,6 deS-NS H. HS/heparin 
and 2,6deS-NS-H produced a significant increase in HPSE transcripts in 
CD44+/CD24- sorted cells from Hs578-T cells. Previous study indicated that HPSE2 
may regulate the enzymatic activity and signaling properties of HPSE, resulting in an 
anti-metastatic effect being proposed (Arvatz et al., 2011, Levy-Adam et al., 2010). 
Analysis of HPSE2 transcription in both cell lines MDA-MB-231 and Hs578-T cells 







beneficial effect on reducing heparanase activity. The upregulation of HPSE in 
tumours has been widely reported in the literature, although our results show that 
HS/heparin and selected modified heparin did appear to significantly increase its 
transcription levels (although the levels of protein could well be controlled by 
stability of mRNA isoforms). In addition, although, the interaction of HPSE2 with 
HS has been proposed to have anti-cancer properties, and are downregulated in 
major types cancer studied, the present study found that the addition of HS/heparin 
or modified heparin resulted in strong overexpression of HPSE2 in both cell lines 
(MDA-MB-231 and Hs578-T cells), pointing to this gene as a potentially interesting 
target for altering the progression of BCSCs. 
Overall, analysis of the effect of HS/heparin and selected chemically modified 
heparin on the differential expression of the genes involved in the HSPG 
biosynthesis in BCSCs demonstrated that there are significant changes in their 
transcript levels. Although some variations were detectable (especially in 2,6 deS-NS 
H treatment in both cell lines MDA-MB-231 and Hs578-T human BCCs), most 







6 General discussion 
Breast cancer is the most common cancer leading to death in women. A small subset 
of tumour cells, called CSCs or tumour-initiating cells (TICs), has been reported to 
contribute to breast cancer therapy failure, due to chemoresistance (Van Pham et al., 
2012). Tumor progression is hypothesized to depend on the CSC theory, which states 
that CSCs self-renew (produce copies of themselves), some of which then 
differentiate to produce cancer cells, ultimately re-grow the cancer leading to relapse. 
These tumorigenic cells (a small fraction of the TICs) are similar to normal stem 
cells, being capable of self-renewal and differentiation, but the balance between 
these two processes is highly deregulated, causing tumour formation (Florio, 2011, 
Girouard and Murphy, 2011). Recently, targeting BCSCs has become a major focus 
in clinical trials and is considered a promising therapeutic option. 
Isolating CSCs for model studies on their properties  
Most commonly FACS has been used to separate CSCs from cell lines or tumor 
tissue, based on the expression of cell-surface markers (Al-Hajj et al., 2003). The 
first identified and isolated were CD44+CD24−/low tumorigenic cells from breast non-
tumourigenic cancer cells in eight of nine patients. (Singh et al., 2004) successfully 
isolated CD133+ brain tumorigenic cells. Following this, by using different surface 
markers, a wide range of solid tumours such as prostate (Collins et al., 2005), 
pancreatic (Olempska et al., 2007) and colon (Ricci-Vitiani et al., 2007), cancer 
initiating cells were isolated successfully. In breast cancer (Al-Hajj et al., 2003) and 
other experimental studies CSCs have been correlated with behavior such as self-
renewal, invasion and resistance to chemo and radio-therapy have also been 
investigated (Economopoulou et al., 2012, Sheridan et al., 2006).  Although several 
studies investigated the role of CSCs in primary tumour growth, using large amounts 
of primary cells, or the technical complexity of studying these cells in vivo, presents 
challenge. Thus, alternative model systems such as cell lines need to be developed 
and exploited to initially understand the mechanisms involved in regulation of CSCs.  
Here, CSCs have been successfully identified and isolated from two of the most 







combination of the CD44 and CD24 putative markers. It was observed that MDA-
MB-231 and Hs578-T cells express significantly higher levels of CD44 and lower 
levels of CD24 compared to other common BCC lines (MCF-7-A, T47D and ZR-75-
1); the percentage of the CD44+/CD24- sub-population varied markedly, and in some 
cases differed compared to previous studies despite using similar methods and 
techniques (Bensimon et al., 2013, Sheridan et al., 2006), perhaps reflecting different 
clonal variations in these lines maintained over time in different labs. In addition, 
although, CD133 has been described as a stemness marker for identification of 
BCSCs, and the CD133+ phenotype of BCCs associated with tumor-initiating 
capacity (Collina et al., 2015, Kagara et al., 2012, Wright et al., 2008), we could not 
observe and expression of the CD133 marker in any of the above studied BCC lines. 
This suggests that various measurement protocols used in different laboratory 
environments (eg antibodies), or different cell culture conditions (eg, serum 
type/source), may lead to lack of direct comparability of results. In addition, due to 
the different experimental protocols, the CSCs isolated may contain some non-CSC 
cancer cells, resulting in artifacts and bias for the analysis of CSC characteristics. 
More over, CD133 may not be restricted to BCSCs. 
CD44+/CD24- sub-populations isolated from MDA-MB-231 and Hs578-T cells 
displayed several properties typically seen in CSCs. It was found that the 
CD44+/CD24- cells demonstrated enhanced growth and increased in vitro cell 
viability compared to CD44-/CD24-. It should be noted that the isolation of the CSC 
sub-population from cancer cells may affect restrictions of the cell microenvironment 
from competitor locations, including neighbouring cells and ECM. It is suggested 
that cell growth in culture has in many aspects much in common with suppressing 
the immune system, such as accelerated proliferation. Our functional analyses of 
BCSC characteristics demonstrated that CD44+/CD24- cells isolated from MDA-
MB-231 and Hs578-T BCCs reveal important novel features of CSCs including 
increased in vitro invasion, migration, adhesion and colony forming ability compared 
to the respective isolated sub-populations (CD44-/CD24-, CD44-/CD24+ and 
CD44+/CD24+). In addition, CD44+/CD24- cells were less apoptotic and more 
resistant to chemotherapeutic agents including doxorubicin, tamoxofin and cisplatin 
compared to the CD44-/CD24- subset. These findings indicate that a distinct 







Effects of HS/heparins on BCSCs 
The experiments here demonstrated clear dose-responsive and structure-dependent 
effects of adding exogenous HS/heparin or modified heparins on the tumourigenic 
behaviour of BCSCs. These effects included significant reductions firstly in the 
actual levels of the CD44+/CD24- sub-populations, and secondly decreases in their 
tumourigenic properties in various functional assays. Although adding different 
concentrations of HS/ heparin and chemically modified heparins to MDA-MB-231 
and Hs578-T BCCs significantly reduced the CD44+/CD24- sub-populations, effects 
at some concentrations particularly at lower concentrations of some heparin 
derivatives (2 deS-NAc H, 6 deS-NAc H and PMH in MDA-MB-231) were to 
significantly increase the CD44+/ CD24- cells. Furthermore, higher concentrations of 
heparin derivatives (1-100 µg/ml) were apparently ineffective in the Hs578-T cell 
line, due in part to larger experimental variations. Care in interpretation of the 
structure-function relationships is also warranted, since the compounds are still 
heterogenous, being derived from the same PMH starting material (Celsus 
Laboratories, Cat. No. PH-3005, OH; USA). In previous work each of the modified 
heparins 1-8 were purified by size exclusion chromatography and treated with ion 
exchange resin prior to NMR analysis, followed by compositional analysis after 
digestion with heparinases I, II and III. It was evident that the polysaccharides were 
not absolutely pure and contained in some cases a low concentration of remaining 
disaccharide building blocks different from that predicted from the modifications 
performed (Table 6.1) (Patey et al., 2006). Nevertheless, these changes support the 
idea that the compounds with markedly differential structural patterns are causing 
both a phenotypic switch away from the CD44+/CD24- phenotype, and also altering 
their responses to the tumour microenvironment.  In the latter context, and perhaps 
most importantly in relation to possible future therapeutic opportunities, the 










Table 6.1 Chemically modified heparins purity (Patey et al., 2006). 
 
*P1, PMIH; P2, N-acetyl; P3, UA-2-OH; P4, UA-2-OH, N-acetyl; P5, GlcN-6-OH; 
P6, GlcN-6-OH, N-acetyl; P7, UA-2-OH, GlcN-6-OH; P8, UA-2-OH, GlcN-6-OH, 
N-acetyl. 
 
Chemoresistance of BCSCs are modified by exogenous heparins 
It is known that conventional chemotherapies used at present are initially effective in 
killing growing differentiated cells and controlling tumor growth. However, these 
therapies have been observed to fail to kill CSCs (Dean et al., 2005). One 
explanation for that is that cells have high tumorigenic properties, making them 
resistant to chemotherapy (Li et al., 2008). A wide range of studies of the resistance 
of BCSCs to chemotherapy has been reported (Li et al., 2008). Specifically, previous 
work suggested that CD44+/CD24−/low BCSCs were more resistant to DNA-
damaging drugs such as (doxorubicin and cisplatin) than the unsorted cells (Wright 
et al., 2008). Therefore, the present study tested the effect of chemotherapy drugs 
(doxorubicin, cisplatin) on unsorted and sorted (CD44+/CD24−/ and CD44-/CD24−) 
cells from MDA-MB-231 and Hs578-T BCCs. Apoptosis results showed a 
significant resistance to both doxorubicin and cisplatin in CD44+/CD24−/ sorted cells 
from MDA-MB-231 and Hs578-T, compared to the unsorted and sorted CD44-
/CD24− cells. It should be noted that these are the front-line therapies in most 
chemotherapies for ER negative breast cancer patients.  
The ER antagonist Tamoxifen has been widely used as a hormone therapy for the 







al., 1996). In contrast, a few studies suggested that, in a dose- and time-dependent 
manner the tamoxifen agent induces apoptosis in triple-negative breast cancer cells 
MDA-MB-231 through downregulation of CIP2A/PP2A/p-Akt signaling (Liu et al., 
2014a). Therefore, in the present studies the effective dose and treatment time of 
tamoxifen were initially identified and optimized by flow cytometry on isolated 
BCSCs and compared with results from CD44-/CD24- or parental cells of both BCC 
lines (MDA-MB-231 and Hs578-T) MCF-7. In contrast to doxorubicin and cisplatin 
drugs, the tamoxifen experimental results demonstrated that no significant increase 
of apoptotic cells occurred at low concentrations of tamoxifen (1-100 nM) at 
different time points 24, 48 and 72 hrs in both MDA-MB-231 and Hs578-T cells.  
High concentrations of tamoxifen however induced a significant increase in 
apoptotic cells compared to untreated cells. Interestingly, CD44+/CD24- cells from 
MDA-MB-231 and Hs578-T lines consisted of less apoptotic cells upon tamoxifen 
treatment compared to CD44-/CD24- and parental cells. Our findings are consistent 
with previous studies demonstrating that BCSCs show a significant resistance to 
undergo apoptosis in response to current chemo- and hormonal therapies, thus 
enhancing malignant behavior of tumours.  
During the metastasis process, cells alter their adhesion abilities to facilitate 
migration through the ECM and basement membranes, migrating into distant organs 
and finally forming metastases after proliferation, as well as promoting angiogenesis 
(Olson and Sahai, 2009). In order to understand the molecular foundation of tumour 
cell invasion, migration, adhesion and chemoresistance it is essential to identify 
molecular systems which underpin these processes, which may then be attractive 
therapeutic targets for CSCs. There is substantial evidence for the role of heparin and 
heparin derivatives as anti-metastasis agents with action against cancer-specific 
mechanisms, including functions of standard heparin/LMWH in inhibiting selectins 
(Läubli et al., 2009), and for low sulfated modified heparins in inhibiting galectin-3 
interactions (Duckworth et al., 2015). As stated before, HS can bind to a wide range 
of proteins and regulate cell motility, and cell-cell and cell-ECM adhesion, through 
molecular signaling pathways (Turnbull et al., 2001). In tumours, the expression of 
HS has a link with tumour development and progression. The studies here have 
employed in vitro BCC cell systems and have helped delineate specific roles for 







resistance, identifying multiple roles of HS/heparin and chemically modified heparin 
in governing these properties of CD44+/CD24- isolated cells from MDA-MB-231 
and Hs578-T BCC lines. It was noted that HS/heparin and chemically modified 
heparins, at notably low concentrations (low ng/ml) in most cases, caused a marked 
inhibition of cell proliferation, invasion, migration and adhesion in CD44+/CD24- 
sorted cells from MDA-MB-231 and Hs578-T human BCCs compared to untreated 
cells. Importantly, a combination of low concentrations of a number of the 
HS/heparin and chemically modified heparins was sufficient, with either 
doxorubicin, cisplatin or tamoxifen, to increase the apoptotic percentage of 
CD44+/CD24- sorted cells from MDA-MB-231 or Hs578T cells compared to cells 
treated with chemotherapy agent alone. Thus, it is clear that CSCs from BCCs can be 
sensitized to induction of apoptosis via a number of chemotherapeutic agents if 
treated with heparin-based compounds, providing potential new opportunities for 
therapeutic strategies to target CSCs more effectively. Only a single dose of 
HS/heparins (10ng/ml) was tested in these experiments, based on optimal doses 
determined for effects on other BCSC properties; thus, in future work it would be 
useful to undertake more detailed dose response studies on this specific aspect of the 
effects of HS/modified heparin on inducing chemoresistance, as this would provide 
valuable information on the likely clinical doses that might be needed. Nevertheless, 
the low dose needed to obtain these effects is very encouraging, since it would easily 
be achievable in vivo, based on existing pharmacokinetic data showing that 3mg/kg 
LMWH administration results in peak blood levels of ~3ug/ml (Zhao et al., 2016)  
Exploring mechanisms underlying CSC regulation by HS/heparins 
CSC markers and drug resistance: As mentioned previously, CD44+/CD24− BCCs 
are associated with tumor-initiating properties, enhanced invasiveness and metastasis 
(Ratajczak et al., 2010) and chemotherapeutic resistance (Pinto et al., 2013). A 
number of markers linked to these properties have been identified and were studied 
here. CD44, a well described CSC marker, was (by definition) highly expressed in 
CD44+/CD24- isolated cells from both cell lines. The present study showed lack of 
constitutive expression of the EpCAM CSC marker in CD44+/CD24- and CD44-
/CD24- sorted cells from parental human BCC lines MDA-MB-231 and Hs578-T. Of 







EpCAM protein, yet MDA-MB-231 and Hs578-T cells have low or even no EpCAM 
expression. The very low expression of EpCAM that was detected in both cell lines 
is thus similar to that described in most previous reports (Martowicz et al., 2012, 
Prang et al., 2005). Over-expression of BCRP/ABCG2 is believed to be involved in 
drug resistance mechanisms (Dean et al., 2005). Consist with this result; ABCG2 
was highly expressed in the CD44+/CD24− cells relative to CD44-/CD24- cells in 
both MDA-MB-231 and Hs578-T human BCCs.  
Moreover, the present study took advantage of the CD44+/CD24- sub-populations as 
BCSC models to demonstrate whether HS/heparin compounds could alter expression 
of CSC markers and drug resistance genes in BCSCs. The results indicated that some 
drug resistance genes and stem cell markers are indeed altered in CD44+/CD24− 
cells. These included firstly downregulation of CD44 expression (consistent with a 
switch towards a CD44-/CD24−! phenotype); and secondly, elevated expression of 
ABCG2 (which would be consistent with a feedback mechanism responding to 
inhibition of ABCG2 activity). Inhibition of ATPase activity of ABCG2 has 
previously been observed for heparin (Chen et al 2014) Future studies to examine the 
direct effects of the HS and modified heparin compounds on ATPase activity of 
ABCG2 are now warranted. Overall HS/ heparin and chemically modified heparins 
have been demonstrated to have pivotal effects on a number of key genes which 
provide plausible mechanisms for decreasing the CD44+/CD24− sub-population of 
BCSCs, and potentially increasing their chemosensitivity.  
Angiogenic factors: Angiogenesis is known to be involved in tumor development 
and progression and is controlled by pro-angiogenic and anti-angiogenic factors 
induced by several cell types in the tumor microenvironment (Bouïs et al., 2006, 
Saarinen et al., 2010). Angiogenesis requires the activation of endothelial cells by 
angiogenic factors, from a quiescent state to a migratory, then proliferative and 
stabilized phenotype; this is induced and controlled by activator and inhibitor 
molecules, most notably growth factors such as VEGF (Nishida et al., 2006). There 
is substantial evidence for the role of angiogenesis in BC growth and progression 
(Boudreau and Myers, 2003, Longatto Filho et al., 2010). The present study 
demonstrated that BCSCs can produce factors which would be expected to promote 







heparins modulate these factors in human BCSCs. Several pro-angiogenic genes 
including Ang-1, Ang-2, VEGFA, VEGFB and IL-8 were highly expressed in 
CD44+/CD24- sub-population cells in comparison to CD44+/CD24- sub-population 
cells in MDA-MB-231 cells. Human BCC line Hs578-T also showed a significant 
increased in Ang-1, VEGFB and IL-8.  Angiogenesis stimulation by BC cells has 
been linked to an increase of VEGF production by the tumor cells and by cells within 
the tumor stroma (Nishida et al., 2006), However, VEGFA and Ang-1 expression 
levels were significant in CD44+/CD24- cells relative to CD44-/CD24- cells. A 
number of these markers were observed to be down-regulated by exposure of 
CD44+/CD24- cells to HS/heparin and modified heparins, indicating that they can 
modulate this important feature of their tumourigenic phenotype.  
In addition, chemokines and their receptors have been demonstrated to be involved 
in CSC-mediated angiogenic factor production (Liekens et al., 2010). The chemokine 
receptor CXCR4 has been observed to play a pivotal role in cancer angiogenesis and 
to be preferentially expressed by glioblastoma stem cells (Ehtesham et al., 2009, 
Liekens et al., 2010). The present study observed that CXCR4 levels were also 
significantly higher in CD44+/CD24− cells relative to CD44-/CD24− in both MDA-
MB-231 and Hs578-T BCCs. Importantly, CXCR4 was significantly downregulated 
in cells treated with HS/heparin and chemically modified heparins. Overall, since 
these compounds differentially affected expression of various angiogenic markers in 
CD44+/CD24- BCCs, it is clear that endogenous HS contributes significantly to a 
greater pro-angiogenic potential of BCCs, and represent useful targets for effective 
anti-angiogenic therapies. 
FGF2/ERK1/2 signalling: ERK1/2 is one class of MAPK intracellular signaling 
cascades implicated in human breast tumors. ERK1/2 signaling pathways were 
estimated to be involved in approximately 30% of human BCs (Whyte et al., 2009). 
A survival analysis reported that a higher expression of pERK1/2 in primary tumors 
impacts metastasis, and a lower expression of pERK1/2 in primary BCs is prognostic 
for relapse-free survival of patients (Mueller et al., 2000). In addition, the expression 
of pERK1/2 can impact a patient's response to treatment (McGlynn et al., 2009, 
Mueller et al., 2000, Santen et al., 2002). Accumulating evidence suggests that FGF2 







Since HS and heparin are known to regulate the FGF2/ERK1/2 pathway (Chua et al., 
2004), we questioned whether FGF2-stimulated ERK1/2 activation could be 
modulated by HS/heparin or chemically modified heparin on BCSCs.  FGF2 
stimulated the ERK1/2 phosphorylation, whereas HS/heparin and chemically 
modified heparins could decrease both the intensity and duration of ERK1/2 
activation in the CD44+/CD24- sub-population from MDA-MB-231 and Hs578-T 
BCCs. An opposite effect was observed when HS/heparin and chemically modified 
heparin was used alone, since a significant increase of ERK1/2 phosphorylation level 
was observed in CD44+/CD24- cells sorted from both MDA-MB-231 and Hs578-T 
cells. Thus, when BCSCs are undergoing active FGF-stimulated responses via 
pERK1/2, the compounds could block this activity.  Thus, interference with 
HS/FGF/FGFR interactions could provide an additional mechanism by which this 
class of compounds suppresses the tumourigenic properties of BCSCs that depend on 
this signaling axis.    
IL-6/STAT3 signalling: Previous results demonstrated that inhibition of IL-6 gene 
expression reduces proliferation of CD44+/CD24– human BCCs, via reduced 
activation of STAT3. In addition, the IL-6/JAK2/Stat3 signaling pathway was 
significantly active in CD44+/CD24– BCCs in comparison to the other cancer cell 
types (Marotta et al., 2011). Due to the high expression of IL-6 and IL-8 in 
CD44+/CD24- sub-population (Sheridan et al., 2006) we were interested in whether 
HS and chemically modified heparins might affect their action in BCSCs. An 
increasing number of IL cytokines have been found to bind to HS and heparin. The 
interaction of IL-6 is highly highly pleiotropic, with HS and heparin found to 
regulate different mechanisms. However, these cytokines may also be released into 
the circulatory system, possibly bound to GAG-peptide fragments or GAG 
oligosaccharides (Mummery and Rider, 2000). Thus, HS may play important roles in 
regulating IL-6 activity. It was found here that HS/heparin and 2,6 deS-NS H 
significantly reduced IL-6 expression in CD44+/CD24- cells of MDA-MB-231 and 
Hs578-T human BCCs. Moreover, treatment of CD44+/CD24- cells with HS/heparin 
and chemically modified heparins attenuated IL-6 signalling measured by inhibition 
of the phosphorylation of STAT3, in both MDA-MB-231 and Hs578-T cells. This 
data indicates a clear role for HS in modulating the STAT3/IL-6 signaling pathway 







cells in therapies using HS/heparin/modified heparins.  
Other mechanisms of action:  The above described work clearly demonstrated effects 
of the compounds were exerted in BCSCs via at least 3 signalling pathways, namely 
FGF2/FGFR and IL-6/Stat3 and VEGF. Since HS is known to be involved in many 
GF signaling pathways, it was reasonable to hypothesise that multiple additional 
pathways might be affected, and this could be one of the principle mechanisms of 
action of the compounds. To explore this possibility some initial experiments using 
Pathscan ELISA slides were undertaken. These studies firstly confirmed effects via 
MAPK/ERK1/2 and Stat3, but secondly revealed for the first time effects of this 
class of compounds on additional pathways including AMPKα, mTOR and S6 
ribosomal protein. Since these pathways are known to be linked to important 
tumourigenic properties of BCSCs, they now provide new targets for more detailed 
mechanism of action studies in the future to evaluate dose responses and structural 
selectivity. Overall, the results also provide further evidence that HS, heparin and 
chemically modified heparins act on BCSC behaviour via modulating (activating or 
inhibiting) multiple signaling pathways, in a selective structure-dependent manner.   
Finally, it has previously been reported that heparin can induce changes in HS 
biosynthesis (Skaletz-Rorowski et al., 1996) Thus we hypothesized that addition of 
exogenous HS, heparin and modified heparins might also act via such mechanisms. 
Initial qRT-PCR analysis indeed revealed significantly altered expression of genes 
for HSPG core proteins, biosynthetic enzymes, extracellular sulfatases and 
heparanase.  These preliminary results suggest additional mechanisms by which the 
compounds influence BCSC behaviour, with a complex interplay between 
endogenous HS production and feedback from responses to exogenous HS and 
related molecules, which collectively influence cell responses to HS-dependent 
proteins. Since this data only demonstrates changes in mRNA levels, further work is 
needed to establish whether changes in protein expression and ultimately HS 
structure are actually induced. But overall this data suggests that this would be a rich 
source of interesting new information on dynamic and responsive changes to the 








Future approaches – towards clinical applications? 
Although more work is needed to further define the multiple mechanisms of action 
of HS and chemically modified heparin polysaccharides on BCSCs, and the 
underlying functions of the endogenous HS in BCSCs, the work presented here 
revealed a number of different ways in which HS may be involved in the 
tumourigenic and metastatic properties of BCSCs. Furthermore, these data have 
opened up a number of avenues for potential exploitation of HS and chemically 
modified heparin polysaccharides in targeting CSCs for BC treatment. To validate 
this possibility in vivo experiments are now warranted. Firstly to explore whether BC 
CSCs pre-treated in vitro with the compounds are subsequently less 
tumourigenic/metastatic when tested in in vivo mouse models. Secondly, it would be 
of interest to test administration of the compounds in vivo, to investigate whether 
tumours induced by injection of BCCs express lower levels of CSCs as would be 
predicted from our studies. And finally to address the question as to whether the 
administration of the compounds in such models confirms that tumours display 
reduced tumour forming ability, metastasis and increased chemosensitivity.  If 
successful these studies would pave the way for clinical trials, perhaps initially in 
triple negative BC patients which are otherwise very difficult to treat with current 
therapies. In this context it is worth commenting that heparin/LMWH as a class have 
an exceptionally long history of safe clinical use; furthermore recently developed 
modified heparins also display notably low toxicity and lack of target anticoagulant 
activity (Duckworth et al., 2015, Kovacsovics et al., 2015), making them ideal for 
such clinical applications.  
In addition, these studies have shown clearly that stem cells are sensitive to 
manipulation by the HS/heparin class of compounds, which control a number of 
important cell regulatory pathways.  In the future, it would be invaluable to explore 
other applications of these compounds to target stem cell functions, for example in 
enhancing the responses of endogenous stem cells in repair and regeneration of 
damaged tissues, and in producing specific stem cells for transplantation to treat 
damage such as spinal cord injury, or for neurodegenerative conditions such as 








To our knowledge, these are the first results clearly demonstrating an association 
between BCSCs response to chemotherapeutic agents and treatment with HS/heparin 
and chemically modified heparin polysaccharides. The results elucidated the 
importance of HS in some molecular signaling pathways underlying critical BCSC 
properties that confer their enhanced tumourigenic properties, and demonstrated that 
the levels of BCSC sub-populations, and their resistance to chemotherapeutic agents, 
can be decreased by HS/heparin compounds, at least in vitro. In addition the studies 
support the view that HSPGs are important regulators of BCSC progression through 
regulation of cell invasion, migration and adhesion. This work demonstrated that  
treatment with HS and chemically modified heparin reduces the BCSC pools both in 
the aggressive triple negative human MDA-MB-231 cell line and in moderately 
aggressive human Hs578-T cells. This reduced CSC stemness was associated with 
downregulation of PAR-1/thrombin, FGF2/ERK1/2, and IL-6/STAT3 signaling 
pathways in triple-negative cells to differentially mediate breast cancer epithelial cell 
proliferation, invasion, migration and adhesion. Thus HS-dependent functions 
emerge as a promising supportive target for combined therapeutic approaches to 
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8  Appendices 
 
Appendix 1 Primers list  
Appendix 1.1 List of the primers and the expected size of Taqman PCR 
products with these primer pairs 
 
Gene Symbol Assay ID Context Sequence Group Gene Name 
18S Hs99999901_s1 N/A Miscellaneous function Eukaryotic 18S rRNA 
ADAM15 Hs00187052_m1 ATTCGCCGGAGGCGGGATGTGGTAA Cam family adhesion molecule ADAM metallopeptidase domain 15 
ADAMTS4 Hs00192708_m1 GACAATGGCTATGGGCACTGTCTCT Cam family adhesion molecule ADAM metallopeptidase with thrombospondin type 1 motif, 4 
ADAMTS5 Hs00199841_m1 GGATGATGGCCATGGTAACTGTTTG Cam family adhesion molecule ADAM metallopeptidase with thrombospondin type 1 motif, 5 
AGRN Hs00394748_m1 GTTCTGTGTGGAAGATAAACCCGGG Other receptor agrin 
CHST11 Hs00905281_s1 TAGAAAACGCTCCCTGTATCTTGCT Other transferase carbohydrate (chondroitin 4) sulfotransferase 11 
CHST15 Hs01031067_m1 GACCCGGAAGCGCTTTGGAATCGTC Transferase carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15 
EXT1 Hs00609162_m1 TTTCAACAACAGAGGTGGATTTCGC Glycosyltransferase exostosin glycosyltransferase 1 
EXT2 Hs00181158_m1 CCCTCCTGCTGTGAAGTGGGGCAGC Glycosyltransferase exostosin glycosyltransferase 2 
EXTL1 Hs00184929_m1 CCTGGACCTGGGCAGACCCAGCGCC Glycosyltransferase exostosin-like glycosyltransferase 1 
EXTL2 Hs01018237_m1 CTCAGTTTGGCAGCAATTTCCTGAT Glycosyltransferase exostosin-like glycosyltransferase 2 
EXTL3 Hs00918601_m1 AAGCCCCCCATCAAGGTGACCTCAC Glycosyltransferase exostosin-like glycosyltransferase 3 
GAPDH Hs99999905_m1 N/A Dehydrogenase glyceraldehyde-3-phosphate dehydrogenase 
GLCE Hs00392011_m1 GTGGGGTTGAAGGTGTGCCATTATC Epimerase/racemase glucuronic acid epimerase 
GPC1 Hs00892476_m1 GTCCGGAAAGTGGCTCAGGTCCCCC Carbohydrate kinase glypican 1 
GPC2 Hs00415099_m1 GCAACTATCTGGATGGTCTCCTGAT Carbohydrate kinase glypican 2 
GPC3 Hs01018936_m1 CAGCCGAAGAAGGGAACTAATTCAG Carbohydrate kinase glypican 3 
GPC4 Hs00155059_m1 GCAAGGTCTCCGTGGTAAACCCCAC Carbohydrate kinase glypican 4 
GPC5 Hs00270114_m1 GACAAAAATTATTGGAACAGGTAAA Carbohydrate kinase glypican 5 
GPC6 Hs00170677_m1 GGACCGGCTGGTCACAGACATAAAA Carbohydrate kinase glypican 6 
HPSE Hs00935036_m1 CCTCATCCTCCTGGGTTCTCCAAAG Glycosidase heparanase 
HPSE2 Hs00222435_m1 CACAAACCACCACAACCACAACTAC Glycosidase heparanase 2 
HS2ST1 Hs00202138_m1 CTCGAAGCTAGAAAGGGCTATTGCA Other transferase heparan sulfate 2-O-sulfotransferase 1 
HS3ST1 Hs00245421_s1 GGAGTTCCTGGTGCGCGATGGCAGG Cadherin heparan sulfate (glucosamine) 3-O-sulfotransferase 1 
HS3ST2 Hs00428644_m1 GGATTGGTACAGGAGCCTGATGCCC Cadherin heparan sulfate (glucosamine) 3-O-sulfotransferase 2 
HS3ST3A1 Hs00925624_s1 AGCGCTGCCAGACCCTGTCCGGCCC Cadherin heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1 
HS3ST3B1 Hs00797512_s1 CTCATGCAGCAGCCTCCTTGCAGAT Cadherin heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1 
HS3ST4 Hs00901124_s1 AGGCTCCTTGCCTGAGTCCTTGAAT Cadherin heparan sulfate (glucosamine) 3-O-sulfotransferase 4 
HS3ST5 Hs00999394_m1 GAGCTTGGATAGGCTACAACCCATT Cadherin heparan sulfate (glucosamine) 3-O-sulfotransferase 5 
HS3ST6 Hs03007244_m1 GGTACCGGAGTCTGATGCCCCGAAC Cadherin heparan sulfate (glucosamine) 3-O-sulfotransferase 6 
HS6ST1 Hs00757137_m1 GCTGCGCACGCCCAGGAAGTTCTAC Other transferase heparan sulfate 6-O-sulfotransferase 1 
HS6ST2 Hs02925656_m1 CCCATGGCCAGCGTCGGGAACATGG Other transferase heparan sulfate 6-O-sulfotransferase 2 
HS6ST3 Hs00542178_m1 ACAGCCACACCAGGAATTTCTATTA Other transferase heparan sulfate 6-O-sulfotransferase 3 
HSPG2 Hs00194179_m1 GGAGACAAGGTGGCGGCCTACGGTG Carbohydrate kinase heparan sulfate proteoglycan 2 
LRP1 Hs00233856_m1 GCCCCTGAGATTTGTCCACAGAGTA Other receptor low density lipoprotein receptor-related protein 1 
NDST1 Hs00925442_m1 TGGACTTGGATTCCCGAGCCTTCCT Cadherin N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 
NDST2 Hs00234335_m1 CCCCAGAAAACAGGGACTACAGCTA Cadherin N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 2 
NDST3 Hs01128584_m1 TGGATTCTGATAGCAGGACATTTCT Cadherin N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 3 
NDST4 Hs00224024_m1 TGTCAAAGATGTGAAGGCATTACTA Cadherin N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 4 
RPLP0 Hs99999902_m1 TGTTTCATTGTGGGAGCAGACAATG Ribosomal protein ribosomal protein, large, P0 
SDC1 Hs00896423_m1 TCAGGTGCAGGTGCTTTGCAAGATA Membrane-bound signaling molecule syndecan 1 
SDC2 Hs00299807_m1 GTGTCGGCGGAGTCGAGAGCAGAGC Other cell adhesion molecule syndecan 2 
SDC3 Hs01568665_m1 GCTCGGGCTACTTCGAGCAGGAGTC Membrane-bound signaling molecule syndecan 3 
SDC4 Hs00161617_m1 GCCGAGTCGATCCGAGAGACTGAGG Other cell adhesion molecule syndecan 4 
SULF1 Hs00290918_m1 ATGACCTACACAGAGGACAGTTATG Esterase sulfatase 1 
SULF2 Hs01016476_m1 CTTCTTCCAAATCACTGGGACAACT Esterase sulfatase 2 
TGFBR3 Hs01114253_m1 TTAGCCACTGCAGGTCCAGAGCCTG Cytokine receptor transforming growth factor, beta receptor III 








Appendix 2 Chemosensitivity data 
!
Appendix 2.1 Comparison of chemosensitivity of MDA-MB-231 and Hs578-T unsorted and 
sorted cells to various concentrations of Doxorubicin. (A) MDA-MB-231 and (B) Hs578-T 
unsorted and FACS sorted cells were exposed to Dox at increasing concentrations (1, 5, 10 µg/ml) for 
24, 48 or 72 hrs. Untreated cells (UT) were used as a control. Apoptotis was measured by Annexin 
V/PI staining and FACS sorting as described in Methods, and the percentage of early and late 
apoptotic cells were calculated. All experiments were performed with triplicate cells, and three 
independent experiments were peformed. Data from one of three representative experiments is shown 
(mean.±.SD, n=2). Data in inset show statistical significance at *= P<.0.05; **= P<.0.01 and ***= 






















































































































































































Appendix 2.2 Comparison of chemosensitivity of MDA-MB-231 and Hs578-T unsorted and 
sorted cells to various concentrations of Cisplatin. (A) MDA-MB-231 and (B) Hs578-T unsorted 
and FACS sorted cells were exposed to Cis at increasing concentrations (0.001, 0.01, 0.1, 1, 10 µM) 
for 24, 48 and 72 hrs. Untreated cells (UT) were used as a control. Apoptotis was measured by 
Annexin V/PI staining and FACS sorting as described in Methods, and the percentage of early and 
late apoptotic cells calculated. All experiments were performed with triplicate cell, and three 
independent experiments were peformed. Data from one of three representative experiments is shown 
(mean.±.SD, n=2). Data in inset show statistical significance at *= P<.0.05; **= P<.0.01 and ***= 





























































































































































































Appendix 2.3 Comparison of chemosensitivity of MDA-MB-231 and Hs578-T unsorted and 
sorted cells at various concentrations of Tamoxifen. (A) MDA-MB-231 and (B) Hs578-T unsorted 
and FACS sorted cells were exposed to Tam at increasing concentrations (1, 10, 100, 1000, 10,000, 
100,000 nM) for 24, 48 and 72 hrs. Untreated cells (UT) were used as a control. Apoptotis was 
measured by Annexin V/PI staining and FACS sorting as described in Methods, and the percentage of 
apoptotic cells calculated. All experiments were performed with triplicate cells, and three independent 
experiments were peformed. Data from one of three representative experiments is shown (mean.±.SD, 
n=2). Data in inset show statistical significance at *= P<.0.05; **= P<.0.01 and ***= P<.0.001 for 





























































































































































































Appendix 3: Flow cytometry data 
Appendix 3.1 Treatment with 
porcine mucosal compound 1 (PerS 
H) reduces the CD44+/CD24- 
subpopulation in BCC lines.  
Following 48 hrs treatment with perS 
H at various concentrations, flow 
cytometry was used to measure the 
CD44+/CD24- subpopulation. MDA-
MB-231 (A) and Hs578-T (B) cell 
lines were maintained in DMEM 
supplemented with 10% FBS, 10µg/ml 
insulin, 0.5 µg/ml hydrocortisone and 2 
mmol/l L-glutamine, in a humidified 
atmosphere containing 5% CO2 at 
37oC. Cells were treated with 1, 10, 
100 ng/ml, 1,10, 100 µg/ml of PerS H 
for 48 hrs. 105 single-cell suspensions 
of MDA-MB-231 and Hs578-T were 
double stained with anti-human CD44 
and CD24. Cells in red region 
corresponding to CD44+/CD24- Isotype 
controls corresponding to MD-MB-231 
and Hs578-T cells are shown. 
Representative data from one of four 
experiments are shown. 
 
 








































































































0.01 ng/ml PerS H  
0.1 ng/ml PerS H  




































































































10 ng/ml PerS H  
100 ng/ml PerS H  













































10 µg/ml PerS H  







Appendix 3.2 Treatment with 
compound 2 (NAc H) reduces 
the CD44+/CD24- subpopulation 
in BCC lines.  Following 48 hrs 
treatment with NAc H at various 
concentrations, flow cytometry 
was used to measure the 
CD44+/CD24- subpopulation. 
MDA-MB-231 (A) and Hs578-T 
(B) cell lines were maintained in 
DMEM supplemented with 10% 
FBS, 10µg/ml insulin, 0.5 µg/ml 
hydrocortisone and 2 mmol/l L-
glutamine, in a humidified 
atmosphere containing 5% CO2 at 
37oC. Cells were treated with 1, 
10, 100 ng/ml, 1,10, 100 µg/ml of 
NAc H for 48 hrs. 105 single-cell 
suspensions of MDA-MB-231 
and Hs578-T were double stained 
with anti-human CD44 and CD24. 
Cells in red region corresponding 
to CD44+/CD24- Isotype controls 
corresponding to MD-MB-231 
and Hs578-T cells are shown. 
Representative data from one of 
four experiments are shown. 
 




























0.001 ng/ml NAc H  

































































































































0.01 ng/ml NAc H  
0.1 ng/ml NAc H  
































































10 ng/ml NAc H  
100 ng/ml NAc H  

















































10 µg/ml NAc H  



















Appendix 3.3 Treatment with 
compound 3 (2 deS-NS H) 
reduces the CD44+/CD24- 
subpopulation in BCC lines.  
Following 48 hrs treatment with 
2 deS-NS H at various 
concentrations, flow cytometry 
was used to measure the 
CD44+/CD24- subpopulation. 
MDA-MB-231 (A) and Hs578-T 
(B) cell lines were maintained in 
DMEM supplemented with 10% 
FBS, 10µg/ml insulin, 0.5 µg/ml 
hydrocortisone and 2 mmol/l L-
glutamine, in a humidified 
atmosphere containing 5% CO2 at 
37oC. Cells were treated with 1, 
10, 100 ng/ml, 1,10, 100 µg/ml 
of 2 deS-NS H for 48 hrs. 105 
single-cell suspensions of MDA-
MB-231 and Hs578-T were 
double stained with anti-human 
CD44 and CD24. Cells in red 
region corresponding to 
CD44+/CD24- Isotype controls 
corresponding to MD-MB-231 
and Hs578-T cells are shown. 
Representative data from one of 
four experiments are shown. 
 
 






















































































































0.01 ng/ml 2 deS-NS H  
0.1 ng/ml 2 deS-NS H  

































































10 ng/ml 2 deS-NS H  
100 ng/ml 2 deS-NS H  













































































10 µg/ml 2 deS-NS H  

































Appendix 3.4 Treatment with 
compound 4 (6 deS-NS H) 
reduces the CD44+/CD24- 
subpopulation in BCC lines.  
Following 48 hrs treatment with 6 
deS-NS H at various 
concentrations, flow cytometry 
was used to measure the 
CD44+/CD24- subpopulation. 
MDA-MB-231 (A) and Hs578-T 
(B) cell lines were maintained in 
DMEM supplemented with 10% 
FBS, 10µg/ml insulin, 0.5 µg/ml 
hydrocortisone and 2 mmol/l L-
glutamine, in a humidified 
atmosphere containing 5% CO2 at 
37oC. Cells were treated with 1, 
10, 100 ng/ml, 1,10, 100 µg/ml of 
6 deS-NS H for 48 hrs. 105 single-
cell suspensions of MDA-MB-231 
and Hs578-T were double stained 
with anti-human CD44 and CD24. 
Cells in red region corresponding 
to CD44+/CD24- Isotype controls 
corresponding to MD-MB-231 
and Hs578-T cells are shown. 
Representative data from one of 
four experiments are shown. 
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CD44 APC 10000 













0.01 ng/ml 6 deS-NS H  
0.1 ng/ml 6 deS-NS H  










































































CD44 APC 10000 













10 ng/ml 6 deS-NS H  
100 ng/ml 6 deS-NS H  




















































10 µg/ml 6 deS-NS H  







Appendix 3.5 Treatment with 
compound 5 (2 deS-NAc H) 
reduces the CD44+/CD24- 
subpopulation in BCC lines.  
Following 48 hrs treatment with 
2 deS-NAc H at various 
concentrations, flow cytometry 
was used to measure the 
CD44+/CD24- subpopulation. 
MDA-MB-231 (A) and Hs578-
T (B) cell lines were maintained 
in DMEM supplemented with 
10% FBS, 10µg/ml insulin, 0.5 
µg/ml hydrocortisone and 2 
mmol/l L-glutamine, in a 
humidified atmosphere 
containing 5% CO2 at 37oC. 
Cells were treated with 1, 10, 
100 ng/ml, 1,10, 100 µg/ml of 2 
deS-NAc H for 48 hrs. 105 
single-cell suspensions of 
MDA-MB-231 and Hs578-T 
were double stained with anti-
human CD44 and CD24. Cells 
in red region corresponding to 
CD44+/CD24- Isotype controls 
corresponding to MD-MB-231 
and Hs578-T cells are shown. 
Representative data from one of 
four experiments are shown. 
 






















































































































0.01 ng/ml 2 deS-NAc H  
0.1 ng/ml 2 deS-NAc H  

































































10 ng/ml 2 deS-NAc H  
100 ng/ml 2 deS-NAc H  













































































10 µg/ml 2 deS-NAc H  

































Appendix 3.6 Treatment with 
compound 6 (6 deS-NAc H) 
reduces the CD44+/CD24- 
subpopulation in BCC lines.  
Following 48 hrs treatment with 6 
deS-NAc H at various 
concentrations, flow cytometry 
was used to measure the 
CD44+/CD24- subpopulation. 
MDA-MB-231 (A) and Hs578-T 
(B) cell lines were maintained in 
DMEM supplemented with 10% 
FBS, 10µg/ml insulin, 0.5 µg/ml 
hydrocortisone and 2 mmol/l L-
glutamine, in a humidified 
atmosphere containing 5% CO2 at 
37oC. Cells were treated with 1, 
10, 100 ng/ml, 1,10, 100 µg/ml of 
6 deS-NAc H for 48 hrs. 105 
single-cell suspensions of MDA-
MB-231 and Hs578-T were double 
stained with anti-human CD44 and 
CD24. Cells in red region 
corresponding to CD44+/CD24- 
Isotype controls corresponding to 
MD-MB-231 and Hs578-T cells 
are shown. Representative data 
from one of four experiments are 
shown.!
 


















































































































0.01 ng/ml 6 deS-NAc H 
0.1 ng/ml 6 deS-NAc H 




















































10 ng/ml 6 deS-NAc H 
100 ng/ml 6 deS-NAc H 

































































10 µg/ml 6 deS-NAc H 


























































Appendix 3.7 Treatment with 
compound 7 (2,6 deS-NS H) 
reduces the CD44+/CD24- 
subpopulation in BCC lines.  
Following 48 hrs treatment with 
2,6 deS-NS H at various 
concentrations, flow cytometry 
was used to measure the 
CD44+/CD24- subpopulation. 
MDA-MB-231 (A) and Hs578-T 
(B) cell lines were maintained in 
DMEM supplemented with 10% 
FBS, 10µg/ml insulin, 0.5 µg/ml 
hydrocortisone and 2 mmol/l L-
glutamine, in a humidified 
atmosphere containing 5% CO2 at 
37oC. Cells were treated with 1, 
10, 100 ng/ml, 1,10, 100 µg/ml of 
2,6 deS-NS H for 48 hrs. 105 
single-cell suspensions of MDA-
MB-231 and Hs578-T were 
double stained with anti-human 
CD44 and CD24. Cells in red 
region corresponding to 
CD44+/CD24- Isotype controls 
corresponding to MD-MB-231 
and Hs578-T cells are shown. 
Representative data from one of 
four experiments are shown. 
 
 





























































































































































0.01 ng/ml 2,6 deS-NS H  
0.1 ng/ml 2,6 deS-NS H  













































































10 ng/ml 2,6 deS-NS H  
100 ng/ml 2,6 deS-NS H  








































10 µg/ml 2,6 deS-NS H  



















Appendix 3.8 Treatment with 
compound 8 (2,6 deS-NAc H) 
reduces the CD44+/CD24- 
subpopulation in BCC lines.  
Following 48 hrs treatment with 
2,6 deS-NAc H at various 
concentrations, flow cytometry 
was used to measure the 
CD44+/CD24- subpopulation. 
MDA-MB-231 (A) and Hs578-T 
(B) cell lines were maintained in 
DMEM supplemented with 10% 
FBS, 10µg/ml insulin, 0.5 µg/ml 
hydrocortisone and 2 mmol/l L-
glutamine, in a humidified 
atmosphere containing 5% CO2 
at 37oC. Cells were treated with 
1, 10, 100 ng/ml, 1,10, 100 µg/ml 
of 2,6 deS-NAc H for 48 hrs. 105 
single-cell suspensions of MDA-
MB-231 and Hs578-T were 
double stained with anti-human 
CD44 and CD24. Cells in red 
region corresponding to 
CD44+/CD24- Isotype controls 
corresponding to MD-MB-231 
and Hs578-T cells are shown. 
Representative data from one of 
four experiments are shown. 
 





















































































































0.01 ng/ml 2,6 deS-NAc H  
0.1 ng/ml 2,6 deS-NAc H  













































































10 ng/ml 2,6 deS-NAc H  
100 ng/ml 2,6 deS-NAc H  

































































10 µg/ml 2,6 deS-NAc H  

































Appendix 4: PathScan analysis data 
 
Appendix 4.1 Screening of the phosphorylation of 18 key signaling molecules in CD44+/CD24- 
sorted cells from MDA-MB-231 BCCs using the PathScan intracellular signaling array. Cells 
were treated or not with 10 ng/ml of HS derivatives (PerS H, NAc H, 2 deS-NS H, 6 deS-NS H, 2,6 
deS-NS H, PMHS and PMH for 48 hrs. Following treatments, cell extracts were prepared and 
analyzed using the PathScan® intracellular signalling array kit. Treatments revealed changes in the 
status of various phosphorylated and signaling molecules. The results are representative of two 









Appendix 4.2 Screening of the phosphorylation of 18 key signaling molecules in CD44+/CD24- 
sorted cells from Hs578-T BCCs using the PathScan intracellular signaling array. Cells were 
treated or not with 10 ng/ml of HS derivatives (PerS H, NAc H, 2 deS-NS H, 6 deS-NS H, 2,6 deS-NS 
H, PMHS and PMH for 48 hrs. Following treatments, cell extracts were prepared and analyzed using 
the PathScan® intracellular signalling array kit. Treatments revealed changes in the status of various 
phosphorylated and signaling molecules. The results are representative of two experiments, each run 
























































































































































































































































































































































































































































































































































































Appendix 4.3 Screening of the phosphorylation of 18 key signaling molecules using the PathScan 
intracellular signaling array studying the effect of FGF-2/HS or heparin derivatives on 
CD44+/CD24- sorted cells from MDA-MB-231 BCCs. Cells were stimulated with 20 ng/ml FGF2 
and treated or not with 10 ng/ml of HS derivatives (PerS H, NAc H, 2 deS-NS H, 6 deS-NS H, 2,6 
deS-NS H, PMHS and PMH) for 60 min. Following treatments, cell extracts were prepared and 
analyzed using the PathScan® intracellular signalling array kit. Treatments revealed changes in the 
status of various phosphorylated and signaling molecules. The results are representative of two 































































































































































































































































































































































































































































Appendix 4.4 Screening of the phosphorylation of 18 key signaling molecules using the PathScan 
intracellular signaling array studying the effect of FGF-2/HS or heparin derivatives on 
CD44+/CD24- sorted cells from Hs578-T BCCs. Cells were stimulated with 20 ng/ml FGF2 and 
treated or not with 10 ng/ml of HS derivatives (PerS H, NAc H, 2 deS-NS H, 6 deS-NS H, 2,6 deS-NS 
H, PMHS and PMH) for 60 min. Following treatments, cell extracts were prepared and analyzed using 
the PathScan® intracellular signalling array kit. Treatments revealed changes in the status of various 
phosphorylated and signaling molecules. The results are representative of two experiments, each run 
in duplicate. Normalized mean luminescence intensity ± SD. 
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